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Abstract 
The physical properties and reactivity of 2,3-dihydro-1H-imidazo[1,2-f]phenanthridinium 
cations (DIPs) and analogous heterocycles have been investigated.  The adapted syntheses 
developed were applied to a range of aryl amines and more elaborate substrates, such as 
bifunctional aminoquinolinium cations and amino functionalised polyoxometalates  
(POMs).   
 
1,2,3,12b-tetrahydroimidazo[1,2-f]phenanthridines (TIPs), an intermediate in the 3-step 
cascade synthesis of DIPs, have also been isolated.  Derivatisation of the TIP structure at 
the imidazo-N position enables control of the reactivity of the intermediate with respect to 
electronic potential and pKa, allowing isolation of a selection of TIP structures.  
Correlations between these parameters and reaction outcome have been made and other 
influences such as steric and solvent effects have also been investigated. 
 
Investigation of the structure and properties of the TIP framework led to the discovery of a 
pH dependent cyclisation between the ring-closed TIP form and the ring-open 
aminoethylphenanthridinium (AEP) form.  The complementary TIP and AEP forms can be 
further manipulated by oxidation or reduction to convert them to their “pH-inert” forms, 
DIP and aminoethyldihydrophenanthridine (AEDP).  These four interchangeable states 
formed the basis of a redox “lockable” molecular switch that could be useful for molecular 
level information processing and data storage. 
 
The pH dependent cyclisation between the TIP and AEP forms was also investigated as a 
targeting mechanism for potential intercalating antitumour agents.  The system looks to 
exploit the pH difference between cancerous tissues and normal tissue to combine high 
cytotoxicity with high selectivity, a desirable trait that is unfortunately absent in most 
chemotherapeutic agents.  Preliminary in vitro assays have shown the TIP/AEP 
frameworks to have IC50 values in the µM range in human ovarian cancer cell lines, 
comparable to cisplatin and the closely related DIP intercalaters. 
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Introduction 
1 FUNCTIONAL ORGANIC MATERIALS 
1.1 Intuition or Inquisition? 
Research in all areas of science can be viewed as a blend of great human minds mixed with 
varying degrees of good fortune.  It would be wonderful to think that the huge leaps 
forward scientific research has given us, particularly in the 20th century, have been the 
product of design and forethought however this would be slightly naive and in most cases 
wrong.  The truth is that many of the greatest discoveries have been largely serendipitous 
in nature and the final applications were rarely considered from the outset.  It is not my aim 
to detract from the successes attributed to the people involved in these discoveries, since it 
was their knowledge and creative thinking that highlighted the gravity of their discoveries 
in the context of the “real world”; it is merely to point out the inherent uncertainty of 
research.  This marriage of labour and luck has proved to be a fitting partnership and has 
led to some truly incredible discoveries; namely Penicillin and Cisplatin being amongst 
some of the most famous examples.1   
 
As time has passed, the observations and subsequent knowledge gained from research has 
always allowed others to build upon it, and so the rate of development in all scientific areas 
has steadily increased with time.  This was famously noted in a correspondence between 
Isaac Newton and Robert Hooke in reference to the works of René Deascartes; 
 
“What Descartes did was a good step. You have added much several ways, and 
especially in taking the colours of thin plates into philosophical consideration.  If I have 
seen a little further it is by standing on the shoulders of Giants” 
 
The contributions of such eminent scientists has led us to the fortunate position we are in 
today, where so much has been learned that it is now possible to use this knowledge and 
apply it to the physical, sociological and ecological problems of today’s world.  As a result 
the research community are now able to approach research with a greater focus on 
application rather than speculation.  Where speculative research creates new techniques 
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and materials without fully knowing what the final applications may be, whilst application 
driven research has a defined problem that researchers aim to solve using the knowledge 
and techniques available.  Neither approach, however, can work on its own, and in reality 
any successful research project will always involve aspects of both. 
 
The successful growth and development of the global pharmaceutical industry is a 
testament to the benefits of this combined approach.  The use of plant and herbal extracts 
to treat illness has been known and practiced around the globe for centuries however it was 
only realized that the activities of such extracts could be attributed to a single organic 
molecule after isolation and characterisation of the active components.  The early 19th 
century saw the isolation of morphine and quinine and demonstrated their activity as 
analgesics and antipyretics, concurrent with the effects observed from the extracts of 
poppy plants and cinchona bark.1  Many other active compounds were discovered and used 
for clinical application over the years but many diseases and illnesses were still prevalent 
at the start of the 20th century.  With the high demand for new treatments coupled with the 
prospect of high financial rewards and social distinction there was great opportunity and 
incentive for chemists and biologists to apply this newfound knowledge in the search for 
drugs.  As fractional distillation and synthetic techniques improved it became more and 
more viable for total synthesis to replace the previous methods of natural product isolation, 
fermentation, and semi-synthesis; leading to the birth of the  pharmaceutical industry as we 
know it.1  Synthetic and analytical techniques have since developed in a somewhat 
symbiotic fashion with the growth of this economical giant, as the industry exploit the 
discoveries of the researchers who are in turn rewarded by the financial success the 
commercial products bring to the industry.  Many of the pharmaceutical products on 
today’s market are therefore a result of the greater understanding of fundamental chemical 
and biological processes, and the application of this knowledge to the synthetic strategies 
of ‘drug design’.2  The true significance of a single discovery therefore may not be realised 
until it is placed in the context of others, from the past, present, or even the future. 
 
So although the pharmaceutical industry may have provided an initial incentive for the 
expansion of research in organic chemistry, many new organic compounds have fulfilled 
their potential by finding applications elsewhere.  Examples of such discoveries include 
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polymers, dyes and macrocycles.  From these discoveries, entire new areas of organic 
chemistry have emerged and they are considered to be distinct areas of research in their 
own right, the products from which have found applications in materials design, catalysis 
and many other areas in addition to medicine.3-5 
 
 
1.2 Macrocycles 
 
1.2.1 Aza-Crowns and Crown Ethers 
Macrocycles are defined as “cyclic systems with rings greater than nine members”,6 and is 
an umbrella term that covers a vast number of cyclic architectures.  These include; 
cyclophanes, calixarenes, cyclodextrins, aza-crowns, thia-crowns, crown ethers, 
cucurbiturils, cryptands, torands, and spherands as some of the most prevalent in the 
literature.5-11  The structures range in composition and complexity but one thing that 
remains common to all is their application in host-guest molecular recognition systems.12-17 
 
Crown ethers are probably the simplest of the examples given above in terms of structure 
however this does not necessarily make their syntheses trivial.  Their synthesis relies on 
the Williamson ether method either in linear or convergent syntheses to produce medium 
to large ring crown ethers with a diversity of functionalities.10,18  Scheme 1 shows the 
synthesis of a chiral 18-crown-6 macrocycle from diethyl tartrate and diethylene glycol.19  
Although the individual reaction steps are fairly straight forward; acetal 
protection/deprotection, transesterification, tosylation and ether formation; the overall 
yields are rarely very high as the final cyclisation step is subject to competitive formation 
of linear and cyclic oligomers of different sizes.  For example in the synthesis shown in 
Scheme 1, combination of the individual reactants in a 1:1 ratio rather than 2:2 forms the 
9-crown-3 derivative in addition to the desired 18-crown-6 product. 
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Scheme 1.  Synthesis of 1,1’,4,4’-tetra-O-benzyl-2,2’:3,3’-bis-O-oxydiethylene-di-L-
threitol. 
 
One method of improving the selectivity of the ring forming reaction for particular sizes is 
to use a template.  An example that utilizes this method of template directed macrocycle 
formation is the synthesis of bis-p-phenylene-34-crown-10 described by Ouchi et al.20  The 
final ring closing step in this synthesis employs caesium toluenesulfonate as a template 
which gives yields as high as 40% for the desired product (Scheme 2). 
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Scheme 2.  Conditions for the ring closing step in the synthesis of of bis-p-phenylene-
34-crown-10. 
 
Chiral crown ethers have found applications as chiral resolving agents and chiral reagents 
for enantioselective reactions,21,22 while the benzo crown ethers have been used to form 
rotaxanes and catenanes through complexations with guests containing pi-electron deficient 
recognition sites such as viologens.23,24  More traditional uses of crown ethers exploit their 
ability to solubalize metal cations in organic solvents for use as phase transfer catalysts.25  
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The properties exhibited by the crown ether hosts is largely determined by the ring size and 
composition and the additional functionalities incorporated in their design; the simplest 
example that demonstrates this tunable behaviour is the preferential binding affinities of K+ 
and Na+ cations by 18-crown-6 and 15-crown-5 respectively, where a slight change in ring 
size results in a reversal in selectivity.18,26  The effects of ring composition are highlighted 
by the increasing affinity of aza-oxa crowns for heavy metals with increasing nitrogen 
content:  Log K values for 18 membered macrocycles and Pb2+ follow the series [18]O6 < 
[18]N2O4 < [18]N4O2 < [18]N6. 6,27  Aza-oxa crowns are particularly valuable as the 
introduction of the nitrogen donor atoms not only alters the binding selectivity but also 
allows for further binding functionality to be introduced to create lariate crowns and 
cryptands.28,29 
 
The importance of nitrogen donors in macrocycle chemistry is highlighted by the fact that 
over half of all synthetic macrocycles contain nitrogen donors.6  Macrocyclic polyamines 
(aza-crowns) are highly versatile ligands as they can be functionalised to a greater extent 
than crown ethers allowing greater control over binding selectivity.  The aza-crowns also 
follow a similar but more specific binding trend to crown ethers with respect to ring size vs 
guest size.  The reason for the increase in binding specificity is due to the differences in the 
ligand-guest orbital interactions.  Oxygen donor atoms are harder electron donors and 
therefore interact better with the hard cations of the alkali metal series whereas the softer 
nitrogen centres have a higher affinity for the softer transition metals.  The valence orbitals 
of the S-block metals are spherical and therefore offer no directional influence on the 
interactions with the electron-donating p-orbitals of the oxygens.  The valence orbitals of 
d-block transition metals however have very defined geometries and so interactions with 
the nitrogen donor atoms are much more specific.  The series of binding constants for 
mononuclear complexes of Ni2+ cations and aza-crowns, [9]N3 < [12]N6 > [21]N7 > 
[24]N8, can be explained by the favourable binding contributions from 6 nitrogen centers 
over 3 to form stable hexacoordinate complexes but when 7 and 8 nitrogens are introduced 
no additional binding effects are seen as the metal center is coordinatively saturated.6  Aza-
crowns form stable dinuclear transition metal complexes when the ring contains >6 
nitrogen donors.  The high binding affinities of aza-crowns to heavy metals like Pb, Hg 
and Ni prompted investigations into their use as biological immobilizing agents for these 
toxic metals.30  Other potential biological applications that have been investigated include; 
INTRODUCTION          6 
_________________________________________________________________________ 
ligands for MRI contrast agents, antimicrobial, psychotropic, antiarrhythmic, vasodilating 
and antihypertensive agents6,31.  The basicity of the nitrogen centers in aza-crowns also 
means that they are almost fully protonated at physiological pH, they have shown high 
affinity for biologically relevant anions such as AMP, ADP and ATP and therefore have 
applications as receptors for these substrates as well.32,33   
 
1.2.2 Rigid Macrocycles 
In any host-guest relationship the selectivity and strength of binding is governed by the 
nature of both components.  The crown macrocycles discussed previously have 
demonstrated how variations in charge, donor atom type, number of donor atoms, overall 
ring size, and additional ring functionality, can be manipulated to alter the selectivity 
towards different guest molecules.  One point that was not discussed was the effect of 
rigidity on such binding events.  Torands are fused-ring analogues of sexipyridine that 
were synthesised in the early 1990s.34,35  These macrocyclic frameworks are very rigid, 
which has a dramatic effect on cation binding.  The calculated stability constants for the 
Na+ and the K+ complexes with the torand shown in Figure 1 are 14.7 and 14.3 
respectively, which are remarkably even stronger than complexes with cryptands and 
cryptaspherands of similar size.36-39   
N
N
N
N
N
N
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N
N
N
N
N
N
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Figure 1.  Structures of sexipyridine and the fused-ring torand analogue 
 
Synthesis of the torand framework is fairly long but straightforward, with all steps except 
the final step proceeding with moderate to high yields (Scheme 3).  
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Scheme 3.  Synthetic route to tributyldodecahydrohexaazakekulene 
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In fact the group of T.W Bell who first synthesised the compound claim that the individual 
steps are sufficiently simple that a single person could prepare over 1g in less than 1 
month.38  The synthetic methodologies developed also offer access to larger torand rings 
and rings functionalised with other substituents.  The reason these reactions proceed 
without any template is that the rigid non-cyclic precursors are pre-organised with 
geometries that favour cyclisation over linear oligomerisation.  The cucurbiturils are 
another class of macrocycles that have very rigid frameworks and are able to be 
synthesized without a template.40,41  These “pumpkin shaped” guest systems have shown 
high affinity for organic dye molecules making them of great interest for applications in 
waste treatments.42,43 
 
The synthetic macrocycle frameworks available offer access to almost every type of 
intermolecular interaction, electrostatic, hydrogen bonding, hydrophobic etc.  It is even 
now possible to combine different types of macrocylic motifs to form hybrid ring systems 
such as calixarene azacrowns and calixarene crowns.44,45  This ability to combine these 
systems enables host systems to be tailored to optimally interact with a specific guest of 
interest.  The work carried out by the groups of Sauvage, Lehn, and Stoddart has used this 
strategy to full effect, which has resulted in some remarkably complex and beautifully 
interconnected architectures.46-54  Figure 2 shows Sauvage’s Cu(I) templated assembly of 
interlocked phenanthroline crown macrocycles55 and Stoddart’s CBPQT4+/DNP 
polyrotaxane.56 
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Figure 2.  (i) Sauvage’s [2]catenate complex; (ii) Stoddart’s CBPQT4+/DNP 
polyrotaxane. 
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1.3 Molecular Machines and Devices 
 
1.3.1 Principles and Definitions  
The Oxford dictionary definition for a device is:  A thing made or adapted for a particular 
purpose, especially a piece of mechanical or electronic equipment.  And a machine is:  An 
apparatus using mechanical power and having several parts, each with a definite function 
and together performing a particular task.57  It can therefore be taken from this that a 
machine is simply a combination of mechanical devices with moving parts.  In the 
macroscopic world it is easy to find examples for both, for example; light bulbs, lenses, 
electrical heaters, even explosives, are all examples of devices; cars, planes, blenders, 
drills, are all examples of machines.  In the molecular world the boundaries between these 
two functioning entities becomes less clear though since the definition of motion is not as 
straightforward.  Brownian motion for example exists in all materials and results in the 
random movement of particles with respect to each other even if the object itself remains 
stationary.  The cis-trans isomerisation of azo-dyes involves movement of the two nitrogen 
substituents relative to one another from a point of reference within the molecule whilst the 
molecule itself may remain in the same position in space.  Rotaxanes are interlocked ring 
and axle supramolecular assemblies that can exhibit translational movement of the ring 
along the length of the axle, the ring can therefore move with respect to the axle position, 
again whilst the complete assembly remains in the same place.  The term “motion” or 
“movement” can therefore be seen to rely heavily on the point of reference you choose to 
take, this can be more easily explained when considering similar examples in the “real 
world”.  If you consider two passengers on a train at a station there are numerous cases that 
can arise by moving the objects in relation to one another, for example; if the train moves 
then the train and the passengers move in relation to the station but not each other; or if the 
passengers swap seats then they have moved in relation to each other but not in relation to 
the train or the station.  The two molecular scale examples given previously can therefore 
be considered as similar processes i.e. conformational changes in the azo molecule or 
rotaxane assembly, or different processes i.e. isomerization of the aza molecule or ring 
shuttling of the macrocyclic ring along the axle, depending what point of reference you 
choose.  In the world of supramolecular chemistry the point of reference is generally 
considered to be taken from any molecular framework that is connected through strong 
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covalent bonds.  Interconnected frameworks that move with respect to each other through 
the manipulation of weaker intermolecular interactions can be classed as “machines”, 
isolated molecular arrangements that alter their configuration or conformation are not 
considered as moving and are therefore classed as “devices”.58  Molecular shuttles,59 
valves60 and motors61 perform a function via movement of their components and are 
examples of “molecular machines”; molecular switches,62,63 sensors,64 and wires65 perform 
a function without movement and are examples of “molecular devices”. 
 
 
1.3.2 Molecular Devices  
The types of molecular devices that have been synthesised to date include wires, sensors, 
and switches.  The function of these molecular devices perform the same basic functions as 
their macroscopic equivalents:  a wire allows the transport of electrons along its length and 
is usually part of a more complex device that involves other input and an output devices; a 
sensor generates a recordable or quantifiable signal in the presence of a particular physical 
stimulus; a switch is very similar to a sensor except the external input signal is deliberately 
applied to control the output.  With the high levels of interest and subsequent growth of the 
field there are now many examples of nano scale devices58 but it is inappropriate to discuss 
more than one or two in detail here.  The examples chosen demonstrate the versatility of 
the molecular frameworks and stimuli that can be used to create such devices. 
 
The first example was created in 1994 by Jean-Marie Lehn’s group where they used 
photochromic and electrochemical properties to control the switching states of a bisphenol 
perfluorocyclopentene (Scheme 4).66,67 
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Scheme 4.  Operation of the dual-mode optical-electrical molecular switching device.  
(redrawn without permission)66 
 
The system utilises the photoconversion of the dithienylethene moiety to switch between 
the “open”, non-conjugated and the “closed”, conjugated states via irradiation with UV and 
visible light.68  The additional hydroquinone functionality also allows the system to be 
electrochemically manipulated to switch to the “locked” quinoid state.  The three states are 
all distinguishable by their absorbance spectra and the subsequent colour changes 
observed; open (colourless), closed (blue), locked (violet).  This type of switch can 
therefore operate in a write-lock-read-unlock-erase manner and could ultimately be used as 
an optical switching device capable of high density information storage. 
 
The second example also exhibits an optical output but uses three inputs in a cooperative 
fashion to create a sensor with AND Boolean logic (Figure 3).69 
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Figure 3.  Structure and fluorescence intensity for the triple input sensor. (images 
adapted and reproduced without permission)69 
 
The structure of the sensor molecule has three recognition sites; (i) a crown ether receptor 
for Na+ cations; (ii) a tertiary amine moiety for H+ ions; and (iii) a phenyliminodiacetate 
receptor for Zn2+ cations.  From the emission spectra it can be seen that the fluorescence 
output for the system is only high when all three inputs, Na+, H+ and Zn2+, are all high, any 
other combination of inputs results in a low output, thus exhibiting AND logic.  The 
system exploits the photoinduced electron transfer (PET) quenching of the fluorescent 
anthracene unit by the electrons from the crown ether oxygens, tertiary amine nitrogen and 
carboxylate anions when in the unbound state, only when all three receptors are bound are 
the PET processes inhibited and fluorescence observed.  This type of system could find use 
in the fast screening of specific medical conditions, for instance, renal failure is indicated 
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by elevated levels of creatinine, urea, and potassium.70  An appropriately designed sensor 
could therefore be used in the preliminary diagnosis of this condition.  
 
1.3.3 Molecular Machines 
Molecular machines use mechanical motion to do work in order to perform their function; 
the motion can be harmonic,71 rotational61 or linear59 and the function will be dependent 
upon the inherent properties of the translational states.  One of the most impressive 
examples demonstrated to date for the application of molecular machines was the work of 
David Leigh et al, who created a photoisomerizable bistable [2]rotaxane capable of 
reversibly altering the polarity of a gold surface when they were physisorbed as 
monolayers (Figure 4).72   
 
Figure 4.  Structure of the photoisomerizable bistable [2]rotaxane and images of the 
irradiation experiment used to transport a droplet of diiodomethane.  (image adapted 
and reproduced without permission)73 
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The [2]rotaxane consists of a hydrophilic fumaramide unit and a hydrophobic 
tetrafluorosuccinamide unit on its dumbbell component, and a dipyridinium tetramide-
based macrocycle ring component.  The macrocycle binds preferentially to the hydrophilic 
fumaride station in the “zero” or “ground” state, leaving the hydrophobic 
tetrafluorosuccinamide unit exposed.  Photoisomerization of the fumaride by irradiation 
with UV light (254 nm) results in translation of the macrocycle to the 
tetrafluorosuccinamide station, thus shielding the hydrophobic region.  When the 
[2]rotaxane assembly was physisorbed as a monolayer on a Au(III) surface with 11-
mercaptoundecanoic acid the surface polarity could be changed when irradiated with UV 
light.  When specific sections of the surface were irradiated, a droplet of diiodomethane 
could be transported across the surface against gravity at slopes of up to 12°.  This 
technology could be useful in the development of lab-on-a-chip and microfluidic devices.   
 
Another elaborate example of a molecular machine that highlights the complexity that it is 
now possible to incorporate in their design is the “molecular elevator” (Figure 5).74  Its 
design and function are a result of the combination of the linear motion developed in the 
synthesis of a [2]rotaxane molecular shuttle75 and the tripodal geometry used to create 
“triply-threaded two-component superbundles”.76  The acid-base controlled recognition 
between the crown ether and the amino and viologen stations results in translational 
movement of the entire triphenylene platform.  The distance between the triphenylene and 
1,3,5-triphenylbenzene platforms can therefore be altered at will and could be useful for 
selective release of guests intercalated within this binding pocket. 
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Figure 5.  Structures and assembly of the “molecular elevator”. (image adapted and 
reproduced without permission)74 
 
The examples shown above are only a very brief highlight of some of the chemistry being 
carried out in this rapidly growing area of research.  The synthetic craftsmanship and 
innovative design of such structures is sure to continue and will inevitably lead to greater 
fundamental understanding of the processes involved as well as applications in materials 
science and drug delivery. 
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2 APPLICATIONS OF HETEROCYCLIC CHEMISTRY 
 
Heterocycles are a class of organic compounds that have applications in a wide range of 
modern research, from drugs77,78 and organic synthesis79; to materials for energy 
transfer80,81 and even hydrogen storage.82  This diversity in their applications comes from 
the array of properties exhibited by the numerous possible heterocyclic structures and the 
subsequent interactions they have with other chemical and biological systems.83  Some 
heterocycles can act as nucleophiles, others as electrophiles, acids, bases, reductants, 
oxidants, and so on.  These properties are controlled by the size and shape of the ring and 
the number, type, and position of the heteroatoms.  Controlling these parameters is crucial 
when designing new frameworks for functional organic molecules and materials. 
  
 
2.1 Heterocycles in Nature 
There is no better architect than nature and evolution, which has utilized organic building 
blocks for millions of years to create some truly astonishing structures.  You simply have 
to look at the crystal structures of a plant light-harvesting complex,84 or a strand of DNA,85 
or a virus protein coat 86 to appreciate the structural complexity that can be achieved.  
However nature is not only a master of design but also of function, which it has 
demonstrated through the exploitation of simple organic molecules or metal cations to 
control complex biological pathways.87  Nature has therefore found a use for many 
heterocyclic frameworks to carry out tasks such as cell signaling, structural integration, and 
catalysis.87   
 
The neurotransmitter, serotonin, is a perfect example of how nature uses heterocyles to 
control signal transduction.88  The majority of the human body's total serotonin is located 
in the gut, where it is used to regulate intestinal movements.  The remainder is synthesized 
in serotonergic neurons in the central nervous system, where it has a vital role in virtually 
all brain functions, including memory, mood, appetite, motor function, and body 
temperature.88  The size and complexity of structure is therefore obviously not a direct 
indication of its importance.   
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Figure 6.  Structures of natural heterocycles. 
 
DNA is one of, if not the most important molecule in any living organism as it contains the 
genetic information that is essential for reproduction.89  The structure was unknown until 
1953, when Watson and Crick proposed the double-stranded helical structure that is so 
commonly known today.85  The integrity of the entire structure is highly dependent upon 4 
molecules, which are of course the aromatic heterocycles guanine, cytosine, thymine and 
adenine.  The two linear strands of DNA are held together by hydrogen bonding 
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interactions between these heteroaromatic bases.  The complimentary nature of the 
hydrogen bonding arrangement is also what allows for selective insertion of the 
corresponding nucleotides during replication and transfer of genetic information.  The pi-
stacking of these base-pairs also aids in stabilising the helical structure. 
 
A large proportion of essential processes in living organisms, including those of signal 
transduction and DNA replication mentioned above, are dependent upon the action of 
enzymes to perform under physiological conditions.90  The catalytic activity of enzymes is 
often dependent not only upon the primary peptide sequence and absolute 3D protein 
structure but also on the involvement of additional species called cofactors.  Cofactors can 
be metal cations such as Mg2+, Zn2+ and Fe3+ or they can be small organic molecules such 
as pyridines and flavins.90  The pyridine derivatives NAD (nicotinamide adenine 
dinucleotide) and NADP (nicotinamide adenine dinucleotide phosphate); and flavins, FAD 
(flavin adenine dinucleotide) and FMN (flavin mononucleotide), are essential cofactors for 
the action of dehydrogenases and oxidoreductases.91  These enzymes and their cofactors 
are used as hydrogen transfer catalysts for the oxidation and reduction of the enzyme 
substrates. 
 
 
2.2 Heterocycles in Drug Synthesis 
The reliance on heterocycles and other small molecules for biological pathways is a very 
important factor in drug design for medicinal chemists.  The interaction of small molecules 
with larger, more complex structures provides an opportunity for the manipulation of 
pathways and their resulting physical traits through the actions of low molecular weight 
drugs.2  As mentioned previously enzymes are involved in almost all biological 
transformations and commonly interact with small molecules,90 they are therefore perfect 
drug targets.  The most common actions of drugs acting on protein targets are through 
binding at the active site (competitive/non-competitive inhibitors) or by inducing structural 
changes through binding elsewhere (allosteric inhibition).92  Inactivation (or activation) of 
the targeted enzyme has a knock-on effect further down the line in the pathway, bringing 
about changes in the substrate/product levels that cause the physical condition.  An 
example of such a condition is antifreeze poisoning, where the ethylene glycol enters the 
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biological pathway via ADH (Alcohol Dehydrogenase) and subsequently produces the 
toxic substance, oxalic acid.  This condition is treated by administering a large dose of 
ethanol, the natural substrate of ADH, to prevent the ethylene glycol entering the pathway 
by competing for the enzyme sites.92 
 
 
2.3 Heterocycles and Cancer 
 
2.3.1 Cancer as a disease 
Cancer is unfortunately not as simple to treat as it is a result of multiple errors in cell 
signaling pathways.  It is not a single disease but a term used to cover over 200 different 
diseases resulting from different cellular defects, which affect various organs throughout 
the body.92  They are all classed under the same term “cancers” because they all result in 
the uncontrolled growth of cancerous cells in the form of tumours.  Tumours can be either 
benign or malignant:  A tumour is benign when the new growth of cells is localized and 
can usually be removed by surgery; a tumour is malignant when the cancer cells are mobile 
and can be distributed around the body, setting up new growths in different areas making 
them very difficult to treat.   
 
2.3.2 Causes of cancer 
The uncontrolled growth is a result of genetic defects in the genes responsible for 
controlling the cell cycle.  The cell cycle is the general process involving the life and death 
of a cell and is strictly controlled by a number of checkpoints to ensure that only the 
correct DNA sequences are replicated in order for the new daughter cells to function 
properly.  Genetic defects are actually very common but during normal cell replication 
they are either repaired, or if repair is not possible, then the cell is terminated so the defect 
is not passed on.  However if the genetic defects occur within the genes coding for proteins 
involved in the control pathways then the chances of cells becoming cancerous begin to 
increase.  Almost all cancers have a defect in at least one of these “control genes”, for 
example cyclins and CDKs (cyclin dependent kinases) are proteins that regulate cell 
growth and division and defects in their genes have been detected in 90% of human 
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cancers.  The loss of a fully functioning regulation and repair mechanism consequently 
makes further mutations easier to be passed on unchecked.  The subsequent build up of 
genetic defects then leads to cancerous cells which have the following characteristics:  
abnormal cell function, insensitive to growth inhibitor signals, abnormalities in cell cycle 
regulation, evasion of apoptosis (no cell death), increased telomerase activity (limitless 
division), angiogenesis (generation of blood vessels) and eventually metastasis (cancer 
spreading).92 
 
Although spontaneous DNA damage can occur through natural errors in the replication 
process, the majority are caused by a number of external factors; chemicals such as 
alkylating agents,93 intercalating agents94,95 and heavy metals;96,97 radiation such as UV, X-
ray and gamma;98 viruses like the human papillomavirus;99 and even lifestyle and diet.100  
The natural safeguards in the regulatory pathways of the cell cycle are very efficient at 
removing minor defects that result from acute exposures to these carcinogens but longer, 
more frequent exposures increase the risk of more serious damage.101  If the damaged 
DNA is not repaired and undergoes replication then this altered DNA sequence is carried 
through cell division and becomes a permanent mutation in that cell lineage.  For a cell to 
become cancerous it has to obtain mutations in at least 5 genes.101    These mutations are 
not acquired by a single cell but through a sequential process of acquisition and expansion, 
where the number of initial mutant cells expands and they then acquire a second mutation, 
then a third, and so on; with each successive mutation becoming more likely, as more and 
more of the normal regulatory processes are lost.  Hence why prolonged exposure to 
mutagens through activities like smoking and working with asbestos increase the incidence 
of cancer in these demographics.101 
 
2.3.3 Treatments for cancer 
Although there are many newly developing cancer treatments under investigation such as 
gene therapy, antibody-directed enzyme prodrug therapy (ADEPT), virus-directed enzyme 
prodrug therapy (VDEPT) and gene-directed enzyme prodrug therapy (GDEPT), the three 
traditional and most common methods for treatment of cancers are surgery, radiotherapy, 
and chemotherapy.102  All three methods offer particular benefits and drawbacks:   Surgery 
cannot guarantee complete removal of all cancerous cells due to their ability to invade 
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neighbouring and far away tissues through metastasis, whilst selectivity and toxicity pose a 
large problem for both radiaton and chemical treatments.  Often a combination of surgery, 
radiotherapy, and chemotherapy, which have complimentary modes of action, leads to the 
most effective treatments.101 
 
Chemotherapy is the term used for the treatment of cancer and other diseases through 
chemical means.103  The drugs available for chemotherapy treatments of cancer can fall 
into a number of categories depending on their mode of action; alkylating agents, mitotic 
inhibitors, antimetabolites, and topoisomerase inhibitors are the most common.104 
 
Alkylating agents target DNA directly through alkylation of the nucleophilic nitrogens of 
the DNA base-pairs such as N-1 and N-3 of adenine, N-3 of cytosine, and N-7 of guanine.  
Alkylation of guanine units is particularly effective in causing mutations since the alkyl-
guanine favours the unnatural enol tautomer, which base-pairs with thymine rather than 
cytosine, resulting in miscoded regions in the DNA.  However the most potent action of 
alkylating agents is the cross-linking of DNA, where the DNA strands become covalently 
linked and can no longer be replicated or translated.105  Important alkylating agents include 
nitrogen mustards, aziridines, nitrosoureas and sulfonic acid esters.106 
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Scheme 5.  Mechanism of action for Lomustine, a nitrosourea alkylating agent. 
 
Nitrosoureas have a dual mode of action as they decompose in the body to form two active 
compounds, an alkylating carbocation and a carbamolating isocyanate.  The alkylating 
agent cross-links DNA through reaction with the O-6 positions of guanine bases or N-3 
positions of cytosine bases.  The active isocyanate forms carbamates through reaction with 
the lysine residues in proteins, which could cause inactivation of DNA repair enzymes, 
thus increasing its potency.  Although cisplatin and other platinum-based chemotherapeutic 
drugs are not alkylating agents as such, they behave in a similar fashion.107  These drugs 
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work by cross-linking the N-7 positions of guanine base units through coordination with 
the platinum centre, which interferes with the cell’s repair mechanisms. 
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Figure 7.  Structures of platinum-based chemotherapeutic drugs, cisplatin and 
carboplatin. 
 
Mitotic inhibitors are a class of anticancer drugs that do not target DNA but are still highly 
effective at terminating cell division.  These compounds work by targeting the proteins 
involved in mitosis, preventing cell division.  The most famous example of such a 
compound is TAXOL (Paclitaxel), which prevents microtubule breakdown of the spindle 
fibres during mitosis.108  The cell is then “frozen” in its undivided state and cell death 
occurs. 
 
Since the discovery of the anticancer properties of dihydrofolate reductase (DHFR) 
inhibitors, such as aminoterpin and methotrexate in the 1940s,109 antimetabolites have been 
used extensively in chemotherapy.110  Methotrexate reduces cell growth and division by 
preventing DNA replication indirectly:  Inhibition of DHFR reduces the levels of 
tetrahydrofolate, a cofactor for the enzyme thymidylate synthase, which then prevents the 
synthesis of deoxythymidine monophosphate (dTMP), the essential precursor for the 
thymidine base units of DNA.  5-fluorouracil is an antimetabolite drug which directly 
inhibits thymidylate synthase with a similar outcome to methotrexate, blockage of 
thymidine and DNA synthesis.  Other antimetabolite drugs include hydroxycarbamide,111 a 
ribonucleotide reductase inhibitor; pentostatin,112 an adenosine deaminase inhibitor; 
gemcitabine,113 an inhibitor of DNA polymerase; and 6-mercaptopurine,114 a purine 
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antagonist.  The high uptake of nutrients in rapidly dividing cancer cells is a feature which 
makes these drugs so effective.  
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Figure 8.  Structures of the antimetabolite drugs 5-fluorouracil and methotrexate; 
and doxorubicin, a topisomerase inhibitor. 
 
Doxorubicin is among the class of cytotoxic agents called topisomerase inhibitors.  
Topoisomerases are enzymes that unwind and wind DNA during replication and 
transcription.115  Doxorubicin intercalates DNA and stabilises the complex topisomerase II 
forms with DNA after unwinding, the DNA is then no longer available for complexation 
with other proteins and cannot undergo replication, ultimately leading to cell death.116 
 
The major drawbacks of all chemotherapeutic drugs regardless of their mode of action are 
those of bioavailability, selectivity, systemic toxicity, and resistance.117  The reasons for 
the difficulties encountered in targeting cancer cells over healthy cells is due to the fact 
that the cancer cells are derived from indigenous tissues and therefore share many 
similarities.  New treatments like ADEPT, VDEPT and GDEPT use the combination of 
genes and viruses to direct or initiate expression of nonhuman enzymes in cancer cells, 
followed by administration of a prodrug substrate for the enzyme, which is then converted 
to the active drug only in the cancerous tissues.102  Exploitation of “the Warburg effect” is 
also providing promising results for more selective chemotherapeutic agents.  The 
Warburg effect is an observation that most cancer cells predominantly produce energy by 
glycolysis and lactic acid fermentation in the cytosol, rather than by oxidation of pyruvate 
in mitochondria like most normal cells.118  This change in the primary metabolic pathways 
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creates distinctions in cancerous tissues, namely increased expression of glycolitic 
enzymes and increased acidity, 119 that could offer new targets and more selective 
treatments.120  
 
 
2.4 2,3-Dihydro-1H-imidazo[1,2-f]phenanthridinium (DIP) heterocycle 
  
2.4.1 DIP Applications in Anti-cancer Therapies 
Previous work within the Cronin research group led to the discovery of a new class of N-
heterocycles, 2,3-dihydro-1H-imidazo[1,2-f]phenanthridinium cations.121  These positively 
charged aromatic frameworks were shown to have moderate binding affinities for DNA122 
and were subsequently investigated for their potential application as anticancer agents. The 
DIP framework was shown to intercalate between the base-pairs of DNA with comparable 
binding affinities to the well known intercalaters, ethidium bromide and chelerythrine.123  
The DIP frameworks were assessed by in vitro assays in human ovarian tumour cell lines 
and showed very high cytotoxicites, some compounds were even more active than 
carboplatin in these cell lines.124  The DIP framework was also shown to have superior 
metabolic stability, with respect to hydroxide addition and reduction, in comparison to 
other well known intercalating frameworks. 
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Figure 9.  Resonance stabilisation of the positive charge in the DIP moiety compared 
to the iminium moiety in the phenanthridinium analogue, chelerythrine. 
 
The reasons for this increased stability come from the resonance stabilization of the 
positive charge in the dihydroimidazolium moiety in comparison to the imminium moiety 
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of analogous phenanthridinium intercalaters (Figure 9).  The initial tests carried out on the 
DIP frameworks were very positive and developing them into drug candidates looked to be 
a strong possibility.  Further investigations of the library of DIP frameworks that had been 
synthesised gave much valued SAR information, which indicated a high dependency upon 
the lipophilicity of the amino side-chain for cytotoxicity.125  It was postulated that the DIP 
frameworks therefore had two types of binding to DNA, intercalation of the 
dihydrophenanthridinium ring system, and additional minor groove binding of the amino 
side-chain.  The mode of action was therefore likely to arise from interactions with the 
DNA-protein complexes formed during transcription and replication, similar to 
topoisomerase inhibitors.116  However the true nature of binding and the mode of action 
were never comfirmed.  Results obtained from in vivo assays in mice transplanted with 
human tumour xenografts were unfortunately not as encouraging as the initial in vitro 
studies.  Very low therapeutic indices were obtained for a large proportion of the DIP 
compounds tested.  The therapeutic index (TI) is defined as the lethal dose of a drug in 
50% of the sample population (LD50) divided by the effective dose (ED50), so a high TI  is 
preferential to a low one as in these cases the effective dose required is much less than the 
lethal dose.  The non-selective effects observed for the DIPs were thought to be caused by 
non-specific DNA binding or by other mechanisms such as membrane insertion.125,126  The 
low TI for the DIPs meant that the compounds were too toxic for further in vivo 
investigations and the pursuit to develop them into potential chemotherapy agents was 
halted.  
 
2.4.2 DIP Synthesis 
Although the application of the DIP heterocycles as anticancer agents was not as 
successful as first hoped, their discovery and synthesis in itself is an interesting story.  The 
DIP heterocylces were serendipitously discovered when attempting to substitute the 
bromoethyl side-chain of 5-(2-bromoethyl)-phenanthridinium bromide (BEP) with primary 
amines.127  Rather than the expected substitution of the bromine via the SN2 mechanism to 
produce the 5-(2-aminoethyl)-phenanthridinium bromide (AEP), a series of reactions led to 
the production of a tetracyclic cation, subsequently characterized as the DIP framework 
(Scheme 6). 
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Scheme 6.  Possible reactions of the BEP cation with primary amines 
 
 
Two possible pathways were proposed for the formation of DIP from BEP, both of which 
involved an addition of the amine to the BEP, followed by cyclisation and finally oxidation 
to DIP.121  The oxidant in the final step was identified as a second equivalent of BEP due 
to the presence of the BEP reduction product, 5-(2-bromoethyl)-5,6-dihydro-
phenanthridine (BEDP), in the final reaction mixture, and the observation of very low 
yields for DIP with respect to BEP (< 50%).  The cyclic 1,2,3,12b-tetrahydroimidazo[1,2-
f]phenanthridine (TIP) intermediate was  characterised in situ via MS and NMR 
spectroscopy.  The identification of the order of the first two steps was however not as 
trivial and required further investigations to identify the correct intermediate species.  The 
BEP framework contains two electrophilic centres which react with the nucleophilic 
primary amines to give the cyclic TIP intermediate.  However it was not apparent whether 
addition occurred at the iminium moiety or the bromoalkyl moiety first (Scheme 7). 
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Scheme 7.  Possible mechanisms of DIP formation. 
 
Path B involves nucleophilic substitution at the bromoethyl side-chain followed by a 5-
endo-trig cyclisation, whereas path A involves α-addition at the iminium moiety followed 
by a 5-exo-tet cyclisation.  The rules of ring closure proposed by Baldwin et al128 
supported the case for the preference of path A over path B due to the energetically 
unfavorable 5-endo-trig cyclisation required for path B, which was corroborated by 
observations made during the reactions of suitably functionalized analogues (Scheme 8).   
 
INTRODUCTION          30 
_________________________________________________________________________ 
N
X
Cl
PhNH2
N
X
HN Ph
D2O/CDCl3
TEA
X = F, OH
MeO
NH2
MeO
N
H
Br
Br Br
rt oC
X
 
Scheme 8.  Reactions confirming the preference of path A over path B. 
 
No reaction was observed when p-methoxyaniline was mixed with 1,2-dibromoethane, 
indicating that intermolecular SN2 of the alkyl bromide was not possible at room 
temperature.  Addition of primary amines to 5-(2-fluoroethyl)-phenanthridinium and 5-(2-
hydroxyethyl)-phenanthridinium chlorides was still possible at room temperature.121  From 
this evidence path A was established as the mechanistic route to DIP from BEP.  Further 
investigations were then made to expand and improve the efficiency of the DIP synthesis 
which led to the development of a biphasic methodology.121  This methodology used phase 
separation to convert the BEP starting material to the TIP intermediate almost 
quantitatively, oxidation by NBS then yielded the DIP product in very high yield (typically 
> 90%) with respect to the amine and the BEP reactants.  Investigations into the use of 
other solvents and co-oxidants were also made which resulted in a portfolio of 
complimentary methodologies for generating DIPs from a wide range of amine 
substrates.127,129 
 
2.4.3 DIP Applications in Inorganic-Organic Hybrid Materials 
Many examples for the applications of organic heterocycles in areas out with the 
traditional biological and medicinal remit have been given so far (see section 1.3 
Molecular Machines and Devices).  Another such example is that of the combination of 
DIP heterocycles with inorganic metal oxide species to produce novel inorganic-organic 
hybrid materials.   
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Polyoxometalates (POMs) are molecular anionic transition metal oxide clusters, they have 
active roles in catalysis,130,131 medicine,132,133 electrochemistry,134 and molecular 
magnetism.135,136  The structures that can be formed vary in shape, size, and function; with 
the synthetic conditions having a direct influence on these properties.137 Experimental 
parameters such as pH, temperature, metal salt composition, cation identity, concentration, 
and stoichiometry can all affect the self assembly of these metal oxide clusters.  Some 
generic examples of the more common POM clusters are shown in Figure 10.   
 
 
Figure 10.  Ball and stick graphical representation of the common POM 
architectures: (i) [M7O24]n- Anderson; (ii) [M12O36(XO4)]n- Keggin; (iii) 
[W18O54(XO4)2]n- Dawson. 
 
 
A large number of derivatives of the Anderson, Keggin, and Dawson cluster types are 
known, with variations in the transition metals, counter cations, and heteropolyanions.  
Alteration of these variables can result in changes in the cluster topology and crystal 
packing of these architectures, which ultimately affects the physical properties and 
applications of the bulk material.138,139  The introduction of organic components into POM 
materials can also have a huge effect on the material properties.  The organic part can be 
incorporated within the structure as a ligand metal complex, as a counterion, or as a 
covalently linked conjugate.140-144  Although there are recent examples using Huisgen 
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coupling to create POM-organic hybrids145 the most common methods for the covalent 
attachment of organic ligands to POM clusters are through coordination to a lacunary POM 
structure.146,147  This can be achieved by using a flexible triol such as pentaerythritol or 
TRIS-Base (tris(hydroxymethyl)aminomethane), where the pendant alcohols can displace 
the terminal hydroxyl ligands of the POM to give the POM-ligand conjugate.144,148  This 
methodology has been used very successfully within the Cronin group to derivatise POM 
clusters.  Cation exchange and cocrystalisation are a much more popular method for the 
incorporation of organic components within POM materials and there are numerous 
examples of these types of compounds.149-151 
 
POM clusters with TBA counter cations are readily soluble in polar organic solvents like 
acetonitrile, acetone, methanol, DMF and DMSO.  Cation exchange of the TBA cations 
with aromatic DIP cations leads to precipitation of highly insoluble aggregates, which have 
very poor solubility in all solvents except DMSO and DMF.152  This rapid alteration of the 
material properties due to this cation exchange reaction can been exploited to create new 
macro scale inorganic-organic hybrid materials with defined macro scale topologies.153  
When single crystals of a polyoxometalate (POM) species [(C4H10NO)40[W72Mn12O268X7], 
where X = Si or Ge, were suspended in an aqueous solution of a DIP cation it was 
observed that a spontaneous microtube growth emerged from the crystal (Figure 11).153  
This phenomenon was discovered by researchers within the Cronin research group where 
efforts have been made to gain understanding of the fundamental interactions of the self 
assembly process and to devise applications for the microtubes formed.   
 
 
Figure 11.  Time-lapse images of a single tube emerging from the POM crystal 
 
The tube growth was shown to be the result of osmotic pressure pumping material out from 
within a semi permeable membrane that forms around the crystal.  When the POM crystal 
contacts the DIP solution, a membrane forms around the crystal, osmotic pressure builds 
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up from the diffusion of water across the membrane, the membrane then ruptures and the 
material is expelled causing microtube growth.  The rate of growth and the tube diameter 
were shown to be a function of the concentration of the DIP solution, and directional 
control was established through potential differences applied across the bulk sample.154  
The integrity of the microtube structures was explored by injecting a fluorescent dye, upon 
which complete containment of the dye within the tubes was achieved.  The scope of the 
system was also investigated and similar growth patterns were obtained for a variety of 
mixtures of POM materials and DIP cations.153  This could therefore lead to the design and 
synthesis of topologically well defined architectures that retain the functionality of the 
original POM material. 
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Aims 
DIP heterocycles are a relatively new organic framework with interesting physical and 
biological properties and much work has been carried out in investigating DIPs as 
intercalating antitumour agents.  However little has been done to explore the potential 
usefulness of these heterocycles and their syntheses in other areas of chemistry.  The aim 
of this project was therefore to expand the chemistry surrounding the synthesis of DIPs to 
create functionalised derivatives that could find uses in areas out with their initial sphere of 
biological activity.    
 
In addition to their potential applications as chemotherapeutic agents, the mechanism of 
formation of DIPs is an intriguing aspect as well.  Previous work established that the 
mechanism involves a 3-step cascade reaction sequence, and although the intermediates 
had been characterised in situ, none of them were isolated.  A priority target was to isolate 
these intermediate structures so their properties could be assessed and new applications 
could be inspired.  Alteration of the reaction conditions and the amino substrates were to 
be investigated in order to achieve this goal. 
 
It was also thought that the use of more complex amine substrates would lead to the 
discovery of new DIP materials with potential applications in areas such as catalysis and 
supramolecular host-guest chemistry.  For example; bifunctionalised quinolinium 
substrates, containing both amine and imminium moieties, could lead to even more 
complex sequential multi-step reactions.  The proposed products of such reactions were 
cyclic or acyclic polycations, depending on the orientations of the functional groups and 
the number of monomeric units, and could be useful for anion binding.  Polyoxometalate 
clusters with covalently bound organic groups show dramatic changes in their physical 
properties compared to their untethered counterparts.  The covalent attachment of DIP-type 
heterocycles to POMs could therefore achieve similar outcomes.  This would require 
appropriately functionalised linkers to be synthesised and methodologies compatible with 
the substrates to be developed.  Investigations into the compatibility of the DIP chemistry 
and these complex amine substrates were therefore intended to be another important aspect 
of this project.  
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Results and Discussion 
3 MACROCYCLIC POLYCATIONS 
3.1 4-Aminoquinoline Macrocycles 
The chemistry of macrocycles has been shown to be a well established research field.  
Synthetic routes vary from templated single step ring-closing reactions to complex multi-
step procedures155-158 and the product applications are inherently dependent upon the 
building blocks used to create the final architectures, which may be large/small, 
aromatic/aliphatic, hydrophobic/hydrophilic, charged/uncharged etc.  The synthesis of new 
macrocyclic cations is therefore an attractive objective for synthetic chemists due to the 
vast number of potential applications for such targets.  The ambitious target devised for 
this project was that of cyclotris(2,3-dihydro-1H-imidazo[1,2-a]quinoline) (CTDIQ3+, 2, 
Scheme 9). 
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Scheme 9.  Proposed CTDIQ3+ target. 
 
The high charge and rigid structure of the target 2 would have potential as an anion binder 
due to its rigid framework and the strong electrostatic interactions it should offer.  The 
proposed route to the target aimed to exploit the facile synthesis of 2,3-dihydro-1H-
imidazo[1,2-a]quinolines (DIQs) developed by Parenty et al,121,127 in a multi-step-one-pot 
reaction with 4-aminoquinoline substrate 1 (Scheme 10).  The mechanism involves four 
main steps; alkylation at the quinoline-N, α-addition of amino-N, 5-exo-tet cyclisation, and 
oxidation.  Repetition of these steps leads to formation of the desired target macrocycle 2, 
providing the steps occur in the correct order and with the desired geometry. 
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Scheme 10.  Proposed mechanism for formation of the CTDIQ3+macrocycle. (a) 1,2-
dibromoethane, TEA, DMF, N2, 90°C, 48h 
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The initial conditions employed were adapted from the 2 step synthesis of DIQs where 
primarily alkylation of quinoline yields a 1-(2-bromoethyl)-quinolinium bromide substrate 
for the subsequent multi-step reaction.121,127  Combination of these steps had the potential 
for multiple side-reactions, such as dimerisation, elimination and non-regioselective 
alkylations, to compete with the desired reaction sequence.  Unfortunately this is exactly 
what was observed.  Upon cooling of the reaction mixture after heating for 48 h the 
reaction was filtered (TEA.HBr crystals collected) and the mother liquor was analysed by 
MS.  The data collected showed no indication of the target molecule, only the initial 
alkylation product plus undesired byproducts were observed (Figure 12). 
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Figure 12.  Observed mass ion signals and possible corresponding fragments for the 
initial one-pot synthesis of CTDIQ3+. 
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The presence of the TEA-bromoethyl conjugate and the lack of any high mass fragments 
indicated that TEA was reacting as a nucleophile as well as a base and that no α-addition 
was occurring between aminoquinolinium species in the reaction mixture.  Attempts to 
isolate the 4-amino-1-(2-bromoethyl)-quinolinium bromide via direct alkylation of the 4-
aminoquinoline substrate with 1,2-dibromoethane were unsuccessful.  The decision was 
therefore made to move towards a step-wise synthesis of a simplified target in order to gain 
more insight as to exactly where the reaction was failing and then to adapt the synthesis 
and build up complexity from there.  The new target structure proposed was that of 4-
amino-1-methylquinolinium toluene-4-sulfonate 3 (Scheme 11).   
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Scheme 11.  4-Amino-1-methylquinolinium toluene-4-sulfonate target. 
 
A series of investigative reactions were performed using the new methylquinolinium 
substrate (Scheme 12).  Refluxing the methylated substrate in DMF and N-
ethyldiisopropylamine for 48 h resulted in recovery of the starting material (~80%) after 
precipitation with Et2O, the same reaction with the addition of 1 eq of non-alkylated 4-
aminoquinoline yielded a similar result.  Refluxing in aqueous NaOH yielded the 
deprotonated compound 4 and not quinolinone  5. 
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Scheme 12.  Investigative reactions with methylquinolinium substrate. 
 
From these results it was concluded that the α-addition step was not occurring due to the 
conjugation between the two nitrogen centres.  The nucleophilicity of the amino-N and the 
electrophilicity of the quinolinium are diminished by delocalisation of the positive charge 
(Scheme 13).  It is also worth noting here that similar α-addition reactions of aryl amines 
are significantly hindered by bulky substituents ortho to the nucleophilic primary amine 
(see section 4.4).  
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Scheme 13.  Conjugation of nitrogen centres in 4-aminoquinolinium species.  
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3.2 3-Aminoquinoline Macrocycles 
It was proposed that aminoquinolines with different substitution arrangements of the amine 
functionality relative to the quinoline nitrogen could overcome this problem.  The choices 
of aminoquinoline replacements were limited by consideration of the electronic and 
geometric properties for each isomer.  3-aminoquinoline contained an unhindered, non-
conjugating amino group and retained a geometry that could still potentially lead to a 1 + 1 
dimer or a 6-membered macrocyclic product (Scheme 14). 
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Scheme 14.  Possible dimeric and macrocyclic products from reactions of the 3-
amionoquinoline substrate. 
 
Direct alkylation of the quinoline-N with 1,2-dibromoethane was again unsuccessful so the 
tactic of methylation was employed and substrate 7 was synthesised (Scheme 15). 
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Scheme 15.  Synthesis and reactions of 3-amino-1-methylquinolinium toluene-4-
sulfonate (7). 
 
The nucleophilicity of the amino-N both before and after alkylation was tested by reacting 
substrates 6 and 7 with acetic anhydride.  Compound 9 was able to be synthesised via both 
synthetic routes, confirming that the amine retained its’ nucleophilic character even after 
alkylation of the quinoline-N.  Unfortunately the successful retention of nucleophilicity did 
not transfer to the successful production of macrocyclic products.  When TEA was added 
to a solution of methylquinolinium substrate 7 in DMF and the reaction mixture was 
analysed by MS after 48 h no peaks could be assigned to macrocycles or oligomers of 7. 
(Figure 13). 
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Figure 13. Observed mass ion pattern and possible fragments for reaction mixture of 
compound 7 plus TEA in DMF. 
 
The observation of mass fragments (m/z = 175.09, 257.3, 338.4) of higher mass than the 
methylquinolinium substrate (m/z = 159.09) was promising as this indicated that the 
substrate was reacting under the standard conditions but could just not produce the target 
structures.  The choice of 3-amino-1-methylquinolinium as the framework for the 
macrocycle building block overcame the problems that had been encountered with the 
previous 4-aminoquinoline derivatives:  The amino-N was no longer conjugated with the 
quinolinium-N and there were no ortho substituents to inhibit the α-addition.  However the 
methylated substrate could not yield the desired products as the 5-membered imidazo ring 
could not be formed. 
 
In order to form a stable macrocyclic framework the 3-aminoquinoline needs to be 
alkylated with the bromoethyl side-chain necessary for formation of the 5-membered 
imidazo ring.  If cyclisation does not occur prior to the oxidation step then the amino group 
will leave before oxidation can occur, or a neutral oxidation product will form through 
deprotonation of the secondary amine centre (Step iv, Scheme 16). 
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Scheme 16.  3-aminoquinoline dimer (i) 1st α-addition; (ii) 2nd α-addition; (iii) 
oxidation; (iv) deprotonation 
 
Alkylation of the quinoline-N with 1,2-dibromoethane would overcome this problem but 
protection/deprotection of the amino-N would need to be introduced to synthesise the 
reactive alkylated substrate as the 3-aminoquinoline cannot be directly alkylated with 1,2-
dibromoethane (Scheme 17).  However it was also proposed that the oxidation step for this 
substrate would be problematic as it was previously reported that reactions of aryl amines 
with 1-(2-bromoethyl)-quinolinium bromide do not oxidise easily and the reaction stops 
after the addition and cyclisation steps.127 
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Scheme 17.  Synthetic strategy for 1-(2-bromoethyl)-3-aminoquinolinium bromide 
and subsequent multi-step reactions to dimer product. 
 
The initial aim of utilizing DIP-type reactions to produce macrocyclic architectures was 
not achieved however the results obtained to date have provided vital information on the 
reactivity of the electrophilic and nucleophilic centres involved.  This has enabled us to 
completely revise our original hypotheses and design a new blueprint for a suitably 
reactive substrate.  The new framework will specifically require:  (i) an unhindered amine; 
(ii) an aliphatic (or non-conjugated) amine; (iii) a 2-bromoethylquinolinium moiety; (iv) 
sufficient distance/rigidity between the reactive centres to prevent intramolecular 
additions; (v) appropriate geometry to allow cyclic products rather than linear oligomers.  
Adhering to these guidelines should give any future attempts a much greater chance of 
success. 
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4 TIP SYNTHESIS – UNDERSTANDING THE REACTION 
4.1 Prevention of oxidation by BEP 
As discussed earlier, a number of methods for the synthesis of the biologically active DNA 
intercalating agents, DIPs, have been developed.121,124,127   These methods utilise a variety 
of solvents and oxidizing agents and are applicable to a range of primary amine substrates.  
Regardless of the changes in the conditions, all the reactions essentially follow the same 3-
step mechanism:  amine addition, cyclisation and oxidation, proceeding through the ring 
open α-adduct and ring closed TIP intermediate species.  Until now, no examples of the α-
adduct had been isolated and only two examples of the TIP had been isolated.  The 
intermediates that could not be isolated were partially characterized in situ by MS and 
NMR spectroscopy.127,129  The two TIP structures that were successfully isolated were 
synthesised from the diamino compounds, ethylenediamine and 4,4’-diaminodiphenyl 
ether, using monophasic reaction conditions and were fully characterized.  Applying the 
same methodology to monoamines always resulted in DIP formation as these TIP 
intermediates are rapidly oxidised by the BEP starting material.  The oxidation step to form 
DIPs using BEP as the oxidant requires a formal hydride transfer and so it is likely that the 
transition state for this will involve pi-stacking of the TIP and the BEP to attain the correct 
geometry for the transfer to occur.  In the case of ethylenediamine the first addition and 
cyclisation reactions could occur as normal but as the second BEP molecule aligns to 
undergo the “hydride transfer” the pendant amine side chain could undergo a second α-
addition and cyclisation, thus consuming the oxidant and preventing oxidation (Scheme 
18). 
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Scheme 18.  Prevention of oxidation via second amine addition. 
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The reaction of the 4,4’-diaminodiphenyl ether is not likely to follow this same hypothesis 
because of the reduced flexibility of the diphenyl ether link.  The inhibition of the 
oxidation must be due to other factors.  The factors affecting the oxidation of aryl-TIPs are 
discussed later in this section.  It should be noted here that both of the TIP dimers can be 
further oxidised to their DIP analogues by the addition of a further two molar equivalents 
of BEP or other oxidising agents, the reaction outcome is therefore heavily reliant on the 
reactant stoichiometry. 
 
For monoamines it is possible to generate the TIP intermediate quantitatively using a 
biphasic methodology, where the TIP intermediate is separated from the BEP reactant via 
phase transfer.121  This method is however limited to hydrophilic primary amines only 
because the alpha addition step must occur in the aqueous phase.  The TIP structures 
generated from these aliphatic amines are unstable and had only been characterized in situ 
by MS and NMR spectroscopy.127,129  It was hypothesised that a synthetic protocol for the 
isolation of monomeric TIP structures could be developed, providing that the main hurdle 
of inhibiting the hydride transfer reaction could be overcome. 
 
The reactivity of the TIP structure with respect to oxidation was thought to be highly 
dependent upon the availability of the N lone pair introduced from the amine nitrogen since 
the inherent high stability of the DIP framework lies within the delocalisation of the 
positive charge over two conjugated nitrogen centres.  Conjugation of the amino-N with 
the side-chain will decrease the ability of this lone pair to stabilize the positive charge in 
the DIP product, thus reducing the driving force for the oxidation step.  Scheme 19 shows 
the resonance representations of TIP and DIP structures with a non-conjugating alkyl side-
chain and a conjugating aryl side-chain.  
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Scheme 19.  Electronic inhibition of TIP oxidation. 
 
4.2 Method development 
Aryl amines were an obvious candidate to investigate this electronic effect however they 
posed a problem as they were incompatible with the synthetic procedures already 
available.  Aryl amines are insoluble in water so the biphasic methodology would separate 
the amine and BEP reactants and no addition reaction could occur.  Monophasic reaction 
conditions had to be used but the solvent needed to be non-protic to prevent pseudo-base 
formation of the BEP under the basic reaction conditions yet remain polar enough to 
solvate the cationic species.  DMF and DMSO are both polar aprotic solvents and initial 
assays carried out in deuterated solvents and analyzed in situ by 1H NMR spectroscopy 
showed promising results (Figure 14).   
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Figure 14.  1H NMR spectrum of the crude reaction mixture after 15 min.  BEP (1eq), 
4-bromoaniline (1eq), TEA (3eq).  Characteristic high field singlet for TIP α-proton is 
evident at ~5.2ppm. 
 
The example reaction shows complete conversion of the reactants to the TIP framework 
with the only byproduct being TEA.HBr, however with the high boiling points of these 
solvents and their miscibility with water it was thought that isolation and purification of the 
sensitive products would be problematic.  Chloroform was screened as a potential solvent 
using the same NMR experimental procedure and a similar outcome was observed, almost 
complete conversion of the BEP and amine to the TIP product (1H NMR Spectrum shown 
in Figure 15). 
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Figure 15.  1H NMR spectrum of the crude reaction mixture after 3 h.  BEP (1eq), 4-
bromoaniline (1eq), TEA (3eq).  Characteristic high field singlet for TIP α-proton is 
evident at ~5.2ppm. 
 
Chloroform was subsequently established as the solvent of choice as it overcame the 
previous issues of product isolation and was still able to solvate the reactants, although 
somewhat sparingly with respect to BEP.  This however proved to be an advantageous trait 
as it created a visual aid for monitoring the reaction process.  The BEP starting material is 
largely insoluble in chloroform but the products are completely soluble, so as the reactants 
are consumed the reaction mixture gradually evolves from an off-white suspension to a 
bright orange solution, thus indicating when the reaction has reached completion.  The 
mother liquor can then be washed with water to remove the salt byproducts, followed by 
low temperature evaporation of solvent and excess TEA under vacuum to isolate the TIP 
product.  A range of amines were investigated and a number of products containing the 
desired TIP framework were isolated using this general methodology (Table 1). 
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Table 1.  TIP products obtained via reaction of primary amines with BEP 
N
N N
10
Br
Br
H
NH2 (1eq)
BEP (1eq)
11
R
RTEA (3eq)
CHCl3
rtoC
TIP (1eq)
+ TEA.HBr (2eq)
 
Entry TIP 11(a-x) 
R = 
pKaa 
Amines 
a-x 
Yield 
(%)b 
Entry TIP 11(a-x) 
R = 
pKaa 
Amines 
a-x 
Yield 
(%)b 
a 
 
10.57 ± 
0.10  
0c m 
F 
3.20 ± 
0.10 
68 
b 
 
10.72 ± 
0.10 
0c n 
F
 
4.66 ± 
0.10 
85 
c 
 
10.80 ± 
0.10  
0c o 
CF3
 
1.10 ± 
0.10  
0d 
d 
11
 
10.80 ± 
0.10 
0c p 
CF3  
3.37 ± 
0.10 
76 
e 
 
10.68 ± 
0.10 
0c q 
Br 
2.54 ± 
0.10  
0d 
f 
 
10.75 ± 
0.20  
70 r 
Br
 
3.90 ± 
0.10 
78 
g 
N
 
6.65 ± 
0.12 
88f s 
MeO2C
 
2.47 ± 
0.10 
68 
h 
MeO
 
5.21 ± 
0.10 
89 t F
F
 
3.64 ± 
0.10 
98 
i 
MeO
MeO
 
4.77 ± 
0.10 
89 u 
F
F
F  
2.62 ± 
0.10  
60 
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j 
 
4.61 ± 
0.10 
73 v 
F
F
F
F
 
1.23 ± 
0.10 
0e 
k 
 
4.84 ± 
0.10 
95 w F
F
F
F
F
 
-0.16 ± 
0.10 
0e 
l 
 
4.31 ± 
0.10 
0d x O
 
-1.54 ± 
0.25  
0e 
(a) pKa values calculated using Advanced Chemistry Development (ACD/Labs) Software 
V8.14 for Solaris (©1994-2009 ACD/Labs); (b) Isolated product yield after normal work-
up; (c) Reactive TIPs can not be isolated from monophasic reaction mixture due to 
consumption via a hydride transfer reaction.  Biphasic reaction conditions can overcome 
the hydride transfer to provide short-lived solutions able to be characterized by MS and 
NMR spectroscopy; (d) No TIP formed due to steric hinderance; (e) No TIP formed due to 
reduced amine nucleophilicity (f) 5.0 eq TEA  
 
4.3 Electronic effects of amine substituents 
From the list of amine substrates investigated it can be seen that there is indeed a 
correlation between the availability of the amino-N lone pair and reaction success.  
Increasing the electron withdrawing capacity of the R group reduces the availability of the 
N lone pair for further conjugation and therefore stabilizes the TIP structure.  Entries a – e 
in Table 1 showed no observation of the corresponding TIP products after work-up, which 
demonstrates that a lack of conjugation from the aliphatic side-chain increases the 
reactivity of the TIP with respect to oxidation.  This was verified by the presence of the 
oxidation product, DIP, in the product mixture for these reactions.  In contrast, aryl amines 
of varying electron deficiency can be reacted with the BEP starting material to generate the 
corresponding TIP structures in moderate to excellent yields (Table 1, entries g-u).  Partial 
conjugation of the N lone pair to the pi-system of the aromatic ring increases the energy 
barrier for the “hydride transfer” from the TIP to the BEP, therefore allowing complete 
conversion of the BEP to the TIP product.  Direct conjugation of the N lone pair to the 
side-chain in the form of an amide or conjugation to a highly electron deficient aromatic 
system did not lead to production of any of the corresponding TIP structures (Table 1, 
entries v-x).  This can be explained by the loss of sufficient nucleophilicity through 
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overcompensating with respect to conjugation of the lone pair.  In these cases the majority 
of the BEP starting material is recovered by filtration; however the presence of 
phenanthridine in the filtrate indicated conversion of some of the material via an 
elimination reaction.   
 
In terms of electronic effects, isolation of TIP structures can be seen as a balancing act 
between having enough nucleophilicity for the primary amine to undergo the first two 
steps whilst retaining enough electron withdrawing capacity to prevent further oxidation.  
It was proposed that the pKa value of the primary amine substrate would be a quick and 
simple measurement that could be useful in predicting the reaction outcome.  From the plot 
in Figure 16 it can be seen that a window for successful TIP isolation can be estimated for 
amines with pKa values of between approximately 2 and 7.  It is notable that an absolute 
correlation between pKa and reaction outcome cannot be formed as the steric effects of the 
amine side chains must be also be considered, which are discussed later in this section. 
 
Figure 16.  Plot showing TIP Product Yield vs Amine pKa.  Circled data point is for 
adamantyl-TIP 11f. 
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The reduction potentials of a selection of DIP analogues 12(a, b, i, j, t) containing a 
mixture of aryl and aliphatic side-chains were measured to corroborate the influence of the 
side-chain on the electronic potential of the DIP framework (Figure 17).   
 
 
Figure 17.  Cyclic Voltammograms of compounds; 12a, R = cyclohexyl; 12b, R = 
isobutyl; 12i, R = 3,4-dimethoxyphenyl; 12j, R = phenyl;  12t, R = 3,4-difluorophenyl; 
at 100 mV/sec.  The reversible reduction waves for all of the DIP compounds occur 
between ca. −1.0 V and −1.5 V.  Two irreversible oxidation waves are also observed at 
ca. +0.9 V and +1.3 V     
 
The reversible reduction waves observed for each DIP compound occur between ca. −1.0 
V and −1.5 V and are assigned to the 2 electron transfer reduction of DIP to TIP.  The two 
irreversible oxidation waves observed at ca. +0.9 V and +1.3 V are due to the single 
electron transfer oxidations of DIP to the radical cation, then to the fully oxidised 
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imidazophenanthridinium (IP) cation.  A plot of the reduction potential values against the 
amine substituent is shown in Figure 18. 
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Figure 18.  Plot of reduction potential values against the amine substituents.  Trend 
shows an increase in the reduction potentials with decreasing electron withdrawing 
character of the amine side-chain. 
 
From this data it can be seen that the values for the reduction potentials increase with the 
decreasing electron withdrawing character of the R groups, this supports the hypothesis 
that the amine N lone pair is involved in stabilizing the positively charged DIP core and 
that alteration of the R group has a direct influence on this. 
 
Conjugation of the amine side-chain not only affects the electronic potential but also 
decreases the pKa of the attached nitrogen centre making it less susceptible to protonation.  
Preventing protonation of the TIP intermediate is equally as important as preventing 
oxidation reactions with BEP as protonation of TIP leads to the generation of 5-(2-
aminoethyl)-phenanthridinium (AEP) structures 13 via ring opening.  This process is 
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reversible (see section 5.1) however once the AEP core forms it can act as a ‘hydride 
acceptor’, in a similar fashion to BEP, leading to further oxidation and complete 
consumption of the TIP in solution (Scheme 20).  
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Scheme 20.  (a) Reversible pH controlled ring opening and closing of TIP-AEP 
structures; (b) Intermolecular hydride transfer between TIP and AEP to form the 
oxidation product, DIP, and the reduction product, 5-(2-aminoethyl)-5,6-
dihydrophenanthridine (AEDP).   
 
This process is the most likely reason why attempts to isolate TIPs by solvent evaporation 
of the organic layers from biphasic DIP synthesis procedures have been unsuccessful.  
Reaction of aliphatic amines such as isopropylamine or isobutylamine with BEP under 
biphasic conditions will generate a solution of the TIP intermediate in the organic phase.121   
As the incompatible TIP and AEP forms 11 and 13 exist in equilibrium it is easy to see 
why the relative stability of these aliphatic-TIP analogues are so low, especially in such 
monophasic solutions:  The position of the equilibrium will tend to favor one form over the 
other depending on the availability of protons in solution and the probability of a 
successful collision and subsequent hydride transfer between the two forms will be 
dependent upon concentration.  There is no proton source in the organic solution so the TIP 
is favoured and is stable in mildly basic solutions for a number of hours.  However upon 
removal of the solvent under vacuum the sample is highly concentrated to an oily residue, 
the probability of the hydride transfer between the TIP and AEP as it forms is now much 
greater and they will irreversibly react, ultimately leading to the consumption of TIP.  This 
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complicated series of reactions was demonstrated by monitoring the acidification of a 
solution of isobutyl-TIP in D6-DMSO with DCl by 1H NMR spectroscopy.  From the 
spectra in Figure 19 it can be seen that the solution of isobutyl-TIP and isobutylamine 
(acting as excess base) is converted to an equimolar mixture of isobutyl-DIP and isobutyl-
AEDP by addition of DCl. 
 
Figure 19.  Isobutyl-TIP consumption via protonation and subsequent hydride 
transfer; structure and assigned peaks for isobutyl-DIP in blue; structure and 
assigned peaks for isobutyl-AEDP  in red. 
 
In the initial solution the excess of the isobutylamine acts as a base so the position of the 
equilibrium greatly favours the TIP form over the AEP form and the lifetime of any AEP 
that does form will be too short for any hydride transfer reaction to occur.  As the base is 
neutralised by the addition of the acid, the equilibrium is shifted more towards the AEP 
form, this allows for both the TIP and AEP forms to coexist in the same solution and 
undergo the hydride transfer reaction.  This produces the equimolar mixture of 5-(2-
aminoethyl)-5,6-dihydrophenanthridine (AEDP) and DIP observed. 
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The thermodynamic driving forces for the hydride transfer reaction are likely to arise from 
the reduction of steric strain and increased delocalization of the positive charge in the 
DIP/AEDP products compared to the TIP/AEP reactants.  This is corroborated by 
consideration of the standard electronic potential of the cell, E°CELL.  Equations 1, 2 and 3 
show the electron half-equations and reduction potentials for the reacting species and the 
overall redox equation for the hydride transfer. 
 
DIP+   +  H+  +  2e-     TIP   Eº   =  ~ −1.3 V  (1) 
AEP+  +  H+  +  2e-     AEDP   Eº   =  ~ −0.6 V  (2) 
TIP  +  AEP+    AEDP + DIP+  E°CELL  =  ~ +0.7 V  (3) 
 
The resulting electronic potential for the cell is calculated as approximately +0.7 V, which 
results in a highly negative value for ∆Gº from the relationship: 
 
∆G° = −n F E°CELL 
 
The thermodynamic forces therefore support the agreement for a spontaneous redox 
reaction under standard conditions. 
 
Although the electrochemical measurements agree with the hypotheses; (i) that a 
spontaneous hydride transfer occurs between TIP and AEP structures under standard 
conditions; and (ii) that the electron withdrawing capacity of the amino side-chain can 
influence the electronic potential for this hydride transfer, they do not support complete 
inhibition of hydride transfer.  Referring back to Figure 17 it can be seen that the reduction 
potentials for the DIPs with aryl amino side-chains are still very high, > −1.0 V, which still 
result in positive values for the electronic potentials, ∆E°, and negative values for ∆Gº of 
hydride transfer.  The hydride transfer reaction between aryl TIPs and phenanthridinium 
based reactants is therefore theoretically possible and there is precedence for the synthesis 
of aryl-DIPs from aryl-TIPs using BEP as the oxidant.121  The effects of the aryl side-
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chains on the reaction outcome must therefore be a kinetic effect rather than 
thermodynamic.  The rate of the hydride transfer reaction simply becomes relatively 
slower than the amine addition and cyclisation.  Hence the following observations: (i) 
when the alkyl amine and BEP reactants are present in a 1:1 ratio, ca. half of the BEP is 
converted to DIP and half is converted to BEDP due to the competing hydride transfer; (ii) 
when an aryl amine and BEP reactants are present in a 1:1 ratio, all of the BEP starting 
material is converted to TIP since there is no longer competition from the relatively slower 
hydride transfer; (iii) when either alkyl or aryl amines and BEP reactants are present in a 
1:2 ratio, half of the BEP is converted to DIP and half is converted to BEDP since the BEP 
is in excess with respect to the amine.  Electronic effects from the amine substituents 
contribute to stabilizing the TIP with respect to oxidation and protonation but they are 
unlikely to be solely responsible, other effects such as sterics must also be considered. 
 
 
4.4 Steric effects of amine substituents 
It was found that steric effects are indeed highly influential on the reaction outcome and 
have an effect at each stage of the multi-step mechanism.  From the series of successfully 
isolated TIP structures (Table 1. entries f - u) a set of structural isomers were selected to 
compare these effects.  From the comparison of electronically similar isomeric pairs (Table 
1, entries k - r) it can be seen that aryl substrates functionalized with bulky substituents at 
the ortho-positions are unable to form the TIP products unlike those that are either meta or 
para substituted.  The only ortho-functionalized substrate able to undergo conversion to the 
TIP product was 2-fluoroaniline (Table 1. entry m), where the fluorine atoms relatively 
small steric bulk is not sufficient to hinder the addition and cyclisation steps.  The reactions 
of 2- and 4-bromoaniline were repeated in D6-DMSO to allow the difference in reactivity 
for the two isomers to be directly compared (Figure 20). 
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Figure 20.  1H NMR spectra of the crude reaction mixtures for; (top) BEP (1eq), 4-
bromoaniline (1eq), TEA (3eq); and (bottom) BEP (1eq), 2-bromoaniline (1eq), TEA 
(3eq). 
 
The NMR reactions showed that the BEP starting material was consumed but no signals 
correlating to the TIP intermediate were observed even after 24 hrs for the reaction of 2-
bromoaniline, compared to the reaction of 4-bromoaniline which had reached complete 
conversion to the TIP in less than 15 min.  The 1H NMR spectrum of the 2-bromoaniline 
reaction shows a complex mixture of components but some of the signals were able to be 
assigned to the amine starting material and also phenanthridine.  A possible explanation for 
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this observation could be that in these cases the highly reactive BEP starting material was 
unable to react with the amine so instead it underwent an elimination reaction in the 
presence of the TEA base. 
 
The isolation of the TIP analogue of adamantamine (Table 1. entry f) was a very important 
discovery as this highlighted the stabilization of the TIP structure primarily through steric 
effects rather than electronic inhibition.  The amine substrate is a non-conjugated aliphatic 
amine with a relatively high pKa value of 10.75.  With no conjugation of the amino-N lone 
pair and the adamantyl group it can be assumed that this compound will have a similar 
electronic potential to other aliphatic TIP analogues.  The inhibition of the hydride transfer 
and subsequent TIP stabilization must therefore be influenced purely by the steric bulk of 
the amine side-chain alone.  A schematic representation of the steric inhibition of the 
hydride transfer is shown in Scheme 21. 
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Scheme 21.  Steric repulsion from bulky adamantyl side-chain inhibits the hydride 
transfer reaction between the TIP and BEP. 
 
To confirm the inhibitory effects of bulkier substituents on hydride transfer, a comparative 
NMR study of the reactions of isobutyl and adamantyl TIPs 11b and 11f with BEP in D6-
DMSO was carried out.  In the former case the reaction resulted in almost instant 
conversion of TIP 11b to DIP 12b as the BEP reactant is reduced, whereas in the latter 
case both TIP 3f and BEP reactants were clearly visible in the reaction mixture even after 9 
hours. 
RESULTS AND DISCUSSION         61 
_________________________________________________________________________ 
 
 
Figure 21.  1H NMR spectra of; (top) solution of isobutyl-TIP 12b in DMSO; (bottom) 
solution of BEP oxidant in DMSO; (middle) mixed TIP and BEP solutions after 5 
min.  Note the residual BEP peaks in the mixture are from the slight excess with 
respect to TIP. 
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Figure 22.  1H NMR spectra of; (top) solution of adamantyl-TIP 12f in DMSO; 
(bottom) solution of BEP oxidant in DMSO; (middle) mixed solutions after 9 hours. 
 
As both amines involved have almost exactly the same pKa (10.72 vs 10.75, Table 1 entries 
b and f) the difference in reactivity these TIPs exhibit towards the BEP oxidant must come 
from the difference in steric bulk of the side-chain alone.  To explain this steric inhibition, 
more detailed structural information for the TIP framework was required.  
 
 
4.5 TIP structure analysis 
The isolated TIP frameworks were fully characterized by traditional techniques:  melting 
point, 1H and 13C NMR, IR, MS, HRMS and elemental analysis, all of which were in 
agreement with the proposed TIP structure.  A very distinctive aspect of the TIP structures 
was the presence of a sharp singlet at ~5 ppm in the 1H NMR spectra due to the α-proton.  
The 1H NMR spectrum of dimethylphenyl-TIP 11k is shown in Figure 23. 
RESULTS AND DISCUSSION         63 
_________________________________________________________________________ 
 
 
Figure 23.  1H NMR spectrum for dimethylphenyl-TIP 11k with the distinctive α-
proton singlet highlighted red. 
 
The assignment of the remaining proton signals was not as trivial due to the high number 
of overlapping signals and identical coupling constants so a COSY spectrum was also 
obtained (Figure 24). 
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Figure 24.  COSY plot for dimethylphenyl-TIP 11k.  Note the lack of coupling for the 
α-proton singlet and the highly symmetrical splitting patterns for the aliphatic ring 
protons. 
 
From this plot, almost all of the individual proton assignments could be made.  These 
assignments are shown in Figure 25.  An interesting feature of this spectrum is the 
unexpectedly simple splitting pattern for the aliphatic ring protons.  The chiral centre 
makes all protons in the ring inequivalent and individual coupling should therefore be 
observed between all of them to give rise to four signals with ddd splitting.  Indeed four 
signals are observed however none appear to be split in this manner, two appear to be 
quartets, and two appear to be triplets in the 1D proton spectrum.  The COSY spectrum 
shows two that Hi & Hl (Figure 25) couple to each other as well as the other two remaining 
ring protons, Hj & Hk, and are therefore ddd’s, but because the J values are all equivalent 
they appear as quartets.  The remaining two protons, Hj & Hk, show the same identical 
coupling to the other two protons, but do not couple to each other, and therefore appear as 
triplets.  The lack of coupling between protons Hj & Hk is due to the dihedral angle 
between these two C-H bonds giving J values of 0 from the Karplus equation: 
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Jjk = A + Bcos2Φ  (0° ≤ Φ ≥ 180°) 
 
A and B are experimentally determined constants; the maximum coupling is observed 
when Φ = 180° or 0°; and the the minimum coupling is observed when Φ = 90°, as is the 
case here. 
 
 
 
Figure 25.  1H NMR spectrum of dimethylphenyl-TIP 11k with assigned signals. 
 
The higher level of saturation in the TIP ring system induces non-planarity and creates 
uncertainty over the spatial positioning of the relevant substituents, the α-carbon and the 
amine side-chain.  As the proximity of the R group to the phenanthridine ring system is 
very close when they are in the same plane, energetically unfavourable steric clashes force 
the R group out of the plane of the phenanthridine (Scheme 22).  The position of the R 
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group with respect to the α-proton can therefore either be syn, A and B; or anti, C and D 
(note there is no energy difference between enantiomers). 
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Scheme 22.  Possible conformations of TIP structure. 
 
The hypothesis of steric inhibition could only be plausible if the orientation of the amine 
side-chain and the α-proton of the TIP are in a syn configuration with respect to each other, 
if they were anti then the size of the amine side-chain would be of little consequence to the 
outcome of the hydride transfer reaction.    Fortunately crystals suitable for single crystal 
X-Ray diffraction were able to be grown for a TIP structure, 1-(4-fluorophenyl)-TIP, 11n.  
Evaporation of a saturated diethyl ether solution of 11n yielded large rod-shaped crystals 
from which the absolute structure was determined (Figure 26.)  The structure crystallised 
as a racemate for which the R enantiomer is shown, the image shows the phenyl side chain 
deflecting out of the plane of the phenanthridine ring system as expected but most 
importantly in the same direction as the α-proton. 
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Figure 26.  Ball and stick representation for structure 11n shows phenyl side-chain 
and α-proton in syn arrangement.   
 
The crystal structure gave absolute confirmation of the structural conformation in the solid 
state but information on the conformation in solution was still required.  Taking into 
consideration the favourable and unfavourable energy contributions for all of the possible 
conformations, the following arguments can be made to identify the syn arrangement as the 
predominant conformation in solution as well.  For the envelope conformation of the 5-
membered ring there are four possible conformations that can interconvert by ring flipping 
and pyramidal inversion processes (Figure 27).  Since the 5-membered ring is part of a 
fused-ring system, the ring flipping process is severely inhibited and the system is 
effectively “locked” in the conformations where the α-proton is axial (Hax).  The two 
possible conformations remaining can then either accommodate the amine R-group on the 
same face as the α-proton (Syn; Req, Hax) or on the opposite face to the α-proton (Anti; Rax, 
Hax).  In ring systems where pyramidal inversion is possible, equatorial substituents are 
preferred.159  The (Syn; Req, Hax) conformation is therefore theoretically the most stable 
arrangement, and will be the most predominant conformer in solution as well as that 
observed for the crystal structure.   
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Figure 27.  Energetically favourable and unfavourable conformations of TIP 
heterocycles. 
 
Irradiation of the α-proton signal (5.29 ppm in CDCl3) for a sample of 4-fluorophenyl-TIP 
11n also gave a strongly positive NOE with the phenyl ring protons meta to the fluorine 
(6.71 ppm in CDCl3).  The spectra are shown in Figure 28.  It is important to note here that 
pyramidal inversion is faster than the NMR experiment timescale therefore it is impossible 
to state that the (Syn; Req, Hax) conformation is the sole, or even the major conformation 
existing in the solution state, it simply proves that this conformation is accessible at room 
temperature in solution.   
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Figure 28.  1H NMR spectrum and overlaid NOE spectrum for 4-fluorophenyl-TIP 
11n. 
 
Incidentally this structural data could also offer another explanation for the high reducing 
power of the TIP framework.  The proposed conformation requires both N lone pair 
orbitals to align antiperiplanar to the C-H bond (See Figure 27, Syn; Req, Hax).  Tricyclic 
orthoamide structures can adopt a similar arrangement which greatly affect the properties 
of the C-H bond.159  The anti periplanar arrangement permits mixing of the lone-pair 
orbitals with the σCH*, weakens the C-H bond, and increases the electron density at the 
methine hydrogen.160,161  Scheme 23 shows a perhydrotriazaphenalane structure and some 
reactions that demonstrate its reductive nature. 
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Scheme 23.  (top) graphical representation of the anomeric effect from the N lone pair 
orbitals; (bottom) reactions of a perhydrotriazaphenalane with common oxidants. 
 
 
5 LOCKABLE MOLECULAR SWITCH 
5.1 pH Controlled Reversible Cyclisation 
The isolation of the TIP framework allowed investigations of their physical and chemical 
properties to be carried out.  One result of these investigations was the behaviour of the 
TIPs in acidic media, where protonation of the ring nitrogen leads to ring opening to form 
a dicationic AEP species (see section 4.3).  The reversibility of this ring opening/closing 
was initially thought to be irreversible due to the selection rules proposed by Baldwin et 
al.128,162-164  These rules state that a 5-endo-trig cyclisation is energetically disfavoured due 
to the preferred angle of nucleophilic attack, α = 109°, only being achievable through 
severe distortion of bond angles and distances.     
 
 
 
RESULTS AND DISCUSSION         71 
_________________________________________________________________________ 
 
 
Figure 29.  Diagram showing preferred trajectories for terminal atoms in selected 5-
membered ring cyclisations. 
 
 
The distance in the chain length between terminal atoms is not sufficient to achieve the 
desired 109° trajectory required for the 5-endo-trig cyclisation but it is long enough to 
allow the 180° angle required for a 5-exo-tet cyclisation.  In the mechanism for DIP 
formation these selection rules are obeyed as the cyclic TIP intermediate was proved to 
form via an α-addition step followed by a 5-exo-tet cyclisation rather than an SN2 
substitution followed by a 5-endo-trig cyclisation.121  In cases where there is an option for 
2 cyclic products these rules are generally obeyed, although there are a few exceptions.163 
 
In the case of the TIP/AEP cyclisation it was initially thought that rather than undergo the 
disfavoured 5-endo-trig cyclisation of the amine, an intermolecular addition of hydroxide 
would be preferred. 
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Scheme 24.  Scheme showing the possible α-addition or cyclisation products for the 
reaction of AEPs in aqueous base. 
 
 
At the time, distinction between the two possible products was ambiguous because MS and 
NMR spectroscopy were the only techniques available since the compounds could not be 
isolated.  Isolation of the stable TIP structures was an important discovery in answering 
this question.  The first reaction to corroborate the preference for cyclisation over 
hydroxide addition was the reversible acid-base initiated ring opening and closing of 4-
fluorophenyl-TIP.  Both the TIP and AEP structures had been isolated and unambiguously 
characterised, so this was an ideal model for this investigation.  A solution of 4-
fluorophenyl-TIP in D6-DMSO was acidified by addition of DCl followed by basification 
with TEA and the solution was analysed by 1H NMR spectroscopy throughout (Figure 30).   
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Figure 30.  1H NMR spectra showing AEP – TIP cyclisation:  (a) reference spectrum 
of characterised 4-fluorophenyl-AEP dichloride salt; (b) experiment spectrum after 
DCl addition; (c) experiment spectrum after TEA addition; (d) reference spectrum of 
characterised 4-fluorophenyl-TIP. 
 
This reaction confirmed the quantitative conversion of the AEP to the TIP upon addition of 
TEA, however the solvent is aprotic and the base is non-nucleophilic, so it is not an exact 
comparison for hydroxide addition.  A second experiment was therefore carried out, where 
a biphasic solution of isobutyl-AEP in water and EtOAc was basified by addition of 
Na2CO3, and after separation of the phases, NBS was added to the organic phase which 
resulted in precipitation of isobutyl-DIP.  The yield of DIP collected by filtration was 
quantitative with respect to the AEP starting material, confirming that deprotonation and 
cyclisation is preferred even in the presence of nucleophilic bases like hydroxide. 
 
5.2 Redox Susceptibilities 
The equilibrium between the AEP and TIP forms was discussed earlier to highlight the 
issue of “hydride transfer” from TIP species to AEP and the problems this creates for 
isolation of these compounds (see section 4.3).  The presence of this potential for hydride 
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transfer is a result of the contrasting redox properties of the AEP and TIP structures, TIPs 
contain a tetrahydroimidazo moiety which is easily oxidised and is therefore a “hydride 
donor”, AEPs contain a phenanthridinium moiety which can be easily reduced and is 
therefore a “hydride acceptor”.  To investigate the solution electrochemistry of these 
compounds, cyclic (CV) and square wave (SWV) voltammetries were obtained for the 
isobutyl-DIP and isobutyl-AEP structures (CV diagrams shown in Figure 31, for SWV 
data see experimental section 9.4.3). 
 
 
Figure 31.  Cyclic voltammograms of isobutyl-DIP (black) and isobutyl-AEP (green) 
 
The CV data shows a pseudoreversible redox wave for the isobutyl-DIP, whereas the redox 
wave for the isobutyl-AEP is irreversible.  SWV estimates the reduction potential of the 
isobutyl-DIP and isobutyl-AEP to be −1.3 V and −0.6 V respectively, which was in 
correspondence with our expectation that the DIP-based system is significantly harder to 
reduce than the AEP species.  Such a large difference in reduction potentials is in 
agreement with our spectroscopic data, confirming the possibility of hydride transfer (see 
section 4.3). 
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5.3 Realization of Dual-mode Switching 
Combination of the pH controlled cyclisation and the contrasting redox properties provided 
an opportunity to combine these two aspects to produce a 4-pole switchable organic 
system.  The phenanthridine-based TIP and AEP heterocycles form the reversible 
switching mode as the two forms are interchangeable and can be converted from one to the 
other under pH control.  These two forms can then also be further manipulated through 
exploitation of their redox potentials to convert them to their respective “pH-inert” forms, 
DIP and AEDP, which forms the irreversible switching mode or “locking” mechanism.  
Figure 32 shows how the 4 forms are connected within the switch. 
 
 
Figure 32.  Scheme showing the reversible pH switching and irreversible redox 
switching modes. 
 
Since the DIP and AEDP forms are inert to pH with respect to the cyclisation, the 
reduction and oxidation steps can be seen to irreversibly lock the pH switching mechanism. 
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5.4 Operation of the Molecular Switch 
Although synthetic routes to each of the four switchable states were available a suitable 
method to identify each of the states and observe the switching mechanism in situ had to be 
devised.  All structural forms had very good chromophores and were therefore active to 
both UV absorption and fluorescence emission spectroscopy, the spectra for each of the 
four structural forms are shown in Figure 33. 
 
Figure 33.  UV absorption (top) and fluorescence emission (bottom) spectra for the 
isobutyl TIP (red), AEP (green), DIP (black) and AEDP (blue). 
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Both UV and fluorescence spectra appeared to give similar levels of structural distinction 
however a combination of UV and 1H NMR spectroscopy were chosen as the most 
appropriate analytical techniques for structural evaluation and performance evaluation.  A 
series of experiments were designed to demonstrate the behavior of the system in solution 
using these techniques.  Due to the contrasting properties of the key switchable states, the 
TIP (neutral, hydride donor) and the AEP (positive charge, hydride acceptor) the system 
behaved very differently when in monophasic and biphasic conditions. 
 
When pH controlled switching was attempted in monophasic conditions the system was 
susceptible to the intermolecular hydride transfer, forming the “pH inert” DIP and AEDP 
forms and terminating the reversible switching (See section 4.3).  However the cyclisation 
process could be carried out under monophasic conditions by using a pH swing,165,166 since 
the proton transfer and cyclisation processes are faster than the hydride transfer when the 
proton availability is at either extreme.  The TIP and AEP can therefore interconvert rather 
than disproportionate to DIP and AEDP.  This was demonstrated using a 1H-NMR 
spectroscopy experiment where an excess of triethylamine (~12 eq) was added to a 
solution of AEP in D6-DMSO (Figure 34).   
 
The fast addition of a large excess of triethylamine causes a pH jump to highly basic levels 
thus rapidly reducing the availability of protons in solution and increasing the rate of 
conversion of AEP to TIP.  The increased rate of deprotonation and cyclisation with 
respect to the hydride transfer means the AEP can be rapidly and quantitatively converted 
to the TIP as the length of time both forms remain in solution is no longer sufficient to 
allow hydride transfer to occur.  Although this demonstrates that the reversible cyclisation 
step can occur in a single phase it was deemed to be inappropriate for repeated switching 
as it would be highly inefficient with respect to acid and base consumption and decreased 
analytical sensitivity through dilution.  It was thought that a biphasic system would be a 
more robust technique for achieving repeatable “clean” switching. 
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Figure 34.  1H NMR Spectra showing AEP-TIP cyclisation in monophasic DMSO via 
rapid pH swing.  
 
 
When a biphasic solution of isobutyl-AEP in D2O and CDCl3 was incrementally made 
more basic with sodium carbonate additions, the cyclisation to isobutyl-TIP and phase 
transfer could be observed by monitoring both phases with 1H NMR spectroscopy.  The 
series of spectra showed a gradual growth of the isobutyl-TIP peaks in the chloroform 
phase, using cyclohexane as an internal reference (Figure 35).  After basification (pH >12) 
of the aqueous phase no AEP could be detected in the D2O phase.  Conversely gradual 
reduction of isobutyl-TIP peaks with respect to cyclohexane in the chloroform phase was 
observed upon acidification with DCl.  Clean spectra of the isobutyl-AEP were obtained 
for the D2O phase both before and after the reaction.  The deprotonation, cyclisation and 
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phase transfer process was faster than could be observed on the NMR timescale therefore 
conversion essentially occurred instantly upon addition of acid or base.   
 
 
Figure 35.  Series of 1H NMR spectra showing increasing and decreasing TIP peaks 
with respect to cyclohexane during basification and acidification steps respectively. 
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Repetition of the cyclisation and phase transfer under biphasic conditions was also 
followed over a number of cycles using UV spectroscopy (Figure 36).  The isobutyl-AEP 
showed absorbance maxima at 366 nm and 324 nm and the isobutyl-TIP showed an 
absorbance maximum at 348 nm.  As each form was only soluble in one of the two phases 
i.e. TIP in the organic phase and AEP in the aqueous phase this allowed both structural and 
quantitative information to be obtained for each phase.  The pH of a biphasic solution of 
isobutyl-AEP was repeatedly switched from ~3 to ~9 over a total number of three cycles 
and UV spectra were recorded for each phase throughout.  The absorbance at the selected 
absorbance maxima for each phase can be seen to switch from high to low inversely as pH 
is altered:  When the pH is low the absorbance of the aqueous phase at 324 nm is at its 
highest, whereas the absorbance of the organic phase is effectively zero as the molecule 
exists completely in the open AEP form.  When the pH is high the absorbance of the 
organic phase at 348 nm is at its highest and the absorbance of the aqueous phase is 
effectively zero as the molecule exists completely in the closed TIP form.  It can be seen 
quite clearly from these experiments that the cyclisation and phase transfer process is rapid 
and essentially quantitative and repeatable without any significant loss of activity. 
 
Figure 36.  Absorption spectra of DCM and aqueous phases at varying  pH:  (i) AEP 
in aqueous phase, pH ~3, blue curve; (ii) Blank DCM phase, pH ~3, red curve; (iii) 
Blank aqueous phase, pH ~9, green curve; (iv) TIP in DCM phase, pH ~9, orange 
curve.  Inset top:  Absorbance changes of aqueous phase at 324 nm.  Inset bottom:  
Absorbance changes of DCM phase at 348 nm. 
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The complimentary redox activity of the interchangeable forms is what allows for the 
selective 'locking' of the system in its open or closed state by reduction or oxidation.  A set 
of similar biphasic experiments monitored by UV and 1H-NMR spectroscopy were 
therefore used to demonstrate the operation of these processes.  When an excess of NaBH4 
was added to a biphasic solution of isobutyl-AEP the complete conversion and phase 
transfer to a new product with an absorbance maxima at 357 nm was observed using UV 
spectroscopy (Figure 37).   
 
 
 
Figure 37.  UV spectra of aqueous (top) and DCM (bottom) phases during reduction 
of AEP to AEDP under biphasic conditions. 
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By comparison of the black and red curves, the reduction and phase transfer was shown to 
be equally as efficient as the reversible pH step.  The final acidification step (blue curves) 
shows inhibition of the cyclisation as the AEP is not reformed, a new absorbance is seen 
due to protonation of the reduced ring-open AEDP form.  With the chromophores of the 
TIP and AEDP being so similar, the absorbance maxima of each are very close, (348 nm 
and 357 nm, respectively), distinction by UV spectroscopy alone was a little ambiguous.  
The DCM layer was therefore concentrated under vacuum to isolate the crude reduction 
product for analysis by 1H NMR spectroscopy (Figure 38).  The spectra of AEDP and TIP 
are very different, the AEDP spectrum contains a characteristic methylene singlet at 4.3 
ppm and the TIP contains an α-proton singlet at 4.8 ppm.  The reduction product could 
therefore be unambiguously identified as the isobutyl-AEDP. 
 
 
Figure 38.  1H NMR spectra of the crude reduction product, AEDP. 
 
When bromine was added to a biphasic solution of isobutyl-TIP the oxidation to isobutyl-
DIP could be seen by the appearance of the new absorbance maxima at 380 nm, 361 nm & 
347 nm in the UV spectrum (Figure 39).   
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Figure 39.  UV spectra of DCM phase during bromine oxidation of TIP to DIP under 
biphasic conditions. 
 
The initial TIP solution formed in the presence of TEA base and addition of bromine water 
resulted in oxidation to the DIP.  Note that the DIP product is not transferred from the 
organic phase and the initial absorbance is suppressed by the basic conditions.  Decreasing 
the pH after oxidation did not yield the UV absorption bands correlating to AEP, again 
demonstrating that the reversible cyclisation process had been inhibited.  The changes in 
the UV spectrum upon re-acidification after oxidation can be explained by protonation 
reducing any suppression of the DIP absorbance through pseudo-base formation. The UV 
spectrum of the DIP form is very distinctive and completely different to the spectra of any 
of the other states, however the same reaction was analysed by 1H NMR spectroscopy for 
clarity and completeness (Figure 40).  The characteristic ring triplets at 5.01 ppm and 4.64 
ppm in the 1H NMR spectrum unambiguously identified isobutyl-DIP as the sole oxidation 
product. 
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Figure 40.  1H NMR spectrum of the oxidation product, DIP, in the CDCl3 phase after 
addition of Br2 to a biphasic solution of TIP in CDCl3/D2O. 
 
The cyclisation process in this heterocyclic molecular system has been shown to operate 
reversibly in both monophasic and biphasic conditions using pH control and reduction and 
oxidation can be used to irreversibly inhibit this process. The preferred use of biphasic 
conditions allows clean reversible operation of the pH modulated cyclisation and repetition 
over a number of cycles.  The selective “locking” oxidation and reduction steps of the TIP 
and AEP forms are also equally efficient and conversion to the “pH-inert” DIP and AEDP 
forms is quantitative.  This combination of two separate control parameters creates a 
switchable system with a gated response, where one parameter controls the other, thus 
allowing for read-write and read only behavior, which is particularly interesting for 
application in molecular data storage devices.  Although the biphasic solution based 
methodologies used here demonstrates the dual functionality of this system very well, it is 
unlikely that any “real” molecular devices will incorporate such a feature.  It was therefore 
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proposed to isolate the switchable substrates on solid surfaces with the aim of enhancing 
performance and creating a more applicable device.  
 
5.5 Amine Derivatisation for Surface Tethered Devices 
The synthetic methodologies for DIPs, TIPs and AEPs are not without limitation but on a 
whole are complimentary and generally applicable for the derivatisation of almost any 
primary amine.  The possibility of creating a framework with an added functionality 
required for surface adsorption was therefore a fairly trivial task.  As one the most 
interesting characteristics of the switchable frameworks are their interesting 
electrochemical properties, gold was chosen as an appropriate substrate because it would 
allow both structural characterisation and electrochemical information to be obtained via 
AFM (atomic force microscopy), whilst also offering simple methods for substrate 
derivatisation.  The target compound was therefore required to incorporate an amine 
functionality compatible with the synthetic methodologies for the introduction of the 
switchable heterocycles, and a thiol/disulfide functionality for surface adsorption.  Due to 
the nucleophilicity of the thiol functionality, simple amino thiol compounds would not be 
able to be directly reacted with the BEP framework as competition between the 
nucleophilic nitrogen and sulfur centres would lead to a mixture of products.  Protection of 
the amino thiol in the form of a disulfide proved to be a successful strategy in the past to 
generate sulfur-DIP analogues and so was adapted for the synthesis of the other 
heterocyclic forms.  Aryl disulfides are easily adsorbed on gold substrates with similar 
adsorption behaviour to aryl thiols so disulfide-DIP analogues should still form SAMs.167  
The commercially available 4-aminophenyl disulfide was reacted with BEP to synthesise 
AEDP, AEP, TIP and DIP analogues 15-18.  Lipoic acid is widely applied as a gold 
substrate linker and so was also used to synthesise derivatives 21 and 22 (Scheme 25). 
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Scheme 25.  Synthesis of phenanthridine based disulfide conjugates. 
 
Attempts to adsorb DIP 18 onto the gold substrates were unsuccessful.  The gold substrates 
were pre-washed (sonicated in isopropanol, then acetone, then CHCl3) then immersed in 
1.0 mM solutions of the sample DIP 18 in CHCl3 (~6 mg in 10 mL) for 12-24h.  The 
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substrates were removed and rinsed thoroughly with CHCl3 then EtOH before drying under 
a flow of nitrogen.  There was no evidence of adsorption even for samples that were 
immersed for up to 5 days.  The immersed substrates were characterized by CV and IR and 
the results obtained were identical to the blank reference substrate.  Attempts to adsorb 
structures 15, 16 and 17 using the same method also failed to yield any derivatised 
substrates.  The reasons for the lack of adsorption of samples of 15-18 could be due to the 
relatively short distance between the bulky heterocycles and the gold substrate.  When you 
consider the adsorption mechanism of disulfides there first has to be an association of the 
disulfide with the gold substrate before the thiolate link can form, this association may be 
severely hindered by the large heterocyclic systems of structures 15-18.  For samples 16 
and 18 there would also be electrostatic repulsion between the positive charges of the 
heterocycles and the positively charged gold substrate.   
 
Interestingly the solution electrochemistry of the DIP disulfide derivative 18 was quite 
different to that of the isobutyl-DIP.  Compound 18 shows non-reversible redox properties 
as shown in the CV diagram in Figure 41.  The first reduction occurred at -0.835 V and the 
second at -1.44 V.  The first reduction peak can be assigned to the disulfide reduction and 
the second reduction peak is likely to be the DIP – TIP reduction.  The irreversible nature 
of the reduction waves is due to dissociation of S-S bond resulting in deposition on the Pt 
electrode.  
-2.0 -1.5 -1.0 -0.5 0.0
V
-1.44 V
-0.835 V
 
Figure 41.  CV of DIP disulfide 18; Pt working electrode in MeCN with TBABr and 
Ag/AgCl reference electrode. 
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Electrochemical deposition of compound 18 was also attempted but no derivatised 
substrate was obtained via this method either. 
 
The synthesis of lipoic acid derivatives 21 and 22 should have been able to overcome the 
issues of surface adsorption by providing enough distance and flexibility between the 
substrate and the heterocycles via the alkyl spacer.  Unfortunately this line of investigation 
was abandoned before the adsorption of these derivatives could be tested.  It was realized 
that the gold-thiolate link and the conditions used for monolayer switching were unlikely 
to be compatible (Scheme 26). 
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Scheme 26.  Scheme showing incompatibilities between the thiolate link and the 
switching conditions.   
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For operation of the switch the derivatised substrates would have to be exposed to a range 
of oxidative, reductive, acidic, and basic conditions to enable switching between the four 
heterocyclic forms.  Since thiolate-gold SAMs can be cleaved by reductive, oxidative, and 
basic conditions168-171 it was thought that the monolayers would be destroyed during the 
switching processes.  This would ultimately render the system useless even if adsorption 
was possible since the derivatised substrate would not be stable during repeated switching.  
A more robust substrate and linker would therefore need to be used in order to investigate 
the behaviour of the switch immobilized on a surface.  Alkyl silicates are possibly the most 
appropriate alternative however electrochemical data for these systems could be difficult to 
obtain.   
 
6 TIP/AEP/DIP BIOACTIVITY COMPARISON 
6.1 pH Controlled Selectivity of AEP/TIPs 
As mentioned previously a major drawback with the DIP framework was their low 
therapeutic indices caused by non-selective toxic effects they exhibit in non-cancerous 
cells (see section 2.4.1).  A number of mechanisms for targeting cancer cells have been 
investigated to create chemotherapeutic agents with increased selectivity, such as 
biomimics, viral conjugates, and antibody conjugates.102  Cancer tissues have been shown 
to have a lower pH compared to regular healthy tissue due to higher quantities of lactic 
acid produced by the increased levels of glycolytic respiration.172  It was proposed that the 
reversibility of the TIP/AEP cyclisation could take advantage of this characteristic to create 
a pH sensitive system with increased cancer selectivity.  The TIP/AEP equilibrium is pH 
dependent and will therefore express each form as a function of pH, AEP will be favoured 
at lower pH and TIP will be favoured at higher pH.  The planar cationic AEP form should 
be more active than the non-planar neutral TIP which should then lead to increased 
cytotoxicity in cancer cells and reduced cytotoxicity in normal cells (Figure 42). 
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Figure 42.  Proposed cytotoxic effects of TIP/AEPs in normal cells (green) and cancer 
cells (pink). 
 
The TIP form is a neutral, non-planar heterocycle making it a very poor candidate for a 
DNA binder since the majority of attributes required for DNA affinity have been removed.  
The lack of positive charge means there will be no electrostatic interactions with the 
negatively charged DNA phosphate backbone and the loss of aromaticity from the ring 
system reduces planarity and pi-character and therefore reduces DNA intercalation.  The 
only mode of activity that could possibly remain would be via minor groove DNA binding.  
Non-specific membrane insertion would also be lessened as the TIP framework is not 
amphiphilic.  In contrast the AEP form is a cationic, planar aromatic heterocycle making it 
a very good candidate for a DNA binder.  The high positive charge means there will be 
strong electrostatic interactions with the negatively charged DNA phosphate backbone, the 
flat aromatic ring system should intercalate between the DNA base pairs, and minor groove 
binding by the amine side-chain will also be possible.  The amphiphilicity of AEPs 
containing long alkyl chains could also increase apoptosis in cancer cells via membrane 
insertion and osmotic bursting.126  The application of this system should ultimately lead to 
an increase in cancer cell termination and reduced cytotoxic effects in normal cells. 
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6.2 AEP/TIP/DIP Comparison Library 
In order to test the pH selectivity hypothesis, firstly a library of compounds had to be 
synthesised and secondly a method of detecting their efficacy had to be developed.  A large 
library of DIP substrates already exists for which their in vitro cytotoxicity was measured 
using an MTT-dye-based microtitration assay.124,125 A similar strategy was therefore 
selected for this work, where a comparative library of compounds would be synthesised 
and sent for activity screening using a high throughput MTT assay.  Once the initial 
efficacy levels for the compounds were confirmed the pH dependency of the DNA binding 
and cytotoxicity could then be investigated.   
 
The general TIP synthesis methodology (see section 4.2) was used to expand the selection 
of TIP frameworks using a range of structurally diverse aromatic amines.  The AEP 
analogues had never before been synthesised from primary amines so a new methodology 
had to be developed for the synthesis of this section of the library.  The DIP analogues had 
mostly been synthesised and tested prior to this study so comparative data could be easily 
sourced, and for those that had not there were numerous methodologies reported that could 
be followed in order to produce the desired DIPs.127,129 
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Scheme 27.  Mechanism of AEP formation from BEP plus a primary amine. 
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The AEP frameworks were generated from the same BEP and primary amine starting 
materials as the TIPs and DIPs so there is therefore significant mechanistic overlap.  The 
initial α-addition and cyclisation steps are identical, however rather than isolation (TIPs) or 
oxidation (DIPs), a final protonation and ring opening step results in formation of the AEP 
structure (Scheme 27). 
Due to these similarities the synthetic methodologies were equally dependent upon the 
nature of the amine side-chain.  For aliphatic amines a biphasic solvent system was 
employed for the amine addition and cyclisation steps and the protonation and ring-
opening steps.  For aromatic amines the TIP first had to be isolated and a monophasic 
acidification procedure could then be used for the protonation and ring opening steps.   
Biphasic methodology for aliphatic AEPs:  A solution of the aliphatic amine in a 
5%Na2CO3 (aq) solution was added to a suspension of the BEP starting material in DCM 
and the reaction stirred under nitrogen.  This allowed for the α-addition step to occur in the 
aqueous phase and subsequently transfer the α-adduct to the organic phase where 
cyclisation would provide the TIP intermediate.  Separation of the phases then allowed for 
a solution of the TIP intermediate to be obtained.  Extraction of the organic phase with 
aqueous acid resulted in protonation, ring-opening and phase transfer of the AEP target to 
the aqueous phase.  The acidic aqueous solution of the AEP could then be concentrated 
under vacuum and precipitated with acetone/EtOAc to yield the AEP dihalide salts.   
 
2-step monophasic methodology for aromatic AEPs:  The TIP intermediates were 
generated using the general methodology developed previously (see section 4.2).  An 
additional methanol trituration was carried out to ensure complete removal of the TEA and 
its hydrobromide salts as they would be difficult to remove from the AEP product salt.  A 
suspension of the TIP intermediate in methanol could then be acidified with concentrated 
acid to provide a solution of the AEP target.  The AEP solution could then be concentrated 
and the product precipitated by addition of acetone.  Both methodologies resulted in the 
isolation of very pure AEP salt products, however the biphasic methodology tended to 
result in slightly higher yields.  This was due to the TIP intermediate not requiring isolation 
and purification in this method. 
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With methods in hand to generate each of the three frameworks to be compared, a small 
library of compounds was synthesised and screened for cytotoxicity in a selection of 
cancer cell lines (Table 2).  The cytotoxicity measurements were carried out by Dr. Jane 
Plumb at the Cancer Research UK, Beatson Laboratories in Glasgow. 
 
Table 2.  TIP/AEP/DIP structures and corresponding IC50 and RF values calculated 
from MTT assay of A2780, A2780/cp70 and MCP1 cell lines. 
IC50 (µM) RF  
Structure A2780 A2780/cp70 MCP1 CP70/
A2780 
MCP1/
A2780 
Cl
Pt
Cl
H2N NH2
Cisplatin
 
0.12 ± 0.04 2.04 ± 0.23 0.47 ± 0.05 16.7 3.9 
NBr N
11r
 
4.91 ± 0.52 10.3 ± 0.6 3.97 ± 0.18 2.1 0.8 
NMeO N
11h
 
1.74 ± 0.54 2.57 ± 0.40 1.05 ± 0.04 1.5 0.6 
NMeO
MeO
N
11i
 
84.3 ± 5.1 28.1 ± 1.9 57.9 ± 1.4 0.3 0.7 
N
MeO
N
11y
 
1.78 ± 0.12 5.93 ± 0.66 5.19 ± 3.30 3.3 2.9 
NMeO2C N
11s
 
19.6 ± 0.1 35.6 ± 4.3 12.0 ± 0.8 1.8 0.6 
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N
F3C
N
11p
 
19.4 ± 0.5 33.3 ± 5.3 12.5 ± 0.7 1.7 0.6 
F N N
11n
 
12.35 ± 1.03 22.45 ± 1.13 14.73 ± 
1.37 
1.8 1.2 
N N
11k
 
5.63 ± 0.99 2.48 ± 0.17 3.06 ± 0.50 0.4 0.5 
N
F
N
11m
 
16.90 ± 1.83 24.30 ± 4.07 13.59 ± 
1.23 
1.4 0.8 
N N N
11g
 
8.45 ± 0.78 4.85 ± 0.53 6.26 ± 0.99 0.6 0.7 
N
F
F
N
11t
 
15.57 ± 1.31 25.83 ± 3.80 16.39 ± 
1.42 
1.7 1.1 
Cl
F N
N
11z
 
10.50 ± 0.69 18.65 ± 1.42 7.66 ± 0.82 1.8 0.8 
N N
NC
11a'
 
21.31 ± 2.24 18.62 ± 2.31 17.78 ± 
0.61 
0.9 0.8 
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NN
11j
 
11.56 ± 1.29 13.26 ± 2.27 14.14 ± 
2.22 
1.2 1.2 
NH2
N Cl
Cl
13b
 
10.26 ± 1.38 7.24 ± 0.97 9.86 ± 0.75 0.7 1.0 
NH2
N
Cl
Cl
13j
 
19.15 ± 0.63 22.90 ± 2.62 19.12 ± 
0.98 
1.2 1.0 
NH2
N
Cl
Cl
13b'
 
17.93 ± 0.61 8.73 ± 1.18 9.54 ± 1.51 0.5 0.5 
NH2
N
Cl
Cl
13a
 
7.01 ± 0.50 7.12 ± 1.05 2.98 ± 0.06 1.0 0.4 
NH2
N
Cl
Cl
13c
 
7.87 ± 1.06 9.22 ± 1.55 5.12 ± 0.02 1.2 0.7 
NH2
N
Cl
Cl
13c'
 
12.09 ± 1.63 11.44 ± 2.20 6.17 ± 0.56 1.0 0.5 
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NH2
N
Cl
Cl
13d'
 
12.02 ± 2.66 2.61 ± 0.37 4.84 ± 0.22 0.2 0.4 
NH2
N
Cl
Cl
13e'
 
9.71 ± 1.00 1.97 ± 0.24
 
2.66 ± 0.23 0.2 0.3 
NH2
N
Cl
Cl
13j'
 
2.27 ± 0.17 0.57 ± 0.11 0.41 ± 0.11 0.3 0.2 
NH2
N
Cl
Cl
MeO
13h
 
9.18 ± 1.51 6.19 ± 0.47 5.16 ± 0.54 0.7 0.6 
NH2
N
Cl
Cl
13k
 
19.74 ± 0.25 12.12 ± 0.37 11.20 ± 
2.42 
0.6 0.6 
NH2
N
Cl
Cl
F
13n
 
21.13 ± 0.57 33.51 ± 3.03 19.60 ± 
1.10 
1.6 0.9 
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NH2
N
Cl
ClF3C
13p
 
18.67 ± 0.21 25.79 ± 3.07 10.14 ± 
0.47 
1.4 0.5 
NH2
N
Cl
Cl
F
F
13t
 
19.56 ± 0.50 23.64 ± 2.73 14.33 ± 
1.03 
1.2 0.7 
NH2
N
Cl
Cl
MeO
MeO
13i
 
99.17 ± 2.05 103.77 ± 
1.83 
66.11 ± 
3.38
 
1.1 0.7 
NN
Br
12j
 
0.73 ± 0.17 1.81 ± 0.11 1.22 ± 0.20 2.5 1.7 
NN
Br
F
12n
 
2.56 ± 0.56 3.12 ± 0.13 3.89 ± 0.77 1.2 1.5 
NN
Br
F3C
12p
 
22.31 ± 1.38 7.31 ± 0.91 15.26 ± 
2.00 
0.3 0.7 
NN
Br
F
12t
F
 
2.01 ± 1.29 3.45 ± 0.37 4.46 ± 0.82
 
1.7 2.2 
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NN
Br
MeO
MeO
12i
 
1.56 ± 0.06 3.63 ± 0.63 2.98 ± 0.39 2.3 1.9 
NN
Br
12a
 
0.84 ± 0.11 2.44 ± 0.03 2.38 ± 0.24 2.9 2.8 
NN
Br
12b'
 
1.26 ± 0.18 1.46 ± 0.14 5.07 ± 0.90 1.2 4.0 
NNHO
Br
12f'
 
3.85 ± 0.15 2.75 ± 0.13 9.65 ± 0.76 0.7 2.5 
NN
MeO2C
Br
12g'
 
12.91 ± 5.13 13.99 ± 1.07 30.90 ± 
2.32 
1.1 2.4 
NN
HO2C
Br
12h'
 
1.55 ± 0.51 8.94 ± 1.98 26.16 ± 
7.68 
5.8 16.9 
NN
HO
Br
12i'
 
0.610 ± 
0.099 
0.498 ± 
0.104 
0.801 ± 
0.090 
0.8 1.3 
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6.3 MTT Dye-based Microtitration Assay Results 
The cell lines that were screened were the human ovarian cancer cell line, A2780, and two 
cisplatin resistant derivatives, A2780/cp70 and MCP1.173  Cell line A2780 contains a 
functioning hMLH1 gene whilst the resistant cell lines do not.  This loss of gene function 
in the resistant cell lines is due to hypermethylation of the hMLH1 promoter, which results 
in the loss of expression of the MLH1 component of the DNA mismatch repair pathway.  
Lack of MLH1 expression has been shown to be related to cisplatin resistance in these cell 
lines,174,175 which is a major problem since cisplatin is a major chemotherapeutic for the 
treatment of ovarian cancers.176 
 
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) is a water soluble, 
yellow coloured dye which can be converted to a dark-blue coloured formazan by 
metabolically active cells.  This metabolism can be exploited to rapidly determine the 
quantity of viable living cells after treatment with the target compounds.  The colour of the 
individual wells in the plates corresponds to the conversion of the MTT, which is directly 
related to the number of living cells within the well.  Therefore an indirect relationship 
between the measured colour change and drug efficacy can be formed.  The assay 
technique was first developed in 1983177 and is the same assay used to determine the 
cytotoxicity of the library DIP compounds previously developed within the Cronin 
group.124,125,178  The cytotoxicity measurements were carried out by Dr. Jane Plumb at the 
Cancer Research UK Beatson Laboratories in Glasgow.  The test results shown in Table 2 
give the IC50 values, defined as the concentration of drug required to kill 50% of the cells; 
and the RF values, calculated by dividing the IC50 value for a given drug for the cisplatin 
resistant cell lines by that obtained for the cisplatin sensitive A2780 cell line. 
 
The library of compounds was designed not only to give information on the general 
cytotoxicity trends of the AEP and TIP forms but also to allow direct comparisons to be 
drawn between these structures and the DIPs.  The library was designed with this in mind 
so there is a large amount of structural overlap between the three compound families with 
respect to the amine side-chains.  Table 3 and the related plots (Figure 43, 44 and 45) show 
the reformatted assay results as a function of the amine side-chain and highlight the 
correlations between the three forms for each cell line. 
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Table 3.  Reformatted MTT assay results for DIP/AEP/TIP comparison 
Amine Side-Chain DIP   IC50 (µM) 
A2780 
A2780/cp70 
MCP1 
AEP  IC50 (µM) 
A2780 
A2780/cp70 
MCP1 
TIP  IC50 (µM) 
A2780 
A2780/cp70 
MCP1 
Methyl 1.26 
1.46 
5.07 
17.93 
8.73 
9.54 
NA (not available) 
Cyclohexyl 0.84 
2.44 
2.38 
7.01 
7.12 
2.98 
NA 
Cyclopentyl 4.63 
6.27 
5.66 
7.87 
9.22 
5.12 
NA 
Cycloheptyl 3.01 
4.59 
3.03 
12.09 
11.44 
6.17 
NA 
n-butyl NA 12.02 
2.61 
4.84 
NA 
Nonyl 0.27 
0.30 
0.47 
9.71 
1.97 
2.66 
NA 
Dodecyl 0.087 
0.052 
0.050 
2.27 
0.57 
0.41 
NA 
Isobutyl 5.12 
5.98 
4.26 
10.26 
7.24 
9.86 
NA 
4-Methoxyphenyl 1.45 
1.10 
0.50 
9.18 
6.19 
5.16 
1.74 
2.57 
1.05 
3,5-Dimethylphenyl NA 19.74 5.63 
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12.12 
11.20 
2.48 
3.06 
4-Fluorophenyl 2.56 
3.12 
3.89 
21.13 
33.51 
19.60 
12.35 
22.45 
14.73 
3-(trifluoromethyl)- 
phenyl 
22.31 
7.31 
15.26 
18.67 
25.79 
10.14 
19.4 
33.3 
12.5 
3,4-Difluorophenyl 2.01 
3.45 
4.46 
19.56 
23.64 
14.33 
15.57 
25.83 
16.39 
3,4-Dimethoxyphenyl 1.56 
3.63 
2.98 
99.17 
103.77 
66.11 
84.3 
28.1 
57.9 
Phenyl 0.73 
1.81 
1.22 
19.15 
22.90 
19.12 
11.56 
13.26 
14.14 
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Figure 43.  Plot of IC50 values for the DIP, AEP and TIP forms in cell line A2780 
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Figure 44.  Plot of IC50 values for the DIP, AEP and TIP forms in cell line 
A2780/CP70 
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MCP1 IC50s
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Figure 45.  Plot of IC50 values for the DIP, AEP and TIP forms in cell line MCP1 
 
At this point it should be noted that data for TIP structures with aliphatic side-chains are 
unavailable due to the lack of stability of these heterocycles (see section 4.1) however a 
number of correlations can be seen to exist from analysis of the data obtained.  Firstly it is 
evident that there is a general trend exhibited in all three cell lines when the three 
heterocycle forms are directly compared for each respective amine, activity is highest in 
the DIPs and the TIPs and AEPs have comparatively lower activity.  This result was very 
surprising since the AEP form was expected to have greater activity than the TIPs.  The 
TIP structures themselves are unlikely to possess high DNA affinity for reasons discussed 
previously therefore their activity is likely to come from a transformation to a more active 
form either in the cell medium or within the cell itself.  As the cell medium is buffered to 
pH 7.4, conversion of the TIP to AEP is possible and could result in the observed activity.  
For drug samples with low aqueous solubility, such as the TIPs, DMSO is often used to 
solvate the drug before addition to the sample wells.  There is precedent for the oxidation 
of TIPs to DIPs in the presence of DMSO as the oxidant therefore these oxidative 
conditions could result in oxidation of the TIP to DIP which could also be responsible for 
the higher activity than expected.  As the IC50 values for the TIPs correlated more closely 
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with the AEPs than the DIPs it was proposed that the active species for the TIP compounds 
was more likely to be the AEP form rather than the DIP form.  Linear regression plots of 
the results agreed with this hypothesis (Figure 46, 47 and 48). 
 
 
Figure 46.  Regression plots of IC50 Values for A2780 Cell Line. 
 
The R2 value for linear regression is very good for the AEP vs TIP plot but not for the DIP 
vs TIP or DIP vs AEP plots.  This indicates that the activities for the AEPs and TIPs are 
related to each other but not to the DIP activities. 
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Figure 47.  Regression plots of IC50 Values for A2780/CP70 Cell Line. 
 
For the A2780/CP70 cell lines the regression plots again showed possible related activity 
between AEPs and TIPs but also showed a possible activity relationship between the DIPs 
and the TIPs. 
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Figure 48.  Regression plots of IC50 Values for MCP1 Cell Line. 
 
For the MCP1 cell lines the linear regression plots are again consistent with activity 
relationships between the TIPs and AEPs only.  Taking into consideration the patterns 
observed in all the data plots, coupled with the small size of the data sets, no conclusions 
can be drawn with absolute confidence.  However there does appear to be a relationship 
between the TIP and AEP activities that warrants further investigation.  Although the 
general activity of the TIP/AEP compounds appears to be lower than the DIPs the 
observation of a relationship between the activity of the AEP and TIP forms is far more 
important in proving the original pH dependence hypothesis.  If the results are related, then 
administering compounds to the cancer cell lines in either the AEP or TIP form leads to in 
vitro conversion to the same form, if the compounds interconvert in a similar fashion in 
vivo then the TIP form should predominate in normal tissues, whilst the AEP form should 
predominate in the cancerous tissues.  As a result of this interconversion, a significant 
increase in the TI’s could be achieved.  
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Another trend familiar to the data sets is that in all three cell lines, all compounds appear to 
react uniformly to changes in the amino side-chain (Figure 43, 44 and 45).  Linear aliphatic 
side-chains offer the highest activities and cyclic aliphatic and substituted aromatic side-
chains have the lowest activities.  This data agrees with the hypothesis of the dual mode 
binding previously presented for SAR studies of DIP compounds.122,125,129  The 
polyaromatic framework intercalates between the DNA base-pairs to give the initial 
binding mode and the amino side-chain then offers further attractions via groove binding.  
Evidence from this previous work by the Cronin group suggests that increasing the minor 
groove binding ability of the side-chain results in an increase in cytotoxicity, however, it 
should be noted that increases in DNA binding does not always translate to increased 
cytotoxicity.179  The nature of the side-chain is therefore responsible for tuning the binding 
strength and subsequent cytotoxicity of such compounds.  The linear aliphatic side-chains 
can easily insert into the minor groove of the DNA structure, displacing the ordered water 
and entropically increasing the net binding energies for such compounds.  Cyclic aliphatic 
and aromatic side-chains are more rigid and are therefore less able to conform to the minor 
groove of the DNA and therefore have a reduced biding energy which results in the lower 
activities observed.     
 
The final trend observed was related to the RF values.  The RF values compare the 
sensitivities of the Cisplatin resistant lines, A2780/CP70 and MCP1, with that of the 
parental A2780 cell line.  RF values for Cisplatin are 16.7 and 3.9 for the CP70 and MCP1 
cell lines respectively, evidently showing a decrease in activity due to resistance.  An RF 
value of  > 1 means that a compound shows cross resistance with cisplatin i.e. whatever 
makes the cells resistant to platinum also makes them resistant that compound.  These 
compounds would therefore not be very interesting as potential treatments for cancer.  
DIPs were reported to have general RF values of < 1 which made them highly attractive 
targets for new anti-cancer therapies.124,125  Compounds that give an RF value of < 1 are of 
interest since they avoid the resistance mechanism for platinum drugs.  Also if the RF 
is very low (< 0.5) it means that the compound is significantly more active in the Cisplatin 
resistant cells than in the parental lines and there is a possibility that it has even targeted 
something present in the resistant cell line that is not present in the parental line.  
Compounds with low RF’s could potentially lead to new chemotherapeutic agents that 
could be used in conjunction with current treatments and allow chemotherapy to continue 
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when cisplatin resistance develops.  The plots of the RF ratios for the AEP, TIP and DIP 
frameworks with respect to the amino side-chain functionality are shown in Figure 49. 
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Figure 49.  Plot of cp70/A2780 RF ratios (top) and MCP1/A2780 RF ratios (bottom) 
for AEP, TIP and DIP frameworks as a function of the amino side-chain. 
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From the RF plots it can be seen that the AEPs and TIPs match, if not slightly better, the 
DIP compounds with respect to their RF values.  For the CP70 data range, the average RF 
values are 1.2, 0.8 and 1.2 for the DIPs, AEPs and TIPs respectively; for the MCP1 data 
range, the average RF values are 1.4, 0.6 and 0.8 for the DIPs, AEPs and TIPs respectively.  
As mentioned previously this is a highly desirable property for new anti-cancer drug 
candidates as they are either unaffected by the same resistance mechanisms as cisplatin or 
are possibly even targeting the resistant strains.  The lack of susceptibility of these 
compounds can be explained by their different mode of action to cisplatin.  Cisplatin is a 
transition metal complex that works by covalently cross-linking DNA base pairs and 
distorting the DNA double helix, preventing replication.  The correlation between cisplatin 
resistance and the loss of MLH1 protein expression suggests the DNA mismatch repair 
system has a role in generating signals that contribute to the generation of apoptotic 
activity.180  The binding mode for AEP/TIPs is suggested to be through intercalation and 
minor groove binding.  However their mechanism for initiating apoptosis must not be 
associated with the mismatch repair proteins coded for by hMLH1 since they retain, or 
even increase, their activity in its absence.  The uniformly low RF values across the range 
for the TIPs and AEPs could prove to be very useful as major changes could be made to 
drug targets to increase their potency without affecting this desirable characteristic. 
 
The comparative cytotoxicity assay of AEP/TIPs/DIPs has yielded the following results:  
(i) IC50 values for the AEP/TIPs are in the µM concentration range, comparable to DIPs; 
(ii) The activities of AEPs and TIPs appear to be related, suggesting a common active 
species; (iii) Interconversion of AEPs and TIPs in vitro is thought to be the reason for this 
association in activity; (iv) RF values for AEP/TIPs are typically ≤ 1 and so are not 
susceptible to the same resistance mechanisms as cisplatin; (v) consequently the induction 
of cell death by AEP/TIPs is not dependent upon the mismatch repair function.  These 
initial observations for the AEP/TIP framework warrant further investigation of the system 
as a possible source of selective chemotherapeutics.  However since it is not possible to 
carry out pH variable assays, the only way to investigate the selectivity aspect would be in 
vivo assays.  The next stage for evaluation of compounds would therefore be human 
tumour xenografts in mice for further clinical development.  These tests provide much 
more data than the in vitro assays, such as compound stability and metabolism, 
bioavailability, tumour suppression, and therapeutic index.  A small selection of 
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compounds have been selected and will be screened for in vivo activity and selectivity 
using this assay. 
 
 
7 POLYOXOMETALATE ORGANIC HYBRIDS 
 
7.1 TRIS-base Phenanthridine Ligands 
Due to the electrochemical properties reported for many polyoxometalate structures181-184 
and the electrochemical properties observed for the phenanthridine based heterocycles 
discussed earlier it was thought that combination of the two could lead to materials with 
interesting new electrochemical properties.  Derivatization of TRIS-base with various 
organic functionalities and subsequent “grafting” onto POM structures has been used to 
successfully derivatize POM clusters.144,185  The synthetic strategy proposed for creating 
phenanthridine-POM conjugates therefore relied upon generation of a suitably 
functionalised TRIS-ligand. 
 
Since the TRIS-base contains a primary amine functionality, it was thought that reaction 
with BEP would yield a suitable phenanthridine-TRIS ligand that could then be “grafted” 
onto the POM cluster.  However no phenanthridine-based conjugates were obtained as 
there were incompatibility issues for all the synthetic strategies available for the reaction of 
TRIS-base with BEP (Scheme 28). 
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Scheme 28.  Proposed reactions of TRIS-base with BEP. 
 
(i) The monophasic DMF methodology for DIP synthesis involves the reaction of 1 eq of 
the amine with 1 eq of BEP to produce the TIP intermediate, a second equivalent of BEP is 
then consumed as the stoichiometric oxidant to yield the DIP product.  For large sterically 
hindered amines this oxidation process is inhibited and so the TIP intermediate cannot be 
converted to the DIP product; (ii) The biphasic Na2CO3/EtOAc methodology for DIP 
synthesis requires phase transfer of the intermediates to the organic phase after the α-
addition and cyclisation steps to produce an organic solution of the TIP.  The intermediates 
generated from TRIS-base addition are less hydrophobic due to the multiple hydroxyl 
groups and therefore do not transfer across the phase barrier during the reaction; (iii) The 
monophasic chloroform methodology for TIP synthesis requires the amine to be soluble in 
organic solvents, which TRIS-base is not.  Changing the solvent system to a polar protic 
solvent was not an option as this lead to the formation of pseudo-base by the addition of 
solvent to the phenanthridinium moiety.  The formation of the pseudo-base product was 
confirmed by a 1H NMR spectroscopy experiment:  TEA was added to a solution of BEP 
in CD3OD and the 1H NMR spectrum was obtained (Figure 50). 
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Figure 50.  1H NMR of methoxy-BEP pseudo-base product. 
 
The synthesis of a protected TRIS-base analogue was therefore proposed as an alternative 
amine substrate that could react cleanly with the BEP reagent and then be deprotected to 
produce the desired aromatic frameworks.   
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Scheme 29.  Synthesis of protected “TRIS-cage” and proposed reaction with BEP and 
aqueous acid deprotection.  
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The synthesis of the amino orthoacetate 24 is a reported procedure and should have been a 
simple 2-step synthesis, however the hydrogenation step was not as easy as expected.  The 
apparatus available for high pressure hydrogenations was an H-cube flow system so 
development of a new procedure that was compatible with this kit was initially 
investigated.  A range of parameters were investigated, specifically catalyst type, pressure, 
temperature, flow rate and reaction time, in an attempt to develop a compatible procedure 
however no amino orthoacetate 24 was ever synthesised.  Conversion of the nitro starting 
material 23 to the hydroxylamine intermediate was relatively successful and produced the 
hydroxylamine in reproducible yields of ~75%.  With the hydroxylamine in hand we 
decided to proceed and investigate the reaction of this compound with the BEP starting 
material, fortunately this reaction was successful and led to the synthesis of a new 
oxadiazinophenanthridine motif. 
 
The reaction of hydroxylamine 27 with BEP and TEA in DMSO led to the formation of the 
2-(1-methyl-2,6,7-trioxa-bicyclo[2.2.2]oct-4-yl)-3,4-dihydro-2H,12bH-1-oxa-2,4a-diaza-
triphenylene, 28 (Scheme 30). 
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Scheme 30.  Reaction of BEP with TRIS-cage hydroxylamine 25 and the subsequent 
ring-opening deprotection reaction. 
 
The structure of 28 was characterised by NMR, MS and IR spectroscopy and fortunately 
good quality single crystals allowed the structure to be unambiguously assigned using 
single crystal X-ray diffraction.   
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Figure 51.  Ball and stick graphical representation of phenthridino-oxadiazine 28. 
 
The six-membered oxadiazine ring can clearly be seen to distort the planarity of the 
system, similar to the TIPs, and although it is difficult to see from this figure, the angle 
between the C-N bond of the TRIS-cage sidechain and the plane of the phenanthridine ring 
system is almost 90°.  Isolation of this compound further demonstrated the high reactivity 
of the BEP and its ability to react with various nucleophiles to generate new heterocyclic 
frameworks.  In the past, BEP has been reacted with primary amines, secondary amines, 
thiols, and even carbon-based nucleophiles.186-188  Attempts were made to oxidise the 
oxadiazinophenanthridine using the standard conditions for TIP-DIP oxidations, however 
these were unsuccessful.  The exchange of the nitrogen at this crucial position appears to 
produce heterocycles without the same “hydride donor” properties as the TIPs.  
Dihydropyrrolophenanthridines, generated by  nucleophilic attack of BEP with carbon-
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based nucleophiles, are also unable to be oxidised under similar conditions.188   Although 
the oxadiazinophenanthridine framework does not appear to possess the same redox 
properties as the TIPs, related phenanthridinotriazine and oxadiazinophenanthridine 
frameworks have previously been reported to have high levels of fungicidal activity 
making this discovery even more exciting.189 The possibility of extending this 
methodology to other hydroxylamines will therefore be investigated as it could lead to the 
development of a new family of biologically active heterocycles and a facile route for their 
synthesis. 
 
Similar to the imidazo ring system of the TIP heterocycles the oxadiazine ring was 
susceptible to ring opening via protonation.  A two-step ring opening and deprotection of 
28 could therefore be carried out in a single reaction to afford the ring open analogue 29.  
This ligand contained the desired functionality we originally set out to achieve; a 
phenanthridine-based heterocycle for potential switching and electron transfer and a triol 
functionality for coordination to the POM metal salt.  Attempts to coordinate the ligand to 
a Mo6 metal salt to generate the derivatized Anderson cluster where however unsuccessful 
and no POM-ligand conjugates were obtained.  The high charge on the ligand was thought 
to be the main barrier for ligand coordination. 
  
Eventually a successful procedure for the problematic hydrogenation step (Scheme 29) was 
found (EtOAc, PtO2 cat., 7 bar, 24h, autoclave) so the original synthesis could be 
completed.  A 1H NMR experiment was used to screen the reaction of the amino 
orthoacetate 24 with BEP and TEA base with positive results.  The spectrum obtained 
(Figure 52) clearly shows the conversion of the BEP starting material to the TIP structure 
as expected.  However attempts were not made to isolate this product as the deprotected 
AEP derivative 26 would have very similar properties to compound 29 and so would also 
be unlikely to coordinate to the metal cluster to give the desired hybrid target.  Efforts were 
therefore shifted towards synthesising an aldehyde functionalised heterocycle and a neutral 
coordinating ligand.  
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Figure 52.  1H NMR of crude reaction mixture for the reaction of 24 (1eq) with BEP 
(1eq) and TEA (3eq). 
 
 
7.2 Phenanthridine Aldehyde Ligands 
Another route to inorganic-organic hybrid structures is available via combination of a 
POM cluster functionalised with a “free” TRIS ligand with an organic aldehyde using a 
Schiff base reaction.  This method has been used to create many hybrid structures of 
varying organic functionality.144,190  A synthetic route to DIP-aldehyde 32 was devised 
with the aim of conjugating it with a TRIS-POM cluster to give the desired hybrid target 
(Scheme 31).   
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Scheme 31.  Synthesis of organic-POM hybrid via Schiff base reaction of DIP-
aldehyde and TRIS-POM. 
 
The protected amine 30 was synthesised in house, in two steps, from commercially 
available p-nitrobenzaldehyde.  Reaction of the amine with BEP first afforded the acetal 
protected DIP 31 which could then be easily deprotected in aqueous acid to give the 
required DIP aldehyde 32.  However subsequent reaction of the DIP-aldehyde with the 
TRIS-Dawson TBA salt, [C4H8NO3P2W15V3O59][ C16H36N]5, did not undergo the desired 
Schiff base reaction.  Instead, when a solution of DIP aldehyde 32 (1eq) in MeCN was 
added to a solution of TRIS-Dawson TBA salt (1eq) in MeCN, a pale yellow precipitate 
formed upon mixing.  The precipitate was collected by filtration and dried under vacuum.  
The isolated product (compound 33) was insoluble in all regular stocked solvents except 
DMSO and DMF.  The product was able to be analysed by 1H NMR spectroscopy.  The 
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Spectrum obtained showed peaks for the DIP aldehyde and peaks correlating to the 
methylene and amino protons of the TRIS-Dawson (Figure 53). 
 
 
Figure 53.  1H NMR spectrum of TRIS-Dawson-DIP-aldehyde precipitate (33).  TRIS 
proton signals are highlighted in red. 
 
The ratio of the DIP signals to TRIS signals is 5:1 which correlates with the direct cation 
exchange of the TBA cations for the aldehyde-DIP.  As the product obtained was very 
poorly soluble the only characterisation obtained was the initial 1H NMR spectrum, 
attempts to recrystallise the material for single crystal XRD have as yet been unsuccessful.   
 
This result is in correspondence with other results obtained within the Cronin group where 
DIP cations have been combined with other POM systems to create self assembling 
microscale tubular structures via cation exchange.153,154  The reasons for the formation of 
these structures is dependent upon the low aqueous solubility of the inorganic-organic 
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hybrid material formed.  This property is not restricted to DIP cations, and microtubes have 
been grown by the exchange of other aromatic cations such as rhodamine.  This has 
inspired a new area of research for the group where investigations into the combination of 
POM clusters with aromatic cations of a more interesting nature are now underway. 
 
 
7.3 Neutral Phenanthridine Ligands 
With the competing cation exchange reaction preventing the possibility of the Schiff base 
reaction of the DIP-aldehyde it was thought that the design of a neutral phenanthridine-
aldehyde ligand would increase the probability of a successful combination with the POM 
cluster.  Investigations into creating such a compatible ligand began with the design of the 
phenanthridinone-aldehyde ligand 34 (Scheme 32). 
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Scheme 32.  Synthesis of phenanthridinone-aldehyde ligand. 
 
The phenanthridinone-aldehyde ligand can be isolated directly from the acetal-DIP 30 by 
stepwise hydrolysis of the DIP and the acetal, affording the required phenanthridinone 
aldehyde 34 in good yields.  Attempts to attach the ligand to both the TRIS-Dawson, 
[C4H8NO3P2W15V3O59][TBA]5, and bis-TRIS-Manganese Anderson, 
[MnMo6O24(C4H8N)2][TBA]3, are underway but have not yet yielded crystals.  Obtaining a 
material with the switchable and redox functionality of the AEP/TIP system is not possible 
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using this synthesis as the phenanthridinone moiety is not susceptible to cyclisation.  
However structures from combination of these ligands with POMs could lead to materials 
with interesting interactions within the crystal lattice due to the possibilities of H-bonding 
from the amine and carbonyl groups and pi-stacking of the phenanthridinone rings.  
 
 
Initial investigative studies have shown that the synthesis of an analogous reduced 
phenanthridine compound could also be a viable route to TIP-aldehyde ligands from DIP-
acetal 31:  DIP frameworks have a very high reduction potential so chemical reduction by 
reducing agents such as sodium cyanoborohydride, sodium borohydride and sodium 
dithionite have been unsuccessful.  Using a much stronger reducing agent like lithium 
aluminium hydride has yielded a successful method for DIP reduction, however the 
reduction product was not the expected TIP framework.  Reduction of isobutyl-DIP 12b 
with LiAlH4 led to isolation of the isobutyl-AEDP not the isobutyl-TIP.  The LiAlH4 must 
reduce the DIP to the TIP form but as the TIP is in equilibrium with the AEP form a 
second, easier reduction of the phenanthridinium/imidazol moiety lead to the AEDP 
product 14b obtained.  The proposed mechanism for this conversion is shown in (Scheme 
33). 
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Scheme 33.  Mechanism for the reduction of isobutyl-DIP to isobutyl-AEDP. 
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The AEDP frameworks can be easily reoxidised to the AEP form simply by heating in 
aqueous acid (Scheme 34). 
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Scheme 34.  Reoxidation of AEDP to AEP in aqueous acid. 
 
Combination of these reduction and oxidation steps could therefore form a synthetic route 
to the TIP-aldehyde ligand 39 from the DIP-acetal 31.  This synthesis could however be 
greatly simplified by isolating the TIP-acetal 36 since the TIP-aldehyde 39 could be easily 
produced from here in a simple two step reaction (Scheme 35).   
 
RESULTS AND DISCUSSION         122 
_________________________________________________________________________ 
O
N
N
O Br
O
NH
O
N H
H
O
N N
O
O
NH2
N
NBS
CHCl3
LiAlH4
THF
HCl(aq)
HCl(aq)
DIP   31TIP   36
AEDP   37AEP   38
O
N N
NaOH(aq)
TIP   39
NH2
O
O OPOM
N
O
O
O
POM
N
N
TIP-POM   40
2Cl
 
Scheme 35.  Proposed scheme for the synthesis of AEP/TIP-aldehyde ligands.  
 
The electrochemical properties of the TIP-POM conjugate 40 could then be studied which 
would hopefully lead to some interesting electron transfer mechanisms between the POM 
cluster and the ligand. 
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8 CONCLUSIONS AND FUTURE WORK 
8.1 Macrocyclic Polycations 
2-bromoethyl alkylated N-heterocycles like quinoline had been previously shown to react 
with primary amines in a 3-step cascade reaction to form DIQ type cationic frameworks.121  
The application of this multi-step reaction sequence to amino-quinolines was investigated 
with the aim of generating complex polycationic macrocycles via a simple one pot 
methodology.  4-aminoquinoline was selected as the initial candidate but failed to yield 
any macrocyclic products.  The position of the amino functionality relative to the 
quinoline-N proved to a key factor for the reactivity of the alkylated substrates and 
consequently the reasons for the different reactivities of 4-aminoquinoline observed.  
Conjugation between the amine and the quinolinium-N centre severely reduces the 
nucleophilicity of the amine and renders it unreactive towards the electrophilic iminium 
centre.  The 4-position of quinoline is also a poor location for the amine functionality due 
to the steric influence of the benzo ring, which hinders nucleophilic attack of the amine.  3-
aminoquinolines overcame these problems with reactivity, and was proven to retain amine 
nucleophilicity even after alkylation of the quinoline-N.  This was only demonstrated with 
simple N-methylated analogues as direct bromoethylation of 3-aminoquinoline was not 
possible without an appropriate protection strategy.  3-Amino-1-(2-bromoethyl)-
quinolininium bromide has been proposed as a suitable substrate for future attempts to 
create cyclic oligomers using this reaction methodology.  The proposed synthesis is shown 
in Scheme 36. 
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Scheme 36.  Proposed synthesis of 3-amino-1-(2-bromoethyl)-quinolininium bromide 
and subsequent multi-step dimerization. 
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There are no foreseeable issues with the synthetic route to the alkylated substrate and the 
multi-step reaction should proceed at least as far as the α-addition and cyclisation steps as 
the substrate fulfils the criteria required for a successful multi-step reaction:  The amine is 
not fully conjugated and should therefore retain nucleophilicity even after alkylation, the 
amine is sterically unhindered, and the relative orientation of the amine and iminium 
moieties should favour dimerization/cyclisation over linear polymerization.  Isolation of 
the neutral unoxidised dimer would be the most likely product from this reaction due to the 
difficulties previously encountered with oxidation of aryl-tetrahydroimidazoquinolines.  
Oxidation could be encouraged by insertion of a bromine at the 2-postion of the 
quinolinium substrate (Scheme 37).  The increased steric hindrance introduced by the 
bromine ortho to the amine would hopefully be overcome by the increased electrophilicity 
of the iminium centre. 
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Scheme 37.  Proposed α-bromination strategy for DIQ-macrocycle/dimer synthesis. 
CONCLUSIONS AND FUTURE WORK        125 
_________________________________________________________________________ 
8.2 TIP Synthesis and Applications 
A methodology for the isolation of 1,2,3,12b-tetrahydroimidazo[1,2-f]phenanthridines  has 
been developed.  The mechanism for their formation from the reaction of primary amines 
with the BEP cation involves an α-addition followed by an intramolecular cyclisation.  The 
inhibition of oxidative hydride loss from the TIP framework is dependent upon the 
availability of the N lone pairs of the incoming amine nuclephile, which can be finely 
tuned by partial conjugation with substituted phenyl side-chains.  The steric bulk of the 
amine side-chain can also inhibit hydride transfer and stabilise the TIP framework.  Both 
the electronic and steric influences are very sensitive and a balance in size and conjugation 
must be achieved for reaction success, i.e. if the level of conjugation is too high, or the 
amine is too sterically crowded, then the α-addition and cyclisation steps cannot proceed; 
if the level of conjugation is too low, or the amine is insufficiently crowded, then there is 
no inhibition of the hydride transfer. 
 
The initial synthetic methodology developed is unquestionably limited to mainly aryl 
primary amines, however our investigations and demonstrated understanding of the 
reaction processes should enable modification of our procedures to accommodate other 
primary amines and enhance the scope of the methodology.  An immediate plan for future 
work will therefore involve functionalizing the phenanthridine ring to investigate the 
subsequent effects electron withdrawing groups and various positions will have on the 
stability of the TIP frameworks.  For example, nitration of the phenanthridine ring should 
reduce the electron density of the phenanthridino ring and could increase the stability of 
TIPs formed from unhindered aliphatic amines (Scheme 38).  The electron withdrawing 
effect of the nitro group removes the electron density from the phenanthridine-N in the 
same way the phenyl rings of aryl-TIPs remove electron density from the amino-N.  The 
facile oxidation to the DIP form could therefore be inhibited, even for TIPs formed from 
the addition of aliphatic amines.  Potential problems with the regioselectivity of nitration of 
phenanthridine191 and reduced nucleophilicity of nitro-phenanthridine would need to be 
addressed as part of this investigation. 
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Scheme 38.  Nitration of phenanthridine and subsequent stabilization of the TIP 
formed. 
 
Other ways to increase the scope of the reaction could be to investigate the application of 
the methodology to other N-heterocycles such as quinolines, quinazolines and pteridines to 
isolate their tetrahydroimidazo derivatives. 
 
Exploiting the reductive nature of the TIP framework is also a priority for any future work 
in this area.  Similar aryl-fused 5-membered di-nitrogen ring systems, such as 2,3-
dihydrobenzo[d]imidazoles, have highly selective reducing properties and have been used 
in the reductive dehalogenation of α-halo ketones, aldehydes, esters, lactones, and 
carboxylic acids, cleanly and almost quantitatively.192,193  TIPs could potentially carry out 
the same conversions equally as well; they have comparable levels of tenability, their 
syntheses are easy, but they are also chiral, making them a potentially useful addition to 
the reagents currently used to carry out such conversions.  
 
8.3 Lockable Molecular Switch 
Acid induced ring opening of the TIP framework leads to the formation of AEP dications.  
The reverse, base induced cyclisation reaction was also found to be possible.  The 
cyclisation process between these heterocyclic systems can operate reversibly in both 
monophasic and biphasic conditions using pH control.  Reduction and oxidation of the 
CONCLUSIONS AND FUTURE WORK        127 
_________________________________________________________________________ 
AEPs and TIPs, respectively, can be used to irreversibly inhibit this process.  These 
reversible and irreversible switching methods were used to form the basis of a solution-
based “lockable molecular switch”.  Attempts to immobilize the switchable frameworks on 
gold substrates, with the hope of enhancing or altering the device performance, were 
unfortunately unsuccessful.  None of the disulfide analogues that were synthesised showed 
any evidence of adsorption onto the gold substrates.  It was thought that steric and 
electronic repulsion between the heterocycles and the gold surface were the reasons for 
lack of adsorption.  Disulfide analogues with longer lipoic acid linkers were synthesised to 
overcome these issues, however, gold was later deemed to be an inappropriate choice of 
substrate for the development of a robust switching device and work on this project was 
halted.    
 
Continuation of this work therefore requires a robust substrate-heterocycle linker that will 
be stable to repeated exposures of the switching conditions, and will also allow for 
structural distinction of the monolayers in each of the four switching states.  A good 
candidate for future surface studies could therefore be SiO2 substrates194 fuctionalized with 
DIP-alkylsilanes.  Self-assembled monolayers on silicon oxide have very high thermal 
stabilities (150°C in air),195-198 are stable to harsh oxidizing (KMnHO4)199 and reducing 
(LiAlH4)200 conditions, and are stable in mildly acidic aqueous media (0.1N HCl for more 
than 40 h).201  The only drawback could be the potential hydrolysis of the Si – O bonds in 
aqueous base (0.1N NaOH resulted in immediate degradation)201 however much milder 
non-nucleophilic bases like TEA could be used for the cyclisation switching step.  A 
simple procedure for the synthesis of these monolayers could be achieved by the in situ 
derivatization of amino terminated monolayers by the addition of BEP (Scheme 39, top).  
The amino terminated monolayers can be easily synthesised from commercial reagents and 
materials.202  Another potential route to SAMs functionalized with DIP-type heterocycles 
could be via microwave-induced imide formation199 (Scheme 39, bottom).  The SAMs 
formed should be stable to the conditions required for interconversion of all forms of the 
heterocyclic component; DIP, TIP, AEP, and AEDP. 
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Scheme 39.  (top) In situ derivatization of amino terminated alkylsilane monolayers to 
form switchable heterocycles chemisorbed on the silicon oxide substrate.  (bottom) 
Microwave-induced imide formation in SAMs. 
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8.4 Bioassay Results 
A library of compounds consisting of AEP/TIP/DIP frameworks was synthesised and their 
cytotoxic activities towards human ovarian cancer cell lines were established.  A large 
amount of structural overlap of the amine side-chains was built into the library to allow the 
best comparison of the SARs for each of the heterocyclic motifs.  The following 
observations and inferences were made for the data obtained:  (i) IC50 values for the 
AEP/TIPs are in the µM concentration range, comparable to DIPs; (ii) the activities of 
AEPs and TIPs appear to be related, suggesting a common active species; (iii) 
interconversion of AEPs and TIPs in vitro is thought to be the reason for the association in 
their activities; (iv) RF values for AEP/TIPs are typically ≤ 1 and so are not susceptible to 
the same resistance mechanisms as cisplatin; (v) consequently the induction of cell death 
by AEP/TIPs is not dependent upon the presence of mismatch repair function.  These 
results are promising and have taken this project closer to realising its goal of creating 
chemotherapeutics with high toxicity and high selectivity.  The next stage for clinical 
evaluation of these compounds will be in vivo assays with human tumour xenografts in 
mice.  These tests will provide data on the compound stabilities and metabolism, 
bioavailabilities, tumour suppression, and therapeutic indices.  The 15 AEP compounds 
will be screened for in vivo activity and selectivity using this assay.  Since the AEPs and 
TIPs consistently gave similar results in vitro but the aqueous solubility of the AEPs is 
significantly better, only the AEP compounds have been selected for the initial in vivo 
testing. 
 
8.5 IP-POM Hybrids 
The synthesis of an imidazophenanthridine-based POM hybrid was attempted via TRIS-
base ligand derivatization and metal coordination, and via Schiff base condensation of 
organic aldehydes and TRIS-POM conjugates.  Neither route resulted in the successful 
isolation of a hybrid structure, however much has been learned about the synthesis of such 
materials and new discoveries were made that could have interesting applications in other 
areas.  In the search for a neutral organic aldehyde ligand two new procedures were 
developed for the conversion of DIPs and AEDPs which could benefit future developments 
of the “lockable molecular switch” (Scheme 40).  
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Scheme 40.  Potential new switching methods for further development of the 
molecular switch.   
 
The DIP reduction and AEDP oxidation methodologies complete the switching loop by 
offering “unlocking” or “reset” procedures to allow complete interconversion of all four 
switching forms. 
 
In the search for suitable TRIS-base protecting strategies an oxadiazinophenanthridine 
motif was discovered by reaction of a hydroxylamine with the BEP.  Related 
oxadiazinophenanthridine and phenanthridinotriazine compounds have be synthesised by 
the reaction of hydroxylamines and hydrazines with 5-(2-oxopropyl)-phenanthridinium 
cations (Scheme 41, top).  These compounds were shown to have excellent fungicidal 
properties.189  The reaction of BEP with these nucleophiles could therefore lead to the 
generation of new heterocycles with potentially high biological activities.  The reaction of 
BEP with hydrazines has been previously used to produce DIP frameworks in the past.129  
The initial reaction mechanism must therefore favour α-addition, followed by a 5-exo-tet 
cyclisation to form the kinetically favoured 5-membered ring TIP product.  However if the 
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TIP intermediate is acidified and the imidazo ring is opened then the product may be able 
to rearrange upon basification to give the 6-membered triazine ring.   
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Scheme 41.  (top) Synthesis of phenanthridinotriazine fungicides.  (bottom) Proposed 
synthesis of analogous phenanthridinotriazine compounds from BEP. 
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Experimental 
9 EXPERIMENTAL 
9.1 Materials 
Solvents for synthesis (AR grade) were supplied by Fisher Chemicals and Riedel-de Haen. 
Nitrogen Gas was supplied by B.O.C. Ltd. and was of commercial grade. Deuterated 
solvents were obtained from Goss Scientific Instruments Ltd. and Cambridge Isotope 
Laboratories Inc. All other reagents were supplied by Sigma-Aldrich Chemical Company 
Ltd., Fisher Chemicals, and Lancaster Chemicals Ltd. Column chromatographies were 
performed on Silica gel 60 obtained from Merck. All commercial starting materials were 
used as supplied, without further purification. Reactions requiring dry conditions were 
undertaken in AR grade solvent previously dried using a Pure Solv 400-5-MD Solvent 
Purification System. 
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9.2 Instrumentation 
The following instruments were used for all analytical and spectroscopic measurements:  
Melting point: Stuart Scientific SMP1 melting point apparatus, using 
capillary tubes.  The given temperatures are uncorrected 
pH measurements: Hanna Instruments HI 9025C microcomputer pH meter  
with a BCH combination pH electrode (309-1065) and HI 
7669/2W temperature probe 
Elemental analysis : EA 1110 CHNS, CE-440 Elemental Analyser. 
Mass spectrometry: Kratos Kompact MALDI III; (ES) LCT Micromass TOF; 
(LSIMS) Micromass Zabspec; (CI / EI) Micromass Prospec; 
JEOL JMS 700 (FAB / EI / CI). 
FT-IR spectroscopy: Shimadzu FTIR-8300 and Jasco FTIR-410 spectrometers, 
data manipulation with Shimadzu HyperIR and JASCO 
software.   
UV-Vis spectroscopy : Shimadzu UV-3101PC UV-VIS-NIR Scanning 
Spectrophotometer.  Data manipulation with Shimadzu 
software.  
NMR spectroscopy: Bruker DPX-400 and Avance-400 (400 MHz 1H, 100 MHz 
13C, 2D experiments).  Data manipulation with Bruker 
Topspin. 
Single X-ray crystallography: Bruker Nonius X8 Advance diffractometer equipped with an 
APEXIICCD detector. 
Oxford Diffraction Gemini S Ultra diffractometer.  Data 
manipulation with SHELXS-97 and SHELXL-97 via 
WinGX. 
Cyclic Voltammetry: VoltaLab PG301; Dynamic-EIS voltametry and CH 
Instruments 620A electrochemical workstation 
Fluorescence spectroscopy: Shimadzu spectrofluorophotometer RF-5301PC  
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9.3 Methods 
When required, syntheses were carried out under nitrogen (oxygen free, dried over calcium 
chloride) using standard Schlenk line techniques.  All reactions were carried out using 
oven-dried glassware. Reactions monitored by TLC were developed under UV, ninhydrin, 
iodine or phosphomolybdic acid; the Rf and eluent are given for characterised compounds 
purified using column chromatography.  Melting points are given in degrees Celsius and 
are uncorrected.  Peaks from mass spectroscopy are given in m/z (with m = mass in Dalton 
and z = charge), starting from the molecular peak, with relative % to basis peak.  Infra red 
spectra were obtained using KBr disc, CaF windows or a Golden Gate; peaks are quoted in 
wave numbers (ν) (cm-1) and their relative intensity are reported as follows: s = strong, m = 
medium, w = weak, b = broad. UV spectroscopy measurements are reported by plotting the 
wavelength (λ) in nm against Absorbance; Molar absorption coefficient (ε) is in M-1.cm-1). 
All NMR spectra were recorded at room temperature unless otherwise stated.  Chemical 
shifts (δ) are given in ppm relative to residual solvent peak.  Coupling constants (J) are 
given in Hz.  Signal multiplicities are expressed as follows: s = singlet, d = doublet, t = 
triplet, q = quartet, m = multiplet, brd = broad.  The degree of substitution at carbon 
positions was determined by DEPT experiments.  X-ray analyses were performed using 
suitable single crystals mounted onto the end of a thin glass fiber using Fomblin oil. X-ray 
diffraction intensity data were measured at on an Oxford Diffraction Gemini S Ultra 
diffractometer or a Bruker Nonius X8 Advance diffractometer equipped with an 
APEXIICCD detector.  Structure solution and refinement was carried out with SHELXS-
97 191 and SHELXL-97 192 via WinGX.193 Corrections for incident and diffracted beam 
absorption effects were applied using analytical and empirical methods.194 
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9.4 Electrochemical Data 
 
9.4.1 Cyclic voltammetry studies of DIPs (12a, b. i, j, t) 
The redox behavior of compounds 12(a, b, i, j, t) were studied in (0.1 M TBAPF6) 
acetonitrile solution using glassy carbon (3 mm) as the working electrode, platinum mesh 
as the auxiliary and Ag/AgCl as the reference electrode.  Figure S1 shows the main 
characteristic peaks associated with the redox couples of compounds 12(a, b, i, j, t) in the 
range of +1.950 V and -1.950 V vs Ag/AgCl at a scan rate of 50 mV s-1. The form of the 
CV diagram remained identical no matter the scanning potential direction.  In all cases, at 
the aforementioned scan rate and scanning towards the negative region of potential values, 
one reversible and two ill-defined irreversible reductions have been revealed while at the 
positive region of potential values, two irreversible oxidation peaks observed. In the case 
of compound 12i a third quasireversible oxidation peak was observed at higher potential 
values. 
 
Compounds 12(a, b, i, j, t), incorporate the same aromatic carbon architecture and reveal 
similar redox behavior. The relative redox potential values are summarized in Table S1.  
 
Table S1.  Cyclic voltammetry data for compounds 12(a, b, i, j, t) at 100 mV/sec. 
 Oxidation couples Reduction couples 
Compound E1/2 (V) E1/2 (V) ∆E (V) 
12t +1.348 -0.084(ill defined) - 
 +0.895 -1.047 0.139 
    
12j +1.326 -0.007(ill defined) - 
 +0.958 -1.193 0.115 
    
12b +1.320   0.064(ill defined) - 
 +0.912 -1.279 0.156 
    
12a +1.314  0.013(ill defined) - 
 +0.888 -1.302 0.121 
 -   
12i +1.595    0.002(ill defined)  
 +1.307 -1.227 0.167 
 +0.885 - - 
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Figure S1.  CV diagrams of compounds; 4a, R = cyclohexyl; 4b, R = isobutyl; 4i, R = 
3,4-dimethoxyphenyl; 4j, R = phenyl;  4t, R = 3,4-difluorophenyl.  Conditions: 1 mM 
of the compound; 0.1 M TBAPF6 as supporting electrolyte; at 25 oC using glassy 
carbon working electrode (3 mm); the potentials are reported relative to Ag/AgCl 
reference electrode; scan rate 50 mVs-1. 
 
Figure S2 represents the voltammogram of compound 12j at different scan rates (50, 100, 
200, 300, 400 mV/sec). The potential values, up to the value of 120, are proportional to 
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scan rate indicating a surface confined effect while up to 400 mV/sec the effect becomes 
diffusion controlled.  The same behaviour was observed for the other 4 compounds as well. 
 
 
Figure S2.  CV diagram of compound 12j (R = phenyl) at scan rates (from inner to 
outer) 50, 100, 200, 300 and 400 mV/sec. 
.  
9.4.2 Cyclic voltammetry studies of DIP 12b and AEP 13b 
The following electrochemical experiments were performed using a CH Instruments 620A 
electrochemical workstation. The electrolyte solution (0.1 M) was prepared from 
recrystallised Bu4NPF6 using dry acetonitrile. A three electrode configuration was used 
with a platinum disc working electrode, a platinum wire counter electrode and a Ag/AgCl 
reference electrode. The solution was purged with nitrogen prior to recording the 
electrochemical data, and all measurements were recorded under a nitrogen atmosphere. 
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Figure S3.  Cyclic voltammograms of compounds 13b (blue line) and 12b (red line) (5 
mg) in acetonitrile (8 ml). Scan rate = 100 mVs-1. 
 
9.4.3 Square wave voltammetry studies of DIP 12b and AEP 13b 
 
 
Figure S4.  Square wave voltammogram of compound 13b (5 mg) in acetonitrile (8 
ml). 
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Figure S5.  Square wave voltammogram of compound 12b (5mg) in acetonitrile (8 
ml). 
 
9.5 UV Spectra Conditions (Ref. Figure 33) 
UV spectra of compounds TIP 11b, DIP 12b, AEP 13b, and AEDP 14b. 
 
Samples prepared as 4×10-5 M solutions in acetonitrile, scan range 240-400 nm, slit width 
2 nm.   
 
The sample of TIP 11b was prepared by basification of a biphasic solution of AEP 13b 
(35.1 mg, 0.1 mmol) in H2O (~1 mL) and DCM (~1 mL) with Na2CO3 (~50 mg) followed 
by separation of layers and removal of DCM solvent under vacuum.  The residue was 
immediately redissolved in acetonitrile and diluted to the desired concentration.  
 
The sample of AEDP 14b was prepared by reduction of a biphasic solution of AEP 13b 
(35.1 mg, 0.1 mmol) in H2O (~1 mL) and DCM (~1 mL) with NaBH4 (~10 mg) followed 
by separation of layers and removal of DCM solvent under vacuum.  The residue was 
immediately redissolved in acetonitrile and diluted to the desired concentration. 
 
9.6 Fluorescence Spectra Conditions (Ref. Figure 33) 
DIP 12b spectrum conditions:  4 x 10-6 M, excitation wavelength 320 nm, scan range 330-
630 nm, slit (ex) 3 nm, slit (em) 5 nm. 
TIP 11b spectrum conditions:  4 x 10-5 M, excitation wavelength 320 nm, scan range 330-
630 nm, slit (ex) 1.5 nm, slit (em) 3 nm. 
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AEP 13b spectrum conditions:  4 x 10-5 M, excitation wavelength 246 nm, scan range 330-
630 nm, slit (ex) 3 nm, slit (em) 3 nm. 
AEDP 14b spectrum conditions:  4 x 10-5 M, excitation wavelength 320 nm, scan range 
330-630 nm, slit (ex) 3 nm, slit (em) 3 nm. 
 
The sample of TIP 11b was prepared by basification of a biphasic solution of AEP 3b 
(35.1 mg, 0.1 mmol) in H2O (~1 mL) and DCM (~1 mL) with Na2CO3 (~50 mg) followed 
by separation of layers and removal of DCM solvent under vacuum.  The residue was 
immediately redissolved in acetonitrile and diluted to the desired concentration.  
 
The sample of AEDP 4 was prepared by reduction of a biphasic solution of AEP 3b (35.1 
mg, 0.1 mmol) in H2O (~1 mL) and DCM (~1 mL) with NaBH4 (~10 mg) followed by 
separation of layers and removal of DCM solvent under vacuum.  The residue was 
immediately redissolved in acetonitrile and diluted to the desired concentration. 
 
 
9.7 In Situ Monitored 1H NMR Experiments 
 
9.7.1 TIP-AEP hydride transfer initiation via acidification (Ref. Figure 19) 
A monophasic solution of TIP 11b was prepared by addition of isobutylamine (0.40 mmol, 
4.0 eq) to BEP 10 (0.10 mmol, 1.0 eq) in D6-DMSO (1.0 mL). Addition of DCl (0.125 
mmol, 1.25 eq) resulted in the complete conversion of TIP 11b to equimolar amounts of 
DIP 12b and AEDP 14b.  
 
9.7.2 Bromoaniline isomer comparison (Ref. Figure 20) 
2- or 4-Bromoaniline (0.054 mmol, 1.0 eq) and TEA (23 µL, 0.162 mmol, 3.0 eq) was 
added to a solution of BEP 10 (20 mg, 0.054 mmol, 1.0 eq) in D6-DMSO (0.8 mL) and the 
reaction progress monitored by 1H NMR spectroscopy. 
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9.7.3 Adamantyl and isobutyl comparison (Ref. Figure 21 & Figure 22) 
A solution of isobutyl-TIP 11b suitable for 1H NMR analysis was prepared by addition of 
isobutylamine (2.8 µL, 0.028 mmol, 1.0 eq) to a biphasic solution of BEP 10 (10 mg, 0.028 
mmol, 1.0 eq) in 5% Na2CO3 (aq) (0.8 mL) and CHCl3 (0.8 mL) and shaking vigorously in 
an NMR tube for 2 min.  The layers were then separated and the organic layer was 
concentrated under vacuum to give a colourless oily residue which was immediately 
redissolved in D6-DMSO (0.8 mL).  A solution of BEP 10 (10 mg, 0.028 mmol, 1.0 eq) in 
D6-DMSO (0.8 mL) was then added to the solution, analysing the solutions by 1H NMR 
spectroscopy both before and after the addition. 
 
A similar reaction was repeated for adamantyl-TIP:  A solution of BEP 10 (10 mg, 0.028 
mmol, 1.0 eq) in D6-DMSO (0.8 mL) was added to a solution of adamantyl-TIP 3f (10 mg, 
0.028 mmol, 1.0 eq) in D6-DMSO (0.8 mL), analysing the solutions by 1H NMR 
spectroscopy both before and after the addition. 
 
9.7.4 4-Fluorophenyl-TIP/AEP cyclisation reversibility (Ref. Figure 30) 
In an NMR tube, 4-fluorophenyl-TIP 11n (10 mg, 0.032 mmol) was dissolved in D6-
DMSO.  DCl (35% wt., 1 drop) was added and the tube was shaken vigorously.  TEA (3 
drops) was then added and the tube was shaken vigorously.  1H NMR spectra were 
obtained before and after each addition. 
 
9.7.5 Monophasic isobutyl-AEP/TIP conversion via pH jump (Ref. Figure 34) 
In an NMR tube, isobutyl-AEP 13b (10 mg, 0.032 mmol) was dissolved in D6-DMSO.  
TEA (53 µL 0.38 mmol, ~12 eq) was then added and the tube was shaken vigorously.  1H 
NMR spectra were obtained before and after the addition of TEA. 
 
9.7.6 Incremental isobutyl-AEP/TIP conversion in biphasic system (Ref. 
Figure 35) 
In an NMR tube, AEP 13b (40 mg, 0.114 mmol) was dissolved in D2O (1.0 mL) and 
CDCl3 (1.0 mL) and cyclohexane (1 drop) were added.  A 1N Na2CO3 solution in D2O was 
added in 30 µL portions (150 µL, 0.15 mmol in total) and the CDCl3 layer was analysed by 
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1H NMR spectroscopy.  The D2O layer was then replaced with fresh D2O (1.0 mL), a 0.5M 
solution of DCl in D2O was then added in 30 µL portions and the CDCl3 layer was 
analysed by 1H NMR spectroscopy. 
 
9.7.7 Br2 oxidation of isobutyl-TIP (Ref. Figure 40) 
In an NMR tube, a 5% Na2CO3 solution in D2O (0.8 mL) was added to a suspension of 
AEP 13b (15 mg, 0.043 mmol) in CDCl3 (0.8 mL) and the tube shaken vigorously.  The 
aqueous phase was removed and replaced with fresh D2O (0.8 mL).  Bromine (2 drops) 
was added, the tube was shaken again and an orange precipitate formed (DIP product).  
The reaction mixture was filtered and a 1H NMR spectrum of the CDCl3 filtrate was 
obtained. 
 
9.7.8 BEP methoxy adduct formation (Ref. Figure 50) 
TEA (23 µL, 0.167 mmol, 3.0 eq) was added to a solution of BEP 10 (20 mg, 0.056 mmol, 
1.0 eq) in CD3OD (0.8 mL) and a 1H NMR spectrum was obtained. 
 
9.7.9 TRIS-cage-TIP (Ref. Figure 52) 
To a solution of 1-methyl-2,6,7-trioxa-bicyclo[2.2.2]oct-4-ylamine (10 mg, 0.069 mmol, 
1.0 eq) and TEA (29 µL, 0.207 mmol, 3.0 eq) in D6-DMSO (0.8 mL) was added BEP 10 
(25 mg, 0.069 mmol, 1.0 eq).  A 1H NMR spectrum was obtained after ~20 min. 
 
9.8 In Situ Monitored UV Switching Experiments 
 
9.8.1 pH switching of isobutyl-AEP/TIP (Ref. Figure 36) 
The initial sample was prepared as a 5×10-5 M solution of AEP 13b (2.2 mg, 0.005 mmol) 
in H2O (100 mL) with a drop of 48% HBr(aq) to reduce the pH to ~3.  DCM (100 mL) was 
added and the biphasic solution was then basified to ~pH 9 by drop-wise addition of TEA.  
The solution was re-acidified to ~pH 3 by drop-wise addition of 48% HBr(aq).  This cycle 
repeated 3 times.  The solution was stirred thoroughly during each addition and left to 
separate for >2min after each addition.  UV spectra were obtained for both the aqueous and 
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organic layers after each addition.  Note:  The lack of accuracy for pH measurements was 
due to incompatibility of pH probe with DCM so universal indicator paper was used 
instead. 
 
9.8.2 NaBH4 reduction of isobutyl-AEP (Ref. Figure 37) 
A 5×10-5 M aqueous solution of AEP 13b was prepared (2.2 mg in 100 mL).  DCM (100 
mL) was added, followed by NaBH4 (6.3 mg, 0.1 mmol, 20 eq) and the reaction stirred for 
~2 min.  TEA was added drop-wise to basify the aqueous phase.  48% HBr(aq) was added to 
acidify the aqueous layer.  The solution was stirred thoroughly during each addition and 
left to separate for >2min after each addition.  UV spectra were obtained for both the 
aqueous and organic layers after each addition.  Note the shift in absorbance maxima upon 
re-acidification at the end of the experiment can be explained by protonation of the AEDP 
product. 
 
9.8.3 Br2 oxidation of isobutyl-TIP (Ref. Figure 39) 
The initial sample was prepared as a 5×10-5 M solution of AEP 13b (2.2 mg, 0.005 mmol) 
in H2O (100 mL).  DCM (100 mL) was added and the biphasic solution was then basified 
to ~pH 8 with TEA (3.5 µL, 0.025 mmol, 5.0 eq).  Bromine was then added and the 
reaction progress was followed using UV spectroscopy.  48% HBr (1 drop) was added at 
the end of the experiment to show the AEP starting material could not be reformed by re-
acidification of the solution.  The increase in absorbance upon acidification can be 
explained by the removal of hydroxide ions that cause DIP 12b to exist as its pseudo base 
analogue at high pH. 
 
9.9 MTT Assays 
Drug sensitivity is determined by a tetrazolium dye-based microtitration assay.178  The cell 
lines used were the human ovarian cancer cell line A2780 and 2 cisplatin resistant 
derivatives (A2780/cp70 and MCP1).173  Both resistant cell lines have lost expression of a 
component (MLH1) of the DNA mismatch repair pathway.  Cells were plated out in 96 
well plates at a density of 500 – 1000 cells/well and allowed to attach and grow for 2 days.  
Cells were exposed to the drug at a range of concentrations for 24 hours and then the 
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medium was replaced with drug free medium for a further 3 days.  On the final day MTT 
(50µl of a 5mg/ml solution) was added to the medium (200 µl) in each well and the plates 
were incubated at 37°C for 4h in the dark.  Medium and MTT were then removed and the 
MTT-formazan crystals were dissolved in DMSO (200 µl). Glycine buffer (25µl per well, 
0.1M, pH 10.5) was added and the absorbance measured at 570nm in a multiwell plate 
reader.  A typical dose-response curve consisted of 8 drug concentrations and 2 wells were 
used per drug concentration.  Results are expressed in terms of the drug concentration 
required to kill 50% of the cells (IC50) estimated as the absorbance value equal to 50% of 
that of the untreated control wells. 
 
The RF value is the resistance factor. It is calculated by dividing the IC50 value for a given 
drug for the cisplatin resistant cell lines by that obtained for the cisplatin sensitive A2780 
cell line. Where the RF is less than 1 it means that the cisplatin resistant cell lines is more 
sensitive to the drug than is the A2780 cell line. 
 
9.10 Crystallography 
Structures were solved using Patterson or Direct methods with SHELXS-97203 or SIR-92204 
using WinGX205 routines. Refinement was accomplished by full matrix least-squares on F2 
via SHELXL-97. All non-hydrogen atoms were refined anisotropically unless stated 
otherwise. Hydrogen atom positions were calculated using standard geometric criteria and 
refined using a riding model. All data manipulation and presentation steps were performed 
using WinGX. Details of interest about the structure refinement are given in the tables. The 
following quantities are given in the information for each structure and were calculated as 
follows: 
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9.10.1 1-(4-Fluorophenyl)-1,2,3,12b-tetrahydroimidazo[1,2-f]phenanthridine 
(11n) 
 
Empirical formula                   C21H17FN2 
       Formula weight                      316.37 
       Temperature                         100(2) K 
       Wavelength                          0.71073 Å 
       Crystal system, space group        Monoclinic, P21/c 
       Unit cell dimensions                a = 7.8862(2) Å    α = 90.00º 
                                           b = 39.4824(12) Å     β = 93.878(2)º 
                                           c = 10.0829(3) Å    γ = 90.00º 
       Volume                              3132.29(16) Å3 
       Z, Calculated density               8,  1.342 Mg/m3 
       Absorption coefficient             0.088 mm-1 
       F(000)                              1328 
       Crystal size                        0.16 x 0.14 x 0.10 mm 
       Theta range for data collection    2.0 to 23.4º 
       Limiting indices                    -8<=h<=8, -41<=k<=43, -11<=l<=11 
       Reflections collected / unique     19890 / 4474 [R(int) = 0.0762] 
       Completeness to theta =   23.4     100.0 % 
       Absorption correction              Empirical 
       Max. and min. transmission         0.982 and 0.996 
       Refinement method                  Full-matrix least-squares on F2 
       Data / restraints / parameters     4474 / 0 / 443 
       Goodness-of-fit on F2              0.957 
       Final R indices [I>2sigma(I)]      R1 = 0.0485, wR2 = 0.0912 
       R indices (all data)                R1 = 0.1018, wR2 = 0.1161 
       Largest diff. peak and hole        0.182 and -0.202 e.Å-3 
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9.10.2 2-(1-Methyl-2,6,7-trioxa-bicyclo[2.2.2]oct-4-yl)-3,4-dihydro-2H,12bH-1-
oxa-2,4a-diazatriphenylene (28) 
 
Empirical formula                   C21H22N2O4 
       Formula weight                      366.41 
       Temperature                         293(2) K 
       Wavelength                          1.54184 Å 
       Crystal system, space group        Orthorhombic, P2(1)2(1)2(1) 
       Unit cell dimensions                a = 5.92460(10) Å    α = 90.00º 
                                           b = 12.44370(10) Å     β = 90.00º 
                                           c = 23.2846(2) Å    γ = 90.00º 
       Volume                              1716.63(4) Å3 
       Z, Calculated density               4,  1.418 Mg/m3 
       Absorption coefficient             0.807 mm-1 
       F(000)                              776 
       Crystal size                        0.43 x 0.10 x 0.09 mm 
       Theta range for data collection    3.55 to 62.41º 
       Limiting indices                    -6<=h<=6, -10<=k<=13, -26<=l<=26 
       Reflections collected / unique     5971 / 2406 [R(int) = 0.0163] 
       Completeness to theta =   62.41      100.0 % 
       Absorption correction              Analytical 
       Max. and min. transmission         0.834 and 0.949 
       Refinement method                  Full-matrix least-squares on F2 
       Data / restraints / parameters     2406 / 0 / 244 
       Goodness-of-fit on F2              1.109 
       Final R indices [I>2sigma(I)]      R1 = 0.0227, wR2 = 0.0572        
R indices (all data)                R1 = 0.0236, wR2 = 0.0573 
       Largest diff. peak and hole        0.108 and -0.139 e.Å-3 
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Figure S6.  Thermal ellipsoid plots for crystal structures of compounds 11n (top) and 
28 (bottom). 
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9.11 Syntheses and Analytical Data 
 
9.11.1     4-Amino-1-methylquinolinium toluene-4-sulfonate (3). 
 
N
NH2
SO O
O
 
 
To a suspension of 4-aminoquinoline (500 mg, 3.47 mmol, 1.0 eq) in diethyl ether (20 mL) 
was added methyl-p-toluenesulfonate (642 mg, 4.16 mmol, 1.2 eq).  The reaction was 
stirred at 40
 
˚C for 69 h.  The suspension was filtered, washing with more ether, to give a 
pale yellow solid (1.02 g, 3.08 mmol, 88.8 %):  mp 241-243 ˚C (MeOH); 1H NMR 
(DMSO, 400 MHz) δ 9.01 (brd, 2H), 8.51 (d, 1H, J=7.2 Hz), 8.49 (d, 1H, J=7.2 Hz), 8.08 
(m, 2H), 7.78 (m, 1Hz), 7.48 (d, 2H, J=8.0 Hz), 7.12 (d, 2H, J=8.0 Hz), 6.79 (d, 1H, J=7.2 
Hz), 4.11 (s, 3H), 2.29 (s, 3H); 13C NMR (DMSO, 100 MHz) δ 157.9 (C), 146.7 (CH), 
145.7 (C), 138.9 (C), 137.6 (C), 134.4 (CH), 128.0 (2 × CH), 126.5 (CH), 125.5 (2 × CH), 
124.2 (CH), 118.4 (CH), 116.8 (C), 101.8 (CH), 41.9 (CH3), 20.8 (CH3); IR (KBr, cm-1) 
3316 (w), 3117 (w), 1680 (m), 1625 (s), 1203 (s), 1182 (s); MS (FAB) m/z (%) 159 (M+) 
(100), 147 (32), 136 (53). 
Product Reference:  Keneford, J. R.; Lourie, E. M.; Morley, J. S.; Simpson, J. C. E.; 
Williamson, J.; Wright, P. H., J. Chem. Soc. 1952, 2595-602. 
 
9.11.2     1-Methyl-1H-quinolin-4-ylideneamine (4). 
 
N
NH
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To a solution of NaOH (250 mg, 6.25 mmol, 10.3 eq) in H2O (1 mL) was added 4-amino-
1-methylquinolinium toluene-4-sulfonate (200 mg, 0.605 mmol, 1.0 eq) and the reaction 
heated to reflux for 23 h.  The reaction was allowed to cool to rt˚C, diluted with H2O (5 
mL) and then extracted with EtOAc (2×10 mL).  The combined organic layers were dried 
over MgSO4 and concentrated under vacuum to give a white powder (50 mg, 0.32 mmol, 
52.3%):  1H NMR (CDCl3, 400 MHz) δ 8.48 (dd, 1H, J=8.2, 1.4 Hz), δ 7.70 (m, 1H), δ 
7.52 (d, 1H, J=7.8 Hz), δ 7.42 (m, 2H), δ 6.28 (d, 1H, J=7.8 Hz), 3.82 (s, 3H); 13C NMR 
(DMSO, 400 MHz) δ 176.3 (C), 145.0 (CH), 140.6 (C), 132.0 (CH), 126.5 (C), 125.5 
(CH), 123.3 (CH), 116.7 (CH), 108.6 (CH), 40.0 (CH3); IR (KBr, cm-1) 3433 (m), 2945 
(w), 1625 (s), 1576 (s), 1493 (m), 1474 (m), 758 (s); MS (EI+) m/z (%) 159.1 (M+H)+ 
(100), 131.1 (84), 130.1 (52). 
Product Reference: Angyal, C. L.; Werner, R. L., J. Chem. Soc. 1952, 2911-2915  
 
9.11.3     3-Amino-1-methylquinolinium-p-toluenesulfonate (7). 
 
N SO O
O
NH2
 
 
To a solution of 3-aminoquinoline (500 mg, 3.47 mmol, 1.0 eq) in DCM (5 mL) was added 
methyl-p-toluenesulfonate (1.292 g, 6.94 mmol, 2.0 eq) and the resultant yellow solution 
stirred at room temperature for 18 h.  The precipitated product was collected by filtration, 
washing with DCM (808 mg, 2.45 mmol, 70.6 %): mp 144-146 ˚C; 1H NMR (DMSO, 400 
MHz) δ 8.84 (d, 1H, J=2.4 Hz), 8.22 (d, 1H, J=7.6 Hz), 8.08 (d, 1H, J=7.6 Hz), 7.98 (d, 
1H, J=2.4 Hz), 7.79 (m, 2H), 7.48 (d, 2H, J=7.8 Hz), 7.12 (d, 2H, J=7.8 Hz), 6.60 (brd, 
2H), 4.52 (s, 3H), 2.29 (s, 3H); 13C NMR (DMSO, 100 MHz) δ 145.8 (C), 143.3 (C), 140.2 
(CH), 137.5 (C), 131.8 (C), 130.5 (C), 129.4 (CH), 129.3 (CH), 128.0 (CH), 127.6 (CH), 
125.5 (CH), 121.9 (CH), 118.6 (CH), 45.4 (CH3), 20.8 (CH3); IR (KBr, cm-1) 3450 (s), 
3317 (s), 3196 (s), 3052 (w), 3002 (w), 1636 (s), 1589 (m), 1530 (s), 1380 (m), 1219 (s), 
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1179 (s), 1120 (s), 1030 (s), 1008 (s); MS (FAB) m/z (%) 160.01 (100) (M+H)+, 159.01 (7) 
(M+), 147.17 (2); Anal. Calcd for C17H18N2 SO3:  C, 61.80; H, 5.49; N, 8.48; Found: C, 
61.35; H, 5.44; N, 8.32. 
Product Reference:  Plakogiannis, F. M.; Lien, E. J. C.;  Biles, J. A., J. Med. Chem., 1971, 
14, 430–432 
 
9.11.4     3-Acetylaminoquinoline (8). 
 
N
H
N
O
 
 
A solution of 3-aminoquinoline (1.0 g, 6.94 mmol, 1.0 eq) in neat acetic anhydride (20 
mL) was heated to 90
 
˚C for 1 h.  The mother liquor was allowed to cool to room 
temperature and concentrated to dryness.  The residue was partitioned between water and 
ethyl acetate, the aqueous layer was basified with 10 % aqueous sodium carbonate 
solution, layers were separated and the aqueous phase further extracted with ethyl acetate.  
Organic extracts were combined and concentrated to dryness.  The crude residue was 
purified by flash column chromatography, eluent:  0-20 % Methanol in Ethyl acetate.  The 
product was obtained as a white solid (1.079 g, 5.79 mmol, 83.4 %):  mp 168-169 ˚C; Rf = 
0.21 in 100% EtOAc; 1H NMR (CDCl3, 400 MHz) δ 8.69 (s, 1H), 8.65 (s, 1H), 7.97 (d, 
1H, J=7.4 Hz), 7.74 (d, 1H, J=7.4 Hz), 7.57 (t, 1H, J=7.4 Hz), 7.49 (s, 1H), 7.47 (t, 1H, 
J=7.4 Hz), 2.21 (s, 3H); 13C NMR (CDCl3, 100 MHz) δ 169.0 (C), 145.6 (C), 143.8 (CH), 
132.0 (C), 129.0 (CH), 128.4 (CH), 128.3 (C), 127.8 (CH), 127.3 (CH), 124.0 (CH), 24.7 
(CH3); MS (EI) m/z (%) 186.06 (54) (M), 144.05 (100), 117.05 (28), 89.02 (24), 63.02 
(11), 43.04 (25). 
Product Reference:  Dauben, Wm. G.; Vaughan, C. Wheaton, Jr., J. Am. Chem. Soc. 1953,  
75,  4651-5. 
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9.11.5     3-Acetylamino-1-methylquinolinium p-toluenesulfonate (9). 
 
N
H
N
O
SO O
O
 
 
To a suspension of 3-acetylaminoquinoline (200 mg, 1.07 mmol, 1.0 eq) in DCM (5 mL) 
was added methyl-p-toluenesulfonate (398 mg, 2.14 mmol, 2.0 eq) and the reaction stirred 
at room temperature for 6 d.  The mother liquor was filtered to remove insoluble 
impurities.  The filtrate was concentrated to dryness and the crude residue triturated with 
diethyl ether to give a pale yellow solid product (250 mg, 0.67 mmol, 62.6 %):  mp 209-
211 ˚C; 1H NMR (DMSO, 400 MHz) δ 11.10 (s, 1H), 9.64 (s, 1H), 9.18 (s, 1H), 8.45 (s, 
1H), 8.43 (s, 1H), 8.14 (t, 1H, J=7.8 Hz), 7.99 (t, 1H, J=7.8 Hz), 7.48 (d, 2H, J=8.0 Hz), 
7.11 (d, 2H, J=8.0 Hz), 4.66 (s, 3H), δ 2.22 (s, 3H), 2.15 (s, 3H); 13C NMR (DMSO, 100 
MHz) δ 169.7 (C), 145.6 (C), 143.7 (CH), 137.6 (C), 135.2 (C), 133.4 (CH), 133.3 (C), 
132.4 (CH), 130.1 (CH), 129.7 (CH), 129.2 (C), 128.1 (CH), 125.4 (CH), 118.9 (CH), 46.0 
(CH3), 23.7 (CH3), 20.8 (CH3); IR (KBr, cm-1) 3540 (w), 3222 (w), 3186 (w), 3141 (w), 
3079 (m), 3025 (m), 1708 (s), 1605 (s), 1605 (m), 1566 (s), 1521 (s), 1492 (m), 1451 (w), 
1424 (m), 1377 (s), 1365 (s), 1264 (s), 1216 (s), 1175 (s), 1119 (s), 1032 (s), 1010 (s); MS 
(EI) m/z (%) 173.1 (1), 159.01 (2), 86 (2), 73.1 (100), 44.1 (100); Anal. Calcd for 
C19H20N2SO3:  C, 61.27; H, 5.41; N, 7.52; Found: C, 60.91; H, 5.35; N, 7.46. 
 
3-amino-1-methylquinolinium-p-toluenesulfonate (100 mg, 0.30 mmol, 1.0 eq) was 
suspended in acetic anhydride (2 mL) and heated to 80 °C for 19 h.  The reaction mixture 
was filtered, washing the residue with EtOAc, to give a pale yeallow powder (63 mg, 0.19 
mmol, 63.0%):  mp 209-211 ˚C; 1H NMR (DMSO, 400 MHz) δ 11.10 (s, 1H), 9.64 (s, 
1H), 9.18 (s, 1H), 8.45 (s, 1H), 8.43 (s, 1H), 8.14 (t, 1H, J=7.8 Hz), 7.99 (t, 1H, J=7.8 Hz), 
7.48 (d, 2H, J=8.0 Hz), 7.11 (d, 2H, J=8.0 Hz), 4.66 (s, 3H), δ 2.22 (s, 3H), 2.15 (s, 3H); 
13C NMR (DMSO, 100 MHz) δ 169.7 (C), 145.6 (C), 143.7 (CH), 137.6 (C), 135.2 (C), 
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133.4 (CH), 133.3 (C), 132.4 (CH), 130.1 (CH), 129.7 (CH), 129.2 (C), 128.1 (CH), 125.4 
(CH), 118.9 (CH), 46.0 (CH3), 23.7 (CH3), 20.8 (CH3). 
Product Reference:  Plakogiannis, Fotios M.; Lien, Eric J., Acta Pharmaceutica Suecica, 
1974, 11, 191-195 
 
9.11.6     5-(2-Bromoethyl)-phenanthridinium bromide (10). 
 
N
Br
Br
 
 
Phenanthridine (5.74 g, 30 mmol, 1.0 eq) was dissolved in 1,2-dibromoethane (52 mL, 600 
mmol, 20.0 eq) and the was solution stirred at 90
 
˚C for 6 d.  The product was filtered and 
washed with more dibromoethane (1 mL) every day, returning the mother liquor to the 
reaction vessel over the 6 d period.  The residues collected were combined and washed 
thoroughly with diethyl ether and dried under vacuum to give the product an off-white 
solid (10.02 g, 27.30 mmol, 91.0 %):  mp 241-243 ˚C (MeOH-Et2O); 1H NMR (DMSO, 
400 MHz) δ 10.43 (s, 1H), 9.26 (d, 1H, J=8.0 Hz), 9.21 (d, 1H, J=8.0 Hz), 8.71 (d, 1H, 
J=8.0 Hz), 8.68 (d, 1H, J=8.0 Hz), 8.48 (t, 1H, J=8.0 Hz), 8.18 (m, 3H), 5.57 (t, 2H, J=6.0 
Hz), 4.24 (t, 2H, J=6.0 Hz); 13C NMR (DMSO, 100 MHz) δ 156.5 (CH), 138.7 (CH), 
134.7 (C), 133.1 (CH), 132.7 (C), 132.3 (CH), 130.7 (CH), 130.5 (CH), 125.8 (C), 125.2 
(CH), 123.4 (CH), 123.1 (C), 119.9 (CH), 58.1 (CH2), 30.6 (CH2); MS (EI+) m/z (%) 315.8 
(M+) (16), 257.9 (6), 236.0 (30), 206.9 (84), 156.1 (19), 101.0 (48). 
Product Reference:  Parenty, A. D. C.; Smith, L. V.; Pickering A. L.; Long, D. –L.; Cronin 
L., J. Org. Chem. 2004, 69, 5934-5946. 
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9.11.7     1-Cyclohexyl-1,2,3,12b-tetrahydroimidazo[1,2-f]phenanthridine 
(11a).   
 
N N
 
 
In an NMR tube, BEP 10 (30 mg, 0.082 mmol, 1.0 eq) was suspended in CDCl3 (1 mL) 
and D2O (1 mL).  Cyclohexylamine (8 µL, 0.082 mmol, 1.0 eq) and Na2CO3 (~50 mg) 
were then added and the solution was shaken for 1 min.  The CDCl3 layer was then 
characterized by MS and 1H and 13C NMR spectroscopy:  1H NMR (CDCl3, 400 MHz) δ 
7.82 (d, 1H, J=8.0 Hz), 7.77 (d, 1H, J=8.0 Hz), 7.51 (d, 1H, J=8.0 Hz), 7.38 (m, 2H), 7.28 
(t, 1H, J=8.0 Hz), 6.93 (t, 1H, J=8.0 Hz), 6.75 (d, 1H, J=8.0 Hz), 4.99 (s, 1H), 3.47 (m, 
1H), 3.30 (m, 3H), 2.78 (m, 1H), 2.01 (m, 2H), 1.85 (m, 2H), 1.69 (m, 1H), 1.32 (m, 5H); 
13C NMR (CDCl3, 100 MHz) δ 144.0 (C), 135.7 (C), 131.8 (C), 129.0 (CH), 127.5 (CH), 
127.3 (CH), 123.7 (CH), 123.5 (CH), 123.1 (C), 123.0 (CH), 118.7 (CH), 113.2 (CH), 75.9 
(CH), 60.7 (CH), 46.7 (CH2), 45.9 (CH2), 32.9 (CH2), 27.8 (CH2), 26.34 (CH2), 26.25 
(CH2), 25.8 (CH2); MS (EI+) m/z (%) 304.2 (M+) (8), 261.1 (10), 193.1 (31), 179.0 (27), 
82.9 (93), 44.0 (100). 
 
9.11.8     1-Isobutyl-1,2,3,12b-tetrahydroimidazo[1,2-f]phenanthridine 
(11b).   
 
NN
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In an NMR tube, BEP 10 (30 mg, 0.082 mmol, 1.0 eq) was suspended in CDCl3 (1 mL) 
and D2O (1 mL).  Isobutylamine (8 µL, 0.082 mmol, 1.0 eq) and Na2CO3 (~50 mg) were 
then added and the solution was shaken for 1 min.  The CDCl3 layer was then 
characterized by MS and 1H and 13C NMR spectroscopy:  1H NMR (CDCl3, 400 MHz) δ 
7.67 (d, 2H, J=7.7 Hz), 7.38 (d, 1H, J=7.7 Hz), 7.30-7.21 (m, 2H), 7.15 (t, 1H, J=7.7 Hz), 
6.78 (t, 1H, J=7.7 Hz), 6.58 (d, 1H, J=7.7 Hz), 4.78 (s, 1H), 3.41 (m, 2H), 3.27 (m, 1H), 
2.85 (m, 1H), 2.33 (m, 2H), 1.78 (m, 1H), 0.98 (d, 3H, J=6.6 Hz), 0.90 (d, 3H, J=6.6 Hz); 
13C NMR (CDCl3, 100 MHz) δ 144.0 (C), 133.2 (C), 132.0 (C), 129.2 (CH), 127.8 (CH), 
127.2 (CH), 124.7 (CH), 123.3 (CH), 122.8 (CH), 121.9 (C), 118.2 (CH), 112.7 (CH), 79.7 
(CH), 62.0 (CH2), 51.6 (CH2), 44.9 (CH2), 28.2 (CH), 21.2 (CH3), 20.9 (CH3); MS (EI+) 
m/z (%) 278.2 (M+) (37), 193.1 (100), 178.0 (43). 
 
9.11.9    1-Cyclopentyl-1,2,3,12b-tetrahydroimidazo[1,2-f]phenanthridine 
(11c).   
 
N N
 
 
In an NMR tube, BEP 10 (30 mg, 0.082 mmol, 1.0 eq) was suspended in CDCl3 (1 mL) 
and D2O (1 mL).  Cyclopentylamine (8 µL, 0.082 mmol, 1.0 eq) and Na2CO3 (~50 mg) 
were then added and the solution was shaken for 1 min.  The CDCl3 layer was then 
characterized by MS and 1H and 13C NMR spectroscopy:  1H NMR (CDCl3, 400 MHz) δ 
7.82 (d, 1H, J=8.0 Hz), 7.76 (d, 1H, J=8.0 Hz), 7.58 (d, 1H, J=8.0 Hz), 7.38 (m, 2H), 7.28 
(t, 1H, J=8.0 Hz), 6.93 (t, 1H, J=8.0 Hz), 6.77 (d, 1H, J=8.0 Hz), 4.92 (s, 1H), 3.38 (m, 
4H), 3.24 (m, 1H), 1.87 (m, 2H), 1.75 (m, 2H), 1.58 (m, 4H); 13C NMR (CDCl3, 100 MHz) 
δ 144.0 (C), 135.0 (C), 131.8 (C), 129.0 (CH), 127.6 (CH), 127.3 (CH), 124.3 (CH), 123.4 
(CH), 122.8 (CH), 122.8 (C), 118.6 (CH), 113.5 (CH), 78.2 (CH), 63.7 (CH), 48.3 (CH2), 
46.3 (CH2), 31.3 (CH2), 29.5 (CH2), 24.2 (CH2), 24.1 (CH2); MS (EI+) m/z (%) 290.1 (M+) 
(30), 193.1 (100), 179.0 (74). 
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9.11.10 1-Dodecyl-1,2,3,12b-tetrahydroimidazo[1,2-f]phenanthridine 
(11d).  
 
N N
H
 
 
In an NMR tube, BEP 10 (30 mg, 0.082 mmol, 1.0 eq) was suspended in CDCl3 (1 mL) 
and D2O (1 mL).  Dodecylamine (19 µL, 0.082 mmol, 1.0 eq) and Na2CO3 (~50 mg) were 
then added and the solution was shaken for 1 min.  The CDCl3 layer was then 
characterized by MS and 1H and 13C NMR spectroscopy.  1H NMR (CDCl3, 400 MHz) δ 
7.78 (m, 2H), 7.36 (m, 3H), 7.25 (t, 1H, J=8.0 Hz), 6.87 (t, 1H, J=8.0 Hz), 6.69 (d, 1H, 
J=8.0 Hz), 4.88 (s, 1H), 3.56 (m, 1H), 3.48 (m, 1H), 3.41 (m, 1H), 2.96 (m, 1H), 2.70 (m, 
1H), 2.53 (m, 1H),  1.63 (m, 2H), 1.29 (m, 18H), 0.91 (t, 3H, J=6.8 Hz); 13C NMR (CDCl3, 
100 MHz) δ 144.1 (C), 132.8 (C), 131.9 (C), 129.2 (CH), 127.9 (CH), 127.2 (CH), 124.9 
(CH), 123.3 (CH), 122.7 (CH), 121.7 (C), 118.2 (CH), 112.7 (CH), 79.5 (CH), 53.7 (CH2), 
51.2 (CH2), 45.2 (CH2), 31.9 (CH2), 29.69 (CH2), 29.65 (CH2), 29.4 (CH2), 29.2 (CH2), 
27.5 (CH2), 22.7 (CH2), 14.2 (CH3); MS (CI+) m/z (%) 407.5 (M+17) (100), 391.5 (M+H)+ 
(59). 
 
9.11.11 1-Tert-butyl-1,2,3,12b-tetrahydroimidazo[1,2-f]phenanthridine 
(11e).   
 
N
N
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In an NMR tube, BEP 10 (30 mg, 0.082 mmol, 1.0 eq) was suspended in CDCl3 (1 mL) 
and tert-butylamine (50 µL, 0.98 mmol, 12.0 eq) was added and the solution was shaken 
for ~5 min.  The CDCl3 layer was then washed with D2O (~1 mL) and excess solvents 
were removed under vacuum.  The oily yellow residue was redissolved in CDCl3 and 
characterized by MS and 1H and 13C NMR spectroscopy:  1H NMR (CDCl3, 400 MHz) δ 
7.74 (d, 1H, J=8.0 Hz), 7.60 (m, 2H), 7.26 (m, 2H), 7.18 (m, 2H), 6.83(t, 1H, J=8.0 Hz), 
6.66 (d, 1H, J=8.0 Hz), 4.86 (s, 1H), 3.38 (m, 1H), 3.19 (m, 3H), 1.11 (s, 9H); 13C NMR 
(CDCl3, 100 MHz) δ 143.7 (C), 136.7 (C), 132.1 (C), 128.8 (CH), 127.12 (CH), 127.06 
(CH), 124.0 (CH), 123.6 (C), 123.5 (CH), 123.0 (CH), 118.5 (CH), 113.8 (CH), 74.5 (CH), 
55.1 (CH2), 47.3 (CH2), 46.9 (C), 28.2 (3 × CH3); MS (EI+) m/z (%) 278 (M+) (20), 263 
(100), 219 (61), 209 (23), 193 (39), 178 (51). 
 
9.11.12 1-Adamantyl-1,2,3,12b-tetrahydroimidazo[1,2-f]phenanthridine 
(11f).   
 
N N
 
 
General TIP synthesis method.  Product isolated as a pale yellow powder (493.1 mg, 1.38 
mmol, 72.6 %):  mp 87-89 ˚C (Et2O); 1H NMR (DMSO, 400 MHz) δ 7.85 (d, 1H, J=7.6 
Hz), 7.73 (m, 1H), δ 7.63 (m, 1H), 7.34 (m, 2H), 7.24 (t, 1H, J=7.6 Hz), 6.88 (t, 1H, J=7.6 
Hz), 6.76 (d, 1H, J=7.6 Hz), 4.96 (s, 1H), 3.64 (m, 1H), δ 3.26 (m, 1H), 2.95 (m, 1H), 2.04 
(s, 3H), 1.85 (m, 3H), 1.62 (m, 10H); 13C NMR (CDCl3, 100 MHz) δ 143.8 (C), 137.0 (C), 
132.12 (C), 128.8 (CH), 127.1 (CH), 127.0 (CH), 124.0 (CH), 123.54 (C), 123.48 (CH), 
122.9 (CH), 118.5 (CH), 113.6 (CH), 76.7 (CH), 55.2 (C), 47.5 (CH2), 44.9 (CH2), 41.1 (3 
× CH2), δ 36.8 (3 × CH2), δ 29.6 (3 × CH); IR (KBr, cm-1) 3736 (w), 2901 (m), 2359 (m), 
1603 (m), 1444 (m), 1211 (w), 746 (s); MS (CI+) m/z (%) 413 (35), 399 (11), 357 (M+H)+ 
(100), 356 (59), 221 (11), 180 (18), 178 (14), 79 (43); HRMS (CI+) Calcd for (C25H29N2)+, 
357.2331; Found, 357.2333. 
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9.11.13 1-(4-Dimethylaminophenyl)-1,2,3,12b-tetrahydroimidazo[1,2-
f]phenanthridine (11g).   
 
NN
N
 
 
General TIP synthesis method.  Product isolated as a pale grey powder (574 mg, 1.68 
mmol, 88.1%):  mp 197-199 ˚C (Et2O); 1H NMR (CDCl3, 400 MHz) δ 7.89 (d, 1H, J=7.8 
Hz), 7.79 (d, 1H, J=7.8 Hz), 7.42 (t, 1H, J=7.8 Hz), 7.34 (t, 1H, J=7.8 Hz), 7.26 (m, 2H), 
7.04 (t, 1H, J=7.8 Hz), 6.83 (m, 3H), 6.77 (m, 2H), 5.30 (s, 1H), 4.15 (m, 1H), 3.80 (m, 
1H), 3.68 (m, 1H), 3.37 (m, 1H), 2.91 (s, 6H); 13C NMR (CDCl3, 100 MHz) δ 144.4 (C), 
143.7 (C), 141.4 (C), 134.6 (C), 131.9 (C), 129.1 (CH), 127.7 (CH), 127.2 (CH), 124.6 
(CH), 124.2 (C), 123.7 (CH), 123.3 (CH), 119.7 (CH), 115.6 (2 × CH2), 115.0 (2 × CH2), 
112.8 (CH), 75.6 (CH), 52.1 (CH2), 44.8 (CH2), 41.9 (2 × CH3); IR (KBr, cm-1) 3433 (w), 
3045 (w), 2927 (w), 2870 (w), 2841 (w), 2787 (w), 1597 (m), 1514 (s), 1493 (m), 1442 
(m), 1372 (m), 1337 (m), 1297 (s), 1210 (m), 809 (m), 749 (s), 734 (m); MS (FAB) m/z 
(%) 342.4 (M+H)+ (100), 206.6 (10), 193.7 (37), 180.8 (23), 136.3 (25); HRMS (FAB) 
Calcd for (C23H24N3)+, 342.1970; Found, 342.1965. 
 
9.11.14 1-(4-Methoxyphenyl)-1,2,3,12b-tetrahydroimidazo[1,2-
f]phenanthridine (11h). 
 
NN
MeO
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General TIP synthesis method.  Product isolated as an off-white powder (561 mg, 1.71 
mmol, 89.4%): mp 167-169 ˚C (Et2O); 1H NMR (CDCl3, 400 MHz) δ 7.88 (d, 1H, J=7.7 
Hz), 7.79 (d, 1H, J=7.7 Hz), 7.42 (t, 1H, J=7.7 Hz), 7.34 (t, 1H, J=7.7 Hz), 7.28 (t, 1H, 
J=7.7 Hz), 7.20 (d, 1H, J=7.7 Hz), 7.04 (t, 1H, J=7.7 Hz), 6.90 (d, 2H, J=9.1 Hz), 6.83 (d, 
1H, J=7.7 Hz), 6.74 (d, 2H, J=9.1 Hz), 5.29 (s, 1H), 4.14 (m, 1H), 3.81 (m, 1H), 3.68 (m, 
1H), 3.38 (m, 1H); 13C NMR (CDCl3, 100 MHz) δ 152.5 (C), 143.6 (C), 143.4 (C), 134.4 
(C), 131.9 (C), 129.2 (CH), 127.8 (CH), 127.2 (CH), 124.5 (CH), 124.2 (C), 123.7 (CH), 
123.4 (CH), 119.9 (CH), 115.4 (2 × CH), 114.6 (2 × CH), 112.9 (CH), 75.6 (CH), 55.8 
(CH3), 52.0 (CH2), 44.8 (CH2); IR (KBr, cm-1) 3435 (w), 3054 (w), 2983 (w), 2929 (m), 
2871 (m), 2851 (w), 2830 (w), 2774 (w), 1600 (m), 1510 (s), 1442 (s), 1371 (s), 1290 (s), 
1245 (s), 1180 (m), 1037 (s), 814 (s), 754 (s), 734 (m); MS (EI+) m/z (%) 328.2 (M+) (24), 
193.1 (100), 165.1 (14), 82.9 (25); HRMS (EI+) Calcd for C22H20N2O, 328.1576; Found, 
328.1575. 
 
9.11.15 1-(3,4-Dimethoxyphenyl)-1,2,3,12b-tetrahydroimidazo[1,2-
f]phenanthridine (11i). 
 
NN
MeO
MeO
 
 
General TIP synthesis method.  Product isolated as a cream powder (610 mg, 1.70 mmol, 
89.1%):  mp 148-150 ˚C (Et2O); 1H NMR (CDCl3, 400 MHz) δ 7.88 (d, 1H, J=7.7 Hz), 
7.79 (d, 1H, J=7.7 Hz), 7.42 (t, 1H, J=7.7 Hz), 7.35 (t, 1H, J=7.7 Hz), 7.29 (t, 1H, J=7.7 
Hz), 7.23 (d, 1H, J=7.7 Hz), 7.05 (t, 1H, J=7.7 Hz), 6.84 (d, 1H, J=8.6 Hz), 6.82 (d, 1H, 
J=7.7 Hz), 6.42 (d, 1H, J=2.8 Hz), 6.29 (dd, 1H, J=8.6 Hz, 2.8 Hz), 5.32 (s, 1H), 4.14 (m, 
1H), 3.85 (m, 1H), 3.69 (m, 1H), 3.39 (m, 1H); 13C NMR (CDCl3, 100 MHz) δ 149.6 (C), 
143.9 (C), 143.5 (C), 142.0 (C), 134.4 (C), 131.9 (C), 129.2 (CH), 127.9 (CH), 127.2 (CH),  
124.5 (CH), 124.2 (C), 123.7 (CH), 123.4 (CH), 120.0 (CH), 112.9 (CH), 112.6 (CH), 
105.5 (CH), δ 100.1 (CH), 75.5 (CH), 56.6 (CH3), 55.9 (CH3) 51.9 (CH2), 44.8 (CH2); IR 
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(KBr, cm-1) 3434 (w), 2996 (w), 2966 (w), 2933 (w), 2879 (w), 2830 (w), 1601 (m), 1515 
(s), 1493 (s), 1447 (s), 1247 (s), 1012 (m), 770 (s), 731 (m); MS (FAB) m/z (%) 359.3 
(M+H)+ (100), 193.6 (35), 180.8 (33), 155.1 (24), 137.3 (13); HRMS (FAB) Calcd for 
(C23H23N2O2)+, 359.1760; Found, 359.1758. 
 
9.11.16 1-(Phenyl)-1,2,3,12b-tetrahydroimidazo[1,2-f]phenanthridine 
(11j).   
 
NN
 
 
General TIP synthesis method.  Product isolated as an orange powder (165 mg, 0.47 mmol, 
87.4%):  mp 196-197 ˚C (Et2O); 1H NMR (CDCl3, 400 MHz) δ 7.78 (dd, 1H, J=8.0, 1.2 
Hz), 7.68 (d, 1H, J=8.0 Hz), 7.32 (td, 1H, J=8.0, 1.2 Hz), 7.20 (m, 4H), 7.10 (d, 1H, J=8.0 
Hz), 6.95 (td, 1H, J=8.0, 1.2 Hz), 6.75 (m, 2H), 6.67 (d, 2H, J=8.0 Hz), 5.25 (s, 1H), 4.01 
(m, 1H), 3.80 (m, 1H), 3.58 (m, 1H), 3.28 (m, 1H); 13C NMR (DMSO, 100 MHz) δ 148.6 
(C), 143.2 (C), 133.7 (C), 131.5 (C), 129.2 (CH), 128.9 (CH), 127.7 (CH), 126.9 (CH), 
123.9 (CH), 123.6 (CH), 123.31 (CH), 123.25 (C), 119.6 (CH), 117.8 (CH), 114.0 (CH), 
113.1 (CH), 74.5 (CH), 50.9 (CH2), 44.3 (CH2); IR (KBr, cm-1: 3443 (w), 3057 (w), 2935 
(w), 2879 (w), 2811 (w), 1259 (w), 1598 (s), 1487 (s), 1442 (s), 1324 (s), 1301 (m), 1210 
(w), 1016 (w), 753 (s), 694 (m); MS (FAB) m/z (%) 299.3 (M+H)+ (100), 180.8 (21), 155.1 
(46), 137.3 (40), 121.5 (16); HRMS (FAB) Calcd for (C21H19N2)+, 299.1548; Found, 
299.1551. 
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9.11.17 1-(3,5-Dimethylphenyl)-1,2,3,12b-tetrahydroimidazo[1,2-
f]phenanthridine (11k).   
 
NN
 
 
General TIP synthesis method.  Product isolated as a pale peach powder (590 mg, 1.81 
mmol, 94.6%):  mp 195-196 ˚C (Et2O); 1H NMR (CDCl3, 400 MHz) δ 7.77 (d, 1H, J=7.7 
Hz), 7.67 (d, 1H, J=7.7 Hz), 7.31 (t, 1H, J=7.7 Hz), 7.22 (t, 1H, J=7.7 Hz), 7.16 (t, 1H, 
J=7.7 Hz), 7.11 (d, 1H, J=7.7 Hz), 6.92 (t, 1H, J=7.7 Hz), 6.71 (d, 1H, J=7.7 Hz), 6.43 (s, 
1H), 6.31 (s, 2H), 5.22 (s, 1H), 3.97 (m, 1H), 3.78 (m, 1H), 3.53 (m, 1H), 3.23 (m, 1H), 
2.19 (s, 6H); 13C NMR (CDCl3, 100 MHz) δ 149.1 (C), 143.5 (C), 138.8 (2 × C), 134.5 
(C), 131.9 (C), 129.2 (CH), 127.8 (CH), 127.2 (CH), 124.6 (CH), 124.3 (C), 123.7 (CH), 
123.4 (CH), 120.2 (CH), 119.1 (CH), 113.0 (2 × CH), 112.1 (CH), 75.0 (CH), 51.2 (CH2), 
44.8 (CH2), 21.7 (2 × CH3); IR (KBr, cm-1) 3433 (w), 3033 (w), 3008 (w), 2877 (w), 2835 
(w), 1611 (s), 1496 (m), 1446 (s), 1349 (s), 1224 (m), 1195 (m), 817 (m), 778 (m), 733 (s), 
687 (m); MS (FAB) m/z (%) 327.4 (M+H)+ (100), 193.7 (32), 180.8 (21), 149.2 (12); 
HRMS (FAB) Calcd for (C23H23N2)+, 327.1861; Found, 327.1862. 
 
9.11.18 1-(2-Fluorophenyl)-1,2,3,12b-tetrahydroimidazo[1,2-
f]phenanthridine (11m).   
 
NN
F
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General TIP synthesis method.  Product isolated as a pale orange powder (411 mg, 1.30 
mmol, 68.0%):  mp 158-159 ˚C (Et2O); 1H NMR (CDCl3 400 MHz) δ 7.88 (d, 1H, J=7.8 
Hz), 7.79 (d, 1H, J=7.8 Hz), 7.41 (t, 1H, J=7.8 Hz), 7.35 (t, 1H, J=7.8 Hz), 7.24 (t, 1H, 
J=7.8 Hz), 7.15 (m, 2H), 7.06 (t, 1H, J=7.8), 7.00 (t, 1H, J=7.8 Hz), 6.92 (m, 1H), 6.84 (d, 
1H, J=7.8 Hz), 6.76 (t, 1H, J=7.8 Hz), 5.44 (s, 1H), 4.35 (m, 1H), 3.73 (m, 2H), 3.33 (m, 
1H); 13C NMR (CDCl3, 100 MHz) δ 154.55 (C), 152.1 (C), 143.8 (C), 137.9 (C), 133.8 
(C), 132.0 (C), 129.2 (CH), 128.0 (CH), 127.2 (CH), 124.2 (CH), 123.8 (CH), 123.4 (CH),  
120.4 (CH), 120.0 (CH), 116.9 (CH), 116.8 (CH), 116.4 (CH), 112.8 (CH), 74.8 (CH), 
53.1 (CH2), 45.2 (CH2); IR (KBr, cm-1) 3426 (w), 3061 (w), 2955 (w), 2897 (w), 2818 (w), 
2758 (w), 1639 (w), 1503 (s), 1447 (s), 1369 (s), 1329 (s), 1302 (s), 1237 (m), 1214 (s), 
1042 (m), 757 (s), 741 (s); MS (FAB) m/z (%) 317.3 (M+H)+ (100), 180.8 (28), 155.1 (34), 
137.3 (30); HRMS (FAB) Calcd for (C21H18FN2)+, 317.1454; Found, 317.1459. 
 
9.11.19 1-(4-Fluorophenyl)-1,2,3,12b-tetrahydroimidazo[1,2-
f]phenanthridine (11n).   
 
NN
F
 
 
General TIP synthesis method.  Product isolated as a white powder (514 mg, 1.63 mmol, 
85.1%):  mp 181-183 ˚C (Et2O); 1H NMR (CDCl3 400 MHz) δ 7.89 (d, 1H, J=8.0 Hz), δ 
7.80 (d, 1H, J=8.0 Hz), 7.43 (t, 1H, J=8.0 Hz), 7.35 (t, 1H, J=8.0 Hz), 7.29 (t, 1H, J=8.0 
Hz), 7.16 (d, 1H, J=8.0 Hz), 7.03 (m, 3H), 6.84 (d, 1H, J=8.0 Hz), 6.71 (d, 1H, J=9.2 Hz), 
6.69 (d, 1H, J=9.2 Hz), 5.29 (s, 1H), 4.13 (m, 1H), 3.83 (m, 1H), 3.69 (m, 1H), 3.40 (m, 
1H); 13C NMR (CDCl3, 100 MHz) δ 157.3 (C), 155.0 (C), 145.4 (C), 143.4 (C), 134.0 (C), 
131.9 (C), 129.2 (CH), 128.0 (CH), 127.2 (CH), 124.3 (CH), 123.4 (CH), 123.5 (CH), 
120.1 (CH), 115.7 (CH), 115.4 (CH), 115.0 (CH), 114.9 (CH), 113.0 (CH), 75.5 (CH), 
51.7 (CH2), 44.9 (CH2); IR (KBr, cm-1) 3442 (w), 3060 (w), 2959 (w), 2891 (w), 2817 (w), 
2756 (w), 1600 (m), 1510 (s), 1485 (m), 1441 (m), 1366 (m), 1317 (m), 1236 (m), 1209 
EXPERIMENTAL          162 
_________________________________________________________________________ 
(m), 1158 (m); MS (FAB) m/z (%) 317.3 (M+H)+ (100), 180.8 (17); HRMS (FAB) Calcd 
for (C21H18FN2)+, 317.1454; Found, 317.1458. 
 
9.11.20 1-(3-Trifluoromethylphenyl)-1,2,3,12b-tetrahydroimidazo[1,2-
f]phenanthridine (11p).   
 
NN
F3C
 
 
General TIP synthesis method.  Product isolated as an orange solid (530 mg, 1.45 mmol, 
75.7%):  mp 147-149 ˚C (Et2O); 1H NMR (CDCl3, 400 MHz) δ 7.90 (d, 1H, J=7.7 Hz), 
7.82 (d, 1H, J=7.7 Hz), 7.45 (t, 1H, J=7.7 Hz), 7.37 (m, 2H), 7.29 (t, 1H, J=7.7 Hz), 7.15 
(m, 3H), 7.00 (s, 1H), 6.87 (m, 2H), 5.37 (s, 1H), 4.13 (m, 1H), 3.92 (m, 1H), 3.71 (m, 
1H), 3.43 (m, 1H); 13C NMR (CDCl3, 100 MHz) δ 148.8 (C), 143.1 (C), 133.5 (C), 131.9 
(C), 131.6 (C), 131.3 (C), 129.5 (CH), 129.3 (CH), 128.1 (CH), 127.3 (CH), 124.3 (C), 
124.0 (CH), 123.8 (CH), 123.7 (CH), 120.3 (CH), 116.8 (CH), 114.5 (CH), 113.3 (CH), 
110.4 (CH), 75.0 (CH), 50.9 (CH2), 44.9 (CH2); IR (KBr, cm-1) 3418 (m), 3066 (w), 2936 
(w), 2888 (w), 2827 (w), 1602 (m), 1489 (m), 1445 (s), 1362 (s), 1349 (s), 1158 (m), 1114 
(s), 1073 (m), 865 (m), 753 (s); MS (FAB) m/z (%) 367.3 (M+H)+ (100), 307.1 (8), 180.8 
(12), 154.9 (6); HRMS (FAB) Calcd for (C22H18F3N2)+, 367.1422; Found, 367.1431. 
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9.11.21 1-(4-Bromophenyl)-1,2,3,12b-tetrahydroimidazo[1,2-
f]phenanthridine (11r).   
 
NN
Br
 
 
General TIP synthesis method.  Product isolated as an brown powder (560 mg, 1.48 mmol, 
77.7%): mp 196-197 ˚C (Et2O); 1H NMR (CDCl3, 400 MHz) δ 7.78 (d, 1H, J=7.7 Hz), 
7.70 (d, 1H, J=7.7 Hz),  7.33 (t, 1H, J=7.7 Hz), 7.27 (m, 2H), 7.25 (t, 1H, J=7.7 Hz), 7.18 
(t, 1H, J=7.7 Hz), 7.03 (d, 1H, J=7.7 Hz), 6.96 (t, 1H, J=7.7 Hz), 6.74 (d, 1H, J=7.7 Hz), 
6.54 (d, 2H, J=9.0 Hz), 5.18 (s, 1H), 3.98 (m, 1H), 3.73 (m, 1H), δ 3.58 (m, 1H), 3.29 (m, 
1H); 13C NMR (CDCl3, 100 MHz) δ 147.70 (C), 143.2 (C), 133.7 (C),  131.9 (C), 131.8 (2 
× CH), 129.3 (CH), 128.0 (CH), 127.2 (CH), 124.23 (C), 124.18 (CH), 123.8 (CH), 123.6 
(CH), 120.2 (CH), 115.7 (2 × CH), 113.1 (CH), 110.1 (C), 75.1 (CH), 51.0 (CH2), 44.9 
(CH2); IR (KBr, cm-1) 3443 (w), 3063 (w), 2932 (w), 2882 (w), 2839 (w), 1590 (s), 1488 
(s), 1460 (s), 1443 (s), 1360 (s), 1345 (s), 1326 (s), 1307 (s), 745 (s), 731 (s); MS (FAB) 
m/z (%) 379.1 (M+H)+ (91), 377.1 (M+H)+ (100), 307.3 (13), 180.8 (39), 155.1 (19); 
HRMS (FAB) Calcd for (C21H18BrN2)+, 377.0653, 379.0635; Found, 377.0648, 379.0634. 
 
9.11.22 1-(4-Methylacetatephenyl)-1,2,3,12b-tetrahydroimidazo[1,2-
f]phenanthridine (11s).  
 
NN
MeO2C
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General TIP synthesis method.  Product isolated as an pale peach powder (460 mg, 1.29 
mmol, 67.6%):  mp 167-168 ˚C (Et2O); 1H NMR (CDCl3, 400 MHz) δ 7.99 (d, 2H, J=9.0 
Hz), 7.90 (d, 1H, J=7.7 Hz), 7.81 (d, 1H, J=7.7 Hz), 7.44 (t, 1H, J=7.7 Hz), 7.36 (t, 1H, 
J=7.7 Hz), 7.28 (t, 1H, J=7.7 Hz), 7.13 (d, 1H, J=7.7 Hz), 7.08 (t, 1H, J=7.7 Hz), 6.87 (d, 
1H, J=7.7 Hz), 6.75 (d, 2H, J=9.0 Hz), 5.43 (s, 1H), 4.09 (m, 1H), 3.99 (m, 1H), 3.91 (s, 
3H), 3.70 (m, 1H), 3.45 (m, 1H); 13C NMR (CDCl3, 100 MHz) δ 204.4 (C), 167.2 (C), 
151.7 (C), 142.9 (C), 133.2 (C), 131.9 (C), 131.2 (CH), 129.3 (CH), 128.1 (CH), 127.2 
(CH), 124.3 (C), 124.1 (CH), 123.8 (CH), 123.7 (CH), 123.0 (CH), 120.4 (CH), 119.3 (C), 
113.4 (CH), 74.6 (CH), 51.7 (CH3), 50.1 (CH2), 45.0 (CH2); IR (KBr, cm-1) 3400 (w), 2938 
(w), 2878 (w), 2839 (w), 1709 (s), 1598 (s), 1516 (m), 1493 (m), 1432 (w), 1279 (s), 1186 
(m), 1115 (m), 768 (m), 751 (m), 733 (m); MS (FAB) m/z (%) 357 (M+H)+ (100), 193 
(36), 154 (31), 136 (20); HRMS (FAB) Calcd for (C23H21N2O2)+, 357.1603; Found, 
357.1602. 
 
9.11.23 1-(3,4-Difluorophenyl)-1,2,3,12b-tetrahydroimidazo[1,2-
f]phenanthridine (11t).   
 
NN
F
F
 
 
General TIP synthesis method.  Product isolated as a pale yellow powder (625 mg, 1.87 
mmol, 97.9%):  mp 154-155 ˚C (Et2O); 1H NMR (CDCl3, 400 MHz) δ 7.89 (d, 1H, J=7.7 
Hz), 7.80 (d, 1H, J=7.7 Hz), 7.45 (t, 1H, J=7.7 Hz), 7.36 (t, 1H, J=7.7 Hz), 7.30 (t, 1H, 
J=7.7 Hz), 7.09 (m, 3H), 6.85 (d, 1H, J=7.7 Hz), 6.57 (m, 1H), δ 6.41 (m, 1H), 5.25 (s, 
1H), 4.08 (m, 1H), 3.81 (m, 1H), 3.69 (m, 1H), 3.41 (m, 1H); 13C NMR (CDCl3, 100 MHz) 
δ 151.8 (dd, JC-F = 245, 14 Hz, C), 145.8 (C), 144.7 (dd, JC-F = 245, 14 Hz, C), 143.1 (C), 
133.5 (C), 131.9 (C), 129.3 (CH), 128.1 (CH), 127.3 (CH), 124.2 (C), 124.1 (CH), 123.8 
(CH), 123.6 (CH), 120.3 (CH), 117.4 (d, JC-F = 20 Hz, CH), 113.2 (CH), 109.0 (CH), 103.1 
(d, JC-F = 20 Hz, CH), 75.4 (CH), 51.4 (CH2), 44.9 (CH2), 19F NMR (CDCl3, 376 MHz): δ -
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136.7 (s, 1F), -152.7 (s, 1F); IR (KBr, cm-1) 3419 (w), 3062 (w), 3031 (w), 2943 (w), 2888 
(w), 2826 (w), 2760 (w), 2675 (w), 1627 (m), 1581 (s), 1520 (s), 1452 (s), 1348 (s), 1224 
(s), 817 (s); MS (FAB) m/z (%) 335.2 (M+H)+ (100), 206.6 (12), 180.8 (51), 157.0 (20); 
HRMS (FAB) Calcd for (C21H17F2N2)+, 335.1360; Found, 335.1363. 
 
9.11.24 1-(3,4,5-Trifluorophenyl)-1,2,3,12b-tetrahydroimidazo[1,2-
f]phenanthridine (11u).   
 
NN
F
F
F
 
 
General TIP synthesis method.  Product isolated as a pale yellow powder (404 mg, 1.15 
mmol, 60.1%):  mp 192-194 ˚C; 1H NMR (CDCl3, 400 MHz) δ 7.78 (d, 1H, J=8.0 Hz), 
7.70 (d, 1H, J=8.0 Hz), 7.35 (t, 1H, J=8.0 Hz), 7.23 (m, 2H), 6.99 (m, 2H), 6.75 (d, 1H, 
J=8.0 Hz), 6.22 (m, 2H), 5.12 (s, 1H), 3.92 (m, 1H), 3.68 (m, 1H), 3.57 (m, 1H), 3.31 (m, 
1H); 13C NMR (CDCl3, 100 MHz) δ 142.8 (C), 133.0 (C), 131.9 (C), 129.3 (CH), 128.2 
(CH), 127.4 (CH), 124.2 (C), 123.8 (2 × CH), 123.7 (CH), 120.5 (CH), 113.4 (CH), 97.9 
(CH), 97.6 (CH), 75.3 (CH), 51.0 (CH2), 45.0 (CH2); IR (KBr, cm-1) 3736 (w), 3070 (w), 
2887 (w), 2359 (w), 1602 (w), 1527 (m), 1253 (m), 1037 (m), 756 (s); MS (EI+) m/z (%) 
352 (M+) (17), 193 (88), 165 (20), 78 (100), 63 (100), 45 (18); HRMS (EI+) Calcd for 
C21H15F3N2, 335.1360; Found, 335.1363. 
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9.11.25 1-(3-Methoxyphenyl)-1,2,3,12b-tetrahydroimidazo[1,2-
f]phenanthridine (11y). 
 
N
MeO
N
 
 
General TIP synthesis method.  Product isolated as a pale orange powder (400 mg, 1.22 
mmol, 63.8%): mp 122-124 ˚C (Et2O); 1H NMR (CDCl3, 400 MHz) δ 7.89 (d, 1H, J=7.7 
Hz), 7.79 (d, 1H, J=7.7 Hz), 7.42 (t, 1H, J=7.7 Hz), 7.35 (t, 1H, J=7.7 Hz), 7.28 (t, 1H, 
J=7.7 Hz), 7.23 (d, 1H, J=7.7 Hz), 7.21 (t, 1H, J=8.2 Hz), 7.05 (t, 1H, J=7.7 Hz), 6.84 (d, 
1H, J=7.7 Hz), 6.45 (dd, 1H, J=8.2 Hz, 2.2 Hz), 6.39 (dd, 1H, J=8.2 Hz, 2.2 Hz), 6.34 (t, 
1H, J=2.2 Hz), 5.34 (s, 1H), 4.09 (m, 1H), 3.91 (m, 1H), 3.81 (s, 3H), 3.68 (m, 1H), 3.39 
(m, 1H); 13C NMR (CDCl3, 100 MHz) δ 160.6 (C), 150.1 (C), 143.3 (C), 143.1 (C), 131.8 
(C), 129.8 (CH), 129.2 (CH), 127.8 (CH), 127.2 (CH), 124.5 (CH), 124.4 (C), 123.7 (CH), 
123.4 (CH), 120.0 (CH), 113.0 (CH), 107.1 (CH), 103.1 (CH), 100.7 (CH), 75.1 (CH), 
55.2 (CH3), 51.0 (CH2), 44.9 (CH2); IR (KBr, cm-1) 3434 (w), 3062 (w), 3032 (w), 3000 
(w), 2970 (w), 2936 (w), 2879 (w), 2838 (m), 2772 (w), 2675 (w), 1601 (s), 1491 (s), 1442 
(s), 1358 (s), 1237 (s), 1168 (s), 1041 (s), 768 (s); MS (FAB) m/z (%) 329.3 (M+H)+ (100), 
180.8 (26), 155.1 (23), 137.3 (22), 84.9 (16); HRMS for (C22H21N2O)+ calcd: 329.1654, 
obsd 329.1655. 
 
9.11.26 1-(3-Chloro-4-fluorophenyl)-1,2,3,12b-tetrahydroimidazo[1,2-
f]phenanthridine (11z). 
 
NN
F
Cl
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General TIP synthesis method.  Product isolated as an off-white powder (418 mg, 1.19 
mmol, 62.4%):  mp 164-165 ˚C (Et2O); 1H NMR (CDCl3, 400 MHz) δ 7.89 (d, 1H, J=7.7 
Hz), 7.81 (d, 1H, J=7.7 Hz), 7.45 (t, 1H, J=7.7 Hz), 7.36 (t, 1H, J=7.7 Hz), 7.31 (t, 1H, 
J=7.7 Hz), 7.13 (d, 1H, J=7.7 Hz), 7.07 (t, 1H, J=7.7 Hz), 7.06 (t, 1H, J=9.1 Hz), 6.85 (d, 
1H, J=7.7 Hz), 6.78 (dd, 1H, J=6.0 Hz, J=3.2 Hz), 6.57 (dt, 1H, J=9.1 Hz, J=3.2 Hz), 5.27 
(s, 1H), 4.08 (m, 1H), 3.81 (m, 1H), 3.69 (m, 1H), 3.40 (m, 1H); 13C NMR (CDCl3, 100 
MHz) δ 151.4 (d, JC-F=238 Hz, CF), 145.8 (C), 143.1 (C), 133.5 (C), 131.9 (C), 129.3 
(CH), 128.1 (CH), 127.3 (CH), 124.2 (C), 124.0 (CH), 123.8 (CH), 123.6 (CH), 121.2 (d, 
JC-F=20 Hz, CCl),  120.3 (CH), 116.6 (d, JC-F=20 Hz, CH), 115.3 (CH), 113.2 (CH), 113.0 
(CH), 75.3 (CH), 51.4 (CH2), 44.9 (CH2); 19F NMR (CDCl3, 400 MHz): δ -130.1 (s),IR 
(KBr, cm-1) 3433 (w), 3034 (w), 2937 (w), 2879 (w), 2845 (w), 2764 (w), 1600 (m), 1505 
(s), 1445 (m), 1361 (m), 1328 (m), 1239 (s), 834 (m), 756 (s), 734 (s); MS (FAB) m/z (%) 
351.2 (M+H)+ (100), 180.8 (33); HRMS (FAB) for (C21H17ClFN2)+ calcd 351.1064, obsd 
351.1069. 
 
9.11.27 1-(3-Cyano-phenyl)-1,2,3,12b-tetrahydro-imidazo[1,2-
f]phenanthridine (11a’) 
 
NN
NC
 
 
General TIP synthesis method.  Product isolated as a pale peach powder (386 mg, 1.19 
mmol, 62.5%):  mp 175-177 ˚C (Et2O); 1H NMR (CDCl3, 400 MHz) δ 7.78 (d, 1H, J=7.8 
Hz), 7.69 (d, 1H, J=7.8 Hz), 7.33 (t, 1H, J=7.8 Hz), 7.23 (m, 2H), 7.18 (t, 1H, J=7.8 Hz), 
7.01 (d, 1H, J=7.8 Hz), 6.96 (m, 2H), 6.87 (s, 1H), 6.81 (dd, 1H, J=8.4 Hz, J=2.2 Hz), 6.74 
(d, 1H, J=7.8 Hz), 5.20 (s, 1H), 3.96 (m, 1H), δ 3.74 (m, 1H), 3.57 (m, 1H), 3.29 (m, 1H); 
13C NMR (CDCl3, 100 MHz) δ 148.7 (C), 142.9 (C), 133.0 (C), 131.9 (C), 129.9 (CH), 
129.4 (CH), 128.2 (CH), 127.4 (CH), 124.3 (C), 123.86 (CH), 123.85 (CH), 123.8 (CH), 
121.4 (CH), 120.5 (CH), 119.4 (C), 118.0 (CH), 116.6 (CH), 113.4 (CH), 113.0 (C), 75.0 
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(CH), 50.7 (CH2), 45.0 (CH2); IR (KBr, cm-1) 3433 (w), 3061 (w), 2946 (w), 2886 (w), 
2846 (w), 2766 (w), 2225 (m), 1596 (s), 1572 (m), 1491 (s), 1444 (s), 1359 (s), 1339 (s), 
1304 (m), 1161 (m); 850 (m), 778 (s), 756 (s), 683 (m); MS (FAB) m/z (%) 324 (M+H)+ 
(100), 193 (32), 180 (20); HRMS (FAB) for (C22H18N3)+ calcd 324.1501, obsd 324.1500. 
 
9.11.28 1-Cyclohexyl-2,3-dihydro-1H-imidazo[1,2-f]phenanthridinium 
bromide (12a). 
 
N
N
Br
 
 
A solution of cyclohexylamine (218 µL, 1.91 mmol, 1.0 eq) in 5% Na2CO3 aqueous 
solution (20mL) was added to a suspension of BEP 10 (700 mg, 1.91 mmol, 1.0 eq) in 
ethyl acetate (30mL).  The resultant biphasic solution was stirred at room temperature 
under N2 for 1 h.  Layers were separated and the organic layer was washed with water (3 × 
10 mL) and brine (1 × 10 mL).  NBS (340 mg, 1.91 mmol, 1.0 eq) was added and the 
reaction was stirred for 30 min.  The resultant suspension was filtered, washing the residue 
with acetone.  The residue was dried under vacuum and collected as a pale yellow solid 
(678 mg, 1.77 mmol, 92.6%):  mp 293-294 ˚C (MeOH-Et2O); 1H NMR (CDCl3 MHz) δ 
8.64 (d, 1H, J=8.0), 8.42 (d, 1H, J=8.0 Hz), 8.30 (d, 1H, J=8.0 Hz), 8.07 (t, 1H, J=8.0 Hz), 
7.83 (t, 1H, J=8.0 Hz), 7.79 (t, 1H, J=8.0 Hz), 7.65 (d, 1H, J=8.0 Hz), 7.58 (t, 1H, J=8.0 
Hz), 5.17 (t, 2H, J=10.6 Hz), 4.74 (t, 2H, J=10.6 Hz), 4.57 (m, 1H), 2.26 (m, 2H), 2.06 (m, 
2H), 1.99 (m, 2H), 1.84 (m, 1H), 1.52 (m, 2H), 1.37 (m, 1H); 13C NMR (DMSO, 100 
MHz) δ 152.6 (C), 135.0 (CH), 135.0 (C), 133.0 (C), 131.4 (CH), 129.5 (CH), 127.8 (CH), 
125.0 (CH), 124.3 (CH), 123.8 (CH), 119.8 (C), 115.72 (CH), 115.65 (C), 57.6 (CH), 45.8 
(CH2), 44.7 (CH2), 30.2 (2 × CH2), 24.6 (CH2), 24.5 (2 × CH2); MS (FAB) m/z (%) 303.3 
(M+) (100), 221.5 (11), 176.8 (11), 155.0 (32). 
Product Reference:  Parenty, A. D. C., University of Glasgow, 2004. 
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9.11.29 1-(3,4-Dimethoxyphenyl)-2,3-dihydro-1H-imidazo[1,2-
f]phenanthridinium bromide (12i). 
 
N
N
Br
OMe
MeO
 
 
To a suspension of BEP 10 (1.00 g, 2.72 mmol, 2.0 eq) in CHCl3 (25 mL) was added was 
added TEA (568 µL, 4.08 mmol, 3.0 eq) and 3,4-dimethoxyaniline (209 mg, 1.36 mmol, 
1.0 eq).  The reaction was stirred under N2 for 24 h.  Solvent was removed under vacuum 
and the residue was triturated with water (2 × 2 mL) then acetone (~30 mL) to give a pale 
yellow powder after drying under vacuum (338 mg, 0.77 mmol, 56.8 %):  mp 307-308 ˚C 
(decomp) (MeOH-Et2O); 1H NMR (DMSO, 400 MHz): δ 8.91 (d, 1H, J=8.2 Hz), 8.82 (d, 
1H, J=8.2 Hz), 8.07 (t, 1H, J=8.2 Hz), 7.93 (t, 1H, J=8.2 Hz), 7.83 (d, 1H, J=8.2 Hz), 7.71 
(t, 1H, J=8.2 Hz), 7.61 (t, 1H, J=8.2 Hz), 7.41 (m, 2H), 7.26 (m, 2H), 4.93 (t, 2H, J=10.4 
Hz), 4.59 (m, 2H), 3.89 (s, 3H), 3.75 (s, 3H); 13C NMR (DMSO, 100 MHz) δ 152.6 (C), 
150.0 (C), 149.7 (C), 135.3 (CH), 135.0 (C), 132.6 (C), 131.5 (CH), 128.7 (CH), 127.1 
(CH), 125.6 (CH), 124.2 (CH), 124.1 (CH), 120.3 (C), 118.9 (CH), 116.1 (CH), 115.1 (C), 
112.6 (CH), 110.2 (CH), 55.8 (2 × CH3), 54.6 (CH2), 46.7 (CH2); IR (KBr, cm-1) 3024 (w), 
2960 (w), 2361 (w), 1595 (m), 1577 (s), 1514 (m), 1442 (m), 1307 (m), 1261 (s), 1240 (m), 
1022 (m), 754 (s); MS (FAB) m/z (%) 357.4 (M+) (100), 307.2 (32), 290.3 (12), 155.0 (43), 
138.2 (42); HRMS (FAB) for (C23H21N2O2+) calcd 357.1603, obsd 357.1600. 
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9.11.30 1-Phenyl-2,3-dihydro-1H-imidazo[1,2-f]phenanthridinium 
bromide (12j). 
 
NN
Br
 
 
NBS (299 mg, 1.68 mmol, 1.0 eq) was added to a solution of 1-phenyl-1,2,3,12b-
tetrahydroimidazo[1,2-f]phenanthridine (500 mg, 1.68 mmol, 1.0 eq) in chloroform ( 30 
mL) and the resultant suspension was stirred at room temperature for 1.5 h.  Solvent was 
removed under vacuum and the residue was triturated with ethyl acetate (3 × 20 mL) and 
diethyl ether (3 × 20 mL).  The product was collected by filtration and dried under vacuum 
to give a pale peach powder (549 mg, 1.58 mmol, 86.6%):  mp >340 ˚C (MeOH-Et2O); 1H 
NMR (DMSO, 400 MHz) δ 8.93 (d, 1H, J=8.0 Hz), 8.83 (d, 1H, J=8.0 Hz), 8.07 (t, 1H, 
J=8.0 Hz), 7.94 (t, 1H, J=8.0 Hz), 7.85 (d, 1H, J=8.0 Hz), 7.71 (m, 6H), 7.55 (t, 1H, J=8.0 
Hz), 7.29 (d, 1H, J=8.0 Hz), 4.96 (t, 2H, J=10.6 Hz), 4.62 (t, 2H, J=10.6 Hz); 13C NMR 
(DMSO, 100 MHz) δ 152.7 (C), 139.2 (C), 135.3 (CH), 135.2 (C), 132.6 (C), 131.6 (CH), 
130.8 (2 × CH), 130.1 (CH), 128.6 (CH), 127.0 (CH), 126.7 (2 × CH), 125.8 (CH), 124.3 
(CH), 124.1 (CH), 120.5 (C), 116.2 (CH), 115.4 (C), 54.4 (CH2), 46.9 (CH2). 
Product Reference:  Parenty, A. D. C.; Smith, L. V.; Pickering A. L.; Long, D. –L.; Cronin 
L., J. Org. Chem. 2004, 69, 5934-5946. 
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9.11.31 1-(4-Fluorophenyl)-2,3-dihydro-1H-imidazo[1,2-
f]phenanthridinium bromide (12n). 
 
N
N
Br
F
 
 
To a solution of 1-(4-fluorophenyl)-1,2,3,12b-tetrahydro-imidazo[1,2-f]phenanthridine 
(250 mg, 0.79 mmol, 1.0 eq) in CHCl3 (30 mL) was added NBS (140 mg, 0.79 mmol, 1.0 
eq) and the reaction was stirred at room temperature for 1h.  The reaction mixture was then 
concentrated under vacuum and the residue was triturated with acetone to give a pale peach 
powder after drying (250 mg,  0.63 mmol, 80.1%):  mp >350˚C (MeOH-Et2O); 1H NMR 
(DMSO, 400 MHz) δ 8.94 (d, 1H, J=8.0 Hz), 8.84 (d, 1H, J=8.0 Hz), 8.08 (t, 1H, J=8.0 
Hz), 7.95 (t, 1H, J=8.0 Hz), 7.83 (m, 3H), 7.73 (t, 1H, J=8.0 Hz), 7.59 (m, 3H), 7.31 (d, 
1H, J=8.0 Hz), 4.95 (t, 2H, J=10.2 Hz), 4.60 (t, 2H, J=10.2 Hz); 13C NMR (DMSO, 100 
MHz) δ 162.3 (d, JC-F=247.8 Hz, C), 152.7 (C), 135.38 (C), 135.35 (CH), 135.1 (C), 132.5 
(C), 131.6 (CH), 129.3 (CH), 128.8 (CH), 127.0 (CH), 125.8 (CH), 124.2 (d, JC-F=24.3Hz, 
CH), 120.4 (C), 118.0 (CH), 117.8 (CH), 116.2 (CH), 115.2 (C), 54.5 (CH2), 46.9 (CH2); 
IR (cm-1) 1577 (m), 1394 (m), 1219 (m), 848 (m), 790 (m), 756 (s), 669 (m); MS (FAB) 
m/z (%) 315.3 (M+) (100); HRMS (FAB) for (C21H16FN2)+ calcd 315.1298, obsd 315.1299. 
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9.11.32 1-(3-Trifluoromethylphenyl)-2,3-dihydro-1H-imidazo[1,2-
f]phenanthridinium bromide (12p). 
 
 
N
N
Br
CF3
 
 
To a suspension of BEP 10 (700 mg, 1.91 mmol, 1.0 eq) in CHCl3 (40 mL) was added 3-
(trifluoromethyl)-aniline (239 µL, 1.91 mmol, 1.0 eq) and TEA (798 µL, 5.73 mmol, 3.0 
eq).  The resultant suspension was stirred under a nitrogen atmosphere for 5 h.  The 
reaction mixture was transferred to a separating funnel and washed with water (2×20 mL) 
and brine (1×20 mL).  The organic phase was then dried over MgSO4 and the solvent was 
removed under vacuum to give a yellow oil.  The oily residue was redissolved in CHCl3 
(50 mL) and NBS (340 mg, 1.91 mmol, 1.0 eq) was added.  The reaction was stirred at 
room temperature for 2 h then filtered, yielding a pale yellow powder after drying under 
vacuum (498 mg).  The filtrate was concentrated under vacuum and the residue was 
triturated with acetone to yield a second batch of product (128 mg).  Combined yield (626 
mg, 1.41 mmol, 73.6%):  mp >350 ˚C (MeOH-Et2O); 1H NMR (DMSO, 400 MHz) δ 8.97 
(d, 1H, J=8.0 Hz), 8.87 (d, 1H, J=8.0 Hz), 8.21 (s, 1H), 8.08 (m, 3H), 7.92 (m, 3H), 7.76 (t, 
1H, J=8.0 Hz), 7.60 (t, 1H, J=8.0 Hz), 7.28 (d, 1H, J=8.0 Hz), 5.00 (t, 2H, J=10.2 Hz), 
4.69 (t, 2H, J=10.2 Hz); 13C NMR (DMSO, 100 MHz) δ 152.9 (C), 140.2 (C), 135.5 (CH), 
135.2 (C), 132.5 (C), 132.1 (CH), 131.7 (CH), 130.9 (CH), 128.7 (CH), 127.0 (CH), 126.5 
(CH), 126.1 (CH), 124.5 (CH), 124.1 (CH), 123.8 (CH), 120.7 (C), 116.4 (CH), 115.1 (C), 
54.1 (CH2), 47.2 (CH2); IR (cm-1) 3032 (w), 1577 (m), 1539 (m), 1325 (m), 1128 (m), 756 
(m), 704 (m); MS (FAB) m/z (%) 365 (M+) (70), 307 (26), 289 (18), 154 (100), 136 (70); 
HRMS (FAB) for (C22H16F3N2)+ calcd 365.1266, obsd 365.1270. 
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9.11.33 1-(3,4-Difluorophenyl)-2,3-dihydro-1H-imidazo[1,2-
f]phenanthridinium bromide (12t). 
 
N
N
Br
F
F
 
 
NBS (340 mg, 1.91 mmol, 1.0 eq) was added to a solution of 1-difluorophenyl-1,2,3,12b-
tetrahydroimidazo[1,2-f]phenanthridine (640 mg, 1.91 mmol, 1.0 eq) in chloroform ( 30 
mL) and the resultant suspension was stirred at room temperature for 1 h.  Solvent was 
removed under vacuum and the residue was triturated with acetone to give the product as a 
pale orange powder after drying under vacuum (700 mg, 1.69 mmol, 88.7%):  mp 355-356 
˚C (MeOH-Et2O); 1H NMR (DMSO, 400 MHz) δ 8.95 (d, 1H, J=8.2 Hz), 8.86 (d, 1H, 
J=8.2 Hz), 8.12 (t, 1H, J=8.2 Hz), 7.96 (m, 2H), 7.88 (d, 1H, J=8.2 Hz), 7.78 (m, 2H), 7.64 
(m, 2H), 7.41 (d, 1H, J=8.2 Hz), 4.97 (t, 2H, J=10.5 Hz), 4.61 (t, 2H, J=10.6 Hz); 13C 
NMR (DMSO, 100 MHz) δ 152.9 (C), 150.1 (dd, JC-F = 252, 13.6 Hz, C), 150.0 (dd, JC-F = 
252, 13.6 Hz, C), 135.8 (C), 135.5 (CH), 135.1 (C), 132.4 (C), 131.6 (CH), 129.0 (CH), 
127.3 (CH), 126.0 (CH), 124.5 (CH), 124.3 (CH), 124.1 (CH), 120.6 (C), 119.7 (d, JC-F = 
19 Hz, CH), 116.9 (d, JC-F = 19 Hz, CH), 116.4 (CH), 115.0 (C), 54.3 (CH2), 47.1 (CH2); 
IR (KBr, cm-1) 3024 (w), 2359 (w), 2332 (w), 1595 (w), 1577 (m), 1541 (m), 1508 (s), 
1456 (m), 1267 (m), 754 (s); MS (FAB) m/z (%) 333 (M+) (100), 307 (53), 289 (53); 
HRMS (FAB) for (C21H15F2N2)+ calcd 333.1203, obsd 333.1205. 
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9.11.34 1-Methyl-2,3-dihydro-1H-imidazo[1,2-f]phenanthridinium   
bromide (12b’). 
 
NN
Br
 
 
To a biphasic solution of methylamine hydrochloride (460 mg, 6.81 mmol, 5.0 eq) in 
EtOAc (20 mL) and 5% Na2CO3 (10 mL) was added BEP 10 (500 mg, 1.362 mmol, 1.0 
eq).  The reaction was stirred under nitrogen for 5 min, the aqueous layer was removed and 
the organic layer washed with H2O (1 × 10 mL) then brine (1 × 10 mL).  NBS (242 mg, 
1.36 mmol, 1.0 eq) was added and the reaction stirred under nitrogen for 1 h.  The 
precipitated product was filtered, washing with diethyl ether and drying under vacuum to 
give a pale yellow powder as the product (419 mg, 1.33 mmol, 97.6%):  mp >350˚C 
(MeOH-Et2O); 1H NMR (DMSO, 400 MHz) δ 8.88 (d, 1H, J=8.0 Hz), 8.71 (d, 1H, J=8.0 
Hz), 8.69 (d, 1H, J=8.0 Hz), 8.14 (t, 1H, J=8.0 Hz), 7.90 (t, 1H, J=8.0 Hz), 7.81 (t, 1H, 
J=8.0 Hz), 7.62 (d, 1H, J=8.0 Hz), 7.60 (t, 1H, J=8.0 Hz), 4.69 (t, 2H, J=10.6 Hz), 4.33 (t, 
2H, J=10.6 Hz), 3.76 (s, 3H); 13C NMR (DMSO, 100 MHz) δ 153.3 (C), 135.2 (CH), 134.7 
(C), 132.9 (C), 131.4 (CH), 129.1 (CH), 128.3 (CH), 125.0 (CH), 124.1 (CH), 123.9 (CH), 
119.7 (C), 116.0 (C), 115.6 (CH), 53.0 (CH2), 45.7 (CH2), 38.1 (CH3). 
Product Reference:  Smith, L. V.; Parenty, A. D. C.; Guthrie, K. M.; Plumb, J.; Brown, R.; 
Cronin, L. Chembiochem 2006, 7, 1757-1763. 
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9.11.35 1-(2-Hydroxy-ethyl)-2,3-dihydro-1H-imidazo[1,2-
f]phenanthridinium bromide (12f’). 
 
N
Br
NHO
 
 
To a suspension of BEP 10 (1.00 g, 2.72 mmol, 1.0 eq) in EtOAc (40 mL) was added a 
solution of ethanolamine (197 µL, 3.26 mmol, 1.2 eq) in 5% Na2CO3 (aq).  The resultant 
biphasic solution was stirred under a nitrogen atmosphere for 2.5 h.  The reaction mixture 
was transferred to a separating funnel and the layers were separated, washing the organic 
phase with H2O (2×20 mL).  The combined organics were dried over MgSO4 and filtered 
before adding NBS (484 mg, 2.72 mmol, 1.0 eq).  The reaction was stirred at room 
temperature for 2 h.  The precipitated product was collected by filtration and dried under 
vacuum to yield the product as a pale yellow powder.  The product was recrystallized from 
EtOH (621 mg, 1.80 mmol, 66.1%):  mp 205-207 ˚C (EtOH); 1H NMR (DMSO, 400 MHz) 
δ 8.89 (d, 1H, J=7.8 Hz), 8.78 (d, 1H, J=7.8 Hz), 8.73 (d, 1H, J=7.8 Hz), 8.14 (t, 1H, J=7.8 
Hz), 7.86 (t, 1H, J=7.8 Hz), 7.85 (t, 1H, J=7.8 Hz), 7.66 (d, 1H, J=7.8 Hz), 7.62 (t, 1H, 
J=7.8 Hz), 4.74 (t, 2H, J=10.6 Hz), 4.48 (t, 1H, J=10.6 Hz), 4.20 (t, 2H, J=5.3 Hz), 3.94 (t, 
2H, J=5.3 Hz); 13C NMR (DMSO, 100 MHz) δ 153.8 (C), 135.2 (CH), 134.7 (C), 132.9 
(C), 131.4 (CH), 129.0 (CH), 128.2 (CH), 125.1 (CH), 124.1 (CH), 123.9 (CH), 119.8 (C), 
115.8 (CH), 115.6 (C), 58.1 (CH2), 52.6 (CH2), 51.3 (CH2), 46.0 (CH2); MS (FAB) m/z 
(%) 265.2 (M+) (100), 219.4 (13). 
Product Reference:  Parenty, A. D. C.; Smith, L. V.; Pickering A. L.; Long, D. –L.; Cronin 
L., J. Org. Chem. 2004, 69, 5934-5946. 
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9.11.36 1-Methoxycarbonylmethyl-2,3-dihydro-1H-imidazo[1,2-
f]phenanthridinium bromide (12g’). 
 
N
Br
N
MeO2C
 
 
To a suspension of of BEP 10 (700 mg, 1.91 mmol, 1.0 eq) in EtOAc (30 mL) was added a 
solution of glycine methyl ester hydrochloride (240 mg, 1.91 mmol, 1.0 eq) and 
triethanolamine (1.425 g, 9.55 mmol, 5.0 eq) in H2O (30 mL).  The reaction was stirred at 
room temperature under nitrogen for 1 h.  The layers were separated and the organic layer 
was washed with H2O (2 × 20 mL) and dried over MgSO4.  NBS (306 mg, 1.72 mmol, 0.9 
eq) was then added and the solution was stirred in the dark for 1 h.  The resultant 
suspension was filtered, washing the residue with Et2O and drying under vacuum to give a 
pale yellow powder (583 mg, 1.56 mmol, 90.8%):  mp 230 °C (decomp); 1H NMR 
(DMSO, 400 MHz) δ 8.96 (d, 1H, J=8.2 Hz), 8.81 (d, 1H, J=8.2 Hz), 8.36 (d, 1H, J=8.2 
Hz), 8.18 (t, 1H, J=8.2 Hz), 7.90 (t, 1H, J=8.2 Hz), 7.89 (t, 1H, J=8.2 Hz), 7.76 (d, 1H, 
J=8.2 Hz), 7.70 (t, 1H, J=8.2 Hz), 5.22 (s, 2H), 4.87 (t, 2H, J=10.6 Hz), 4.36 (t, 2H, J=10.6 
Hz), 3.79 (s, 3H); 13C NMR (DMSO, 100 MHz) δ 186.2 (C), 153.8 (C), 135.5 (CH), 134.6 
(C), 132.3 (C), 131.5 (CH), 129.5 (CH), 127.1 (CH), 125.7 (CH), 124.2 (CH), 123.9 (CH), 
120.0 (C), 116.3 (CH), 115.1 (C), 53.0 (CH3), 52.1 (CH2), 51.7 (CH2), 46.3 (CH2). 
Product Reference:  Smith, L. V.; de la Fuente, J. M.; Guthrie, K. M.; Parenty, A. D. C.; 
Cronin, L. New J. Chem. 2005, 29, 1118-1120. 
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9.11.37 1-Carboxymethyl-2,3-dihydro-1H-imidazo[1,2-
f]phenanthridinium bromide (12h’). 
 
N
Br
N
HO2C
 
 
48 % HBr (aq) (5 mL) was added to a solution of 1-methoxycarbonylmethyl-2,3-dihydro-
1H-imidazo[1,2-f]phenanthridinium bromide (400 mg, 1.07 mmol, 1.0 eq) in H2O (10 mL) 
and the reaction solution stirred for 2 h.  The solvents were removed under vacuum to give 
a pale peach powder (344 mg, 0.96 mmol, 89.8%):  mp 280 °C (decomp); 1H NMR 
(DMSO, 400 MHz) δ 8.95 (d, 1H, J=8.0 Hz), 8.79 (d, 1H, J=8.0 Hz), 8.39 (d, 1H, J=8.0 
Hz), 8.17 (t, 1H, J=8.0 Hz), 7.90 (t, 1H, J=8.0), 7.89 (t, 1H, J=8.0), 7.74 (d, 1H, J=8.0 Hz), 
7.68 (t, 1H, J=8.0 Hz), 5.12 (s, 2H), 4.86 (t, 2H, J=10.5 Hz), 4.36 (t, 2H, J=10.5 Hz); 13C 
NMR (MeOD, 100 MHz) δ 170.5 (C), 156.1 (C), 137.1 (C), 136.8 (CH), 134.2 (C), 132.8 
(CH), 130.5 (CH), 128.3 (CH), 127.2 (CH), 125.5 (CH), 125.1 (CH), 122.1 (C), 117.1 
(CH), 53.6 (CH2), 52.9 (CH2), 47.7 (CH2); IR (KBr, cm-1) 3429 (w), 2779 (m), 2588 (m), 
2506 (m), 1714 (s), 1573 (s), 1549 (s), 1449 (m), 1401 (m), 1300 (m), 1259 (s), 1201 (s), 
1108 (w), 753 (m), 715 (m), 631 (m); MS (FAB) m/z (%) 307.3 (26), 279.3 (M+) (100), 
155.1 (64), 137.3 (61); HRMS (FAB) for (C17H15N2O2)+ calcd 279.1134, obsd 279.1138. 
 
9.11.38 1-(4-Hydroxy-phenyl)-2,3-dihydro-1H-imidazo[1,2-
f]phenanthridin-4ium bromide (12i’). 
 
NN
HO
Br
 
EXPERIMENTAL          178 
_________________________________________________________________________ 
 
To a solution of BEP 10 (500 mg, 1.36 mmol, 2.0 eq) in MeOH (15 mL) was added a 
solution of 4-aminophenol (74 mg, 0.68 mmol, 1.0 eq) and TEA (285 µL, 2.04 mmol, 3.0 
eq) in MeOH (5 mL).  The reaction mixture was shaken vigorously for 1 min then left to 
stand for 24 h.  Brown crystals were filtered, washing them with MeOH and diethyl ether 
before drying under vacuum.  The product was collected as a brown crystalline solid (194 
mg, 0.49 mmol, 72.4%):  mp >350˚C; 1H NMR (DMSO, 400 MHz) δ 8.88 (d, 1H, J=8.0 
Hz), 8.78 (d, 1H, J=8.0 Hz), 8.05 (t, 1H, J=8.0 Hz), 7.91 (t, 1H, J=8.0 Hz), 7.79 (d, 1H, 
J=8.0 Hz), 7.69 (t, 1H, J=8.0 Hz), 7.57 (t, 1H, J=8.0 Hz), 7.53 (d, 2H, J=9.2 Hz), 7.37 (d, 
1H, J=8.0 Hz), 7.03 (d, 2H, J=9.2 Hz), 4.89 (t, 2H, J=10.6 Hz), 4.52 (t, 2H, J=10.6 Hz); 
13C NMR (DMSO, 100 MHz) δ 158.4 (C), 152.5 (C), 135.2 (CH), 134.9 (C), 132.7 (C), 
131.5 (CH), 129.9 (C), 128.6 (CH), 128.1 (2 × CH), 126.9 (CH), 125.5 (CH), 124.2 (CH), 
124.0 (CH), 120.2 (C), 117.1 (2 × CH), 116.0 (CH), 115.4 (C), 54.6 (CH2), 46.6 (CH2); IR 
(KBr, cm-1) 3448 (w), 3108 (s), 3021 (m), 1609 (s), 1595 (s), 1576 (s), 1547 (s), 1513 (s), 
1494 (s), 1446 (s), 1391 (m), 1303 (s), 1262 (s), 1227 (s), 1166 (s), 845 (s), 788 (s), 751 
(s), 718 (s), 666 (s); MS (FAB) m/z (%) 313 (14) (M+), 232 (17), 157 (32), 79 (100); Anal. 
Calcd for C21H17BrN2O:  C, 64.13; H, 4.36; N, 7.12; Found: C, 63.96; H, 4.33; N, 7.08. 
 
9.11.39 5-(2-Cyclohexylaminoethyl)-phenanthridinium chloride; 
hydrochloride (13a). 
 
NH2
N
Cl
Cl
 
 
To a suspension of BEP 10 (700 mg, 1.91 mmol, 1.0 eq) in DCM (40 mL) was added 
cyclohexylamine (219 µL, 1.91 mmol, 1.0 eq) and 5% Na2CO3 (20 mL).  The reaction 
mixture was stirred for 3 hr under nitrogen before transferring to a separating funnel.  
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Phases were separated and the organic phase was washed with water (1 × 10 mL) then 
extracted into 1N HCl (2 × 20 mL).  The acidic extract was concentrated under vacuum 
and the residue triturated with acetone to afford a pale yellow powder as the product (691 
mg, 1.83 mmol, 95.9%):  mp 252-253 ˚C; 1H NMR (D2O, 400 MHz) δ 9.90 (s, 1H), 8.94 
(d, 1H, J=8.2 Hz), 8.85 (d, 1H, J=8.2 Hz), 8.40 (d, 1H, J=8.2 Hz), 8.26 (m, 2H), 7.99 (m, 
3H), 5.36 (t, 2H, J=6.8 Hz), 3.74 (t, 2H, J=6.8 Hz), 3.07 (m, 1H), 1.93 (m, 2H), 1.67 (m, 
2H), 1.50 (m, 1H), 1.11 (m, 5H); 13C NMR (D2O, 100 MHz) δ 155.5 (CH), 139.0 (CH), 
135.2 (C), 132.8 (CH), 132.5 (CH), 132.4 (C), 130.6 (CH), 130.5 (CH), 126.2 (C), 124.9 
(CH), 123.3 (C), 122.6 (CH), 118.3 (CH), 58.4 (CH), 53.6 (CH2), 42.2 (CH2), 28.6 
(2×CH2), 24.3 (CH2), 23.8 (2×CH2); IR (KBr, cm-1) 3405 (m), 2963 (m), 2857 (m), 2627 
(m), 2490 (m), 2431 (m), 2368 (w), 1626 (s), 1582 (m), 1448 (m), 1347 (m), 1261 (m), 
1030 (m), 916 (m), 761 (s); 610 (m); MS (FAB) m/z (%) 305.4 (M+) (100), 155.1 (25), 
137.3 (16); HRMS (FAB) for (C21H25N2)+ calcd 305.2018, obsd 305.2016. 
 
9.11.40 5-(2-Isobutylaminoethyl)-phenanthridinium chloride; 
hydrochloride (13b). 
 
NH2
N Cl
Cl
 
 
BEP 10 (250 mg, 0.68 mmol, 1.0 eq) was added to a biphasic solution of isobutylamine 
(67.5 µL, 0.68 mmol, 1.0 eq) in ethyl acetate (20 mL) and 5% Na2CO3 aqueous solution 
(20 mL).  The solution was stirred at room temperature for 3 h before transferring it to a 
separating funnel, where the phases were separated and the organic phase was washed with 
water (2 × 5 mL) and brine (1 × 5 mL).  Conc. HCl (3 drops) was then added to the organic 
layer to form the hydrochloride salt.  Evaporation of the solvent and trituration of the 
residue with diethyl ether yielded the product as a pale yellow solid (187 mg, 0.53 mmol, 
78.3%):  mp 234-235 ˚C; 1H NMR (DMSO, 400 MHz) δ 10.72 (s, 1H), 10.08 (s, 2H), 9.25 
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(d, 1H, J=8.0 Hz), 9.18 (d, 1H, J=8.0 Hz), 8.89 (d, 1H, J=8.0 Hz), 8.60 (d, 1H, J=8.0 Hz), 
8.43 (t, 1H, J=8.0 Hz), 8.15 (m, 3H), 5.69 (t, 2H, J=6.2 Hz), 3.69 (m, 2H), 2.84 (m, 2H), 
2.10 (sept, 1H, J=6.8 Hz), 0.99 (d, 6H, J=6.8 Hz); 13C NMR (DMSO, 100 MHz) δ 157.4 
(CH), 138.2 (CH), 134.7 (C), 133.3 (C), 133.1 (CH), 132.0 (CH), 130.3 (CH), 130.2 (CH), 
126.1 (C), 125.1 (CH), 123.8 (C), 123.1 (CH), 120.0 (CH), 54.3 (CH2), 53.1 (CH2), 45.5 
(CH2), 25.4 (CH), 20.3 (2 × CH3); IR (KBr, cm-1) 3412 (s), 2959 (m), 2706 (m), 1627 (s), 
1535 (m), 1451 (s), 761 (s); MS (EI+) m/z (%) 280.3 (M+) (11), 278.3 (5), 235.2 (36), 
194.2 (100), 180.2 (30), 165.1 (23); HRMS (FAB) for (C19H23N2)+ calcd 279.1861, obsd 
279.1862. 
 
9.11.41 5-(2-Cyclopentylaminoethyl)-phenanthridinium chloride; 
hydrochloride (13c). 
 
NH2
N
Cl
Cl
 
 
To a suspension of BEP 10 (700 mg, 1.91 mmol, 1.0 eq) in DCM (40 mL) was added 
cyclopentylamine (188 µL, 1.91 mmol, 1.0 eq) and 5% Na2CO3 (20 mL).  The reaction 
mixture was stirred for 2.5 hr under nitrogen before transferring to a separating funnel.  
Phases were separated and the organic phase was washed with water (1 × 10 mL) then 
extracted into 1N HCl (2 × 20 mL).  The acidic extract was concentrated under vacuum 
and the residue triturated with acetone to afford a pale yellow powder as the product (647 
mg, 1.78 mmol, 93.2%):  mp 255-257 ˚C; 1H NMR (D2O, 400 MHz) δ 9.89 (s, 1H), 8.88 
(d, 1H, J=8.2 Hz), 8.79 (d, 1H, J=8.2 Hz), 8.39 (d, 1H, J=8.2 Hz), 8.25 (m, 2H), 8.06-7.93 
(m, 3H), 5.37 (t, 2H, J=6.8 Hz), 3.73 (t, 2H, J=6.8 Hz), 3.53 (p, 1H, J=7.1 Hz), 1.96 (m, 
2H), 1.54 (m, 6H); 13C NMR (D2O, 100 MHz) δ 155.3 (CH), 138.9 (CH), 135.0 (C), 132.7 
(CH), 132.5 (CH), 132.2 (C), 130.6 (CH), 130.4 (CH), 126.0 (C), 124.7 (CH), 123.1 (C), 
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122.5 (CH), 118.2 (CH), 60.4 (CH), 53.5 (CH2), 44.0 (CH2), 29.0 (2×CH2), 23.4 (2×CH2); 
IR (KBr, cm-1) 3405 (m), 2960 (m), 2646 (m), 2438 (w), 1627 (s), 1581 (m), 1535 (m), 
1453 (m), 1348 (w), 920 (w), 760 (s), 611 (w), 493 (w); MS (FAB) 291.0 (M+) (100), 
180.1 (22); HRMS (FAB) for (C20H23N2)+ calcd 291.1861, obsd 291.1864. 
 
9.11.42 5-(2-(4-Methoxyphenyl)-aminoethyl)-phenanthridinium chloride; 
hydrochloride (13h). 
 
NH2
N
Cl
Cl
MeO
 
 
To a suspension of BEP 10 (700 mg, 1.91 mmol, 1.0 eq) in CHCl3 (50 mL) was added p-
anisidine (235 mg, 1.91 mmol, 1.0 eq) and TEA (798 µL, 5.73 mmol, 3.0 eq).  The 
resultant suspension was stirred under a nitrogen atmosphere for 20 min.  The reaction 
mixture was transferred to a separating funnel and washed with water (2×20 mL) and 5% 
Na2CO3 (aq) (2×20 mL).  The organic phase was then dried over MgSO4 and the solvent 
was removed under vacuum to give an off-white powder.  The dry residue was dissolved in 
DCM (50 mL) and extracted into 0.1 M HCl (2×20 mL).  The aqueous extracts were 
combined and concentrated under vacuum to give an orange oil which was vitrified by 
addition of acetone.  The product was collected by filtration, dried under vacuum and 
collected as pale peach powder (626 mg, 1.56 mmol, 81.7 %):  mp 205-207 ˚C (MeOH-
Et2O); 1H NMR (CD3OD, 400 MHz) δ 10.20 (s, 1H), 9.19 (d, 1H, J=7.8 Hz), 9.12 (d, 1H, 
J=7.8 Hz), 8.69 (d, 1H, J=7.8 Hz), 8.59 (d, 1H, J=7.8 Hz), 8.46 (t, 1H, J=7.8 Hz), 8.24 (t, 
1H, J=7.8 Hz), 8.19 (t, 1H, J=7.8 Hz), 8.15 (t, 1H, J=7.8 Hz), 7.32 (d, 2H, J=8.9 Hz), 6.91 
(d, 2H, J=8.9 Hz), 5.65 (t, 2H, J=6.3 Hz), 4.21 (t, 2H, J=6.3 Hz), 3.76 (s, 3H); 13C NMR 
(DMSO, 100 MHz) δ 157.0 (CH), 138.2 (CH), 134.6 (C), 133.2 (C), 133.0 (CH), 132.1 
(CH), 130.3 (CH), 130.2 (CH), 126.0 (C), 125.1 (CH), 123.6 (C), 123.1 (CH), 119.9 (CH), 
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114.8 (CH), 55.4 (CH3), 54.2 (CH2), 47.2 (CH2); IR (cm-1) 2999 (w), 2588 (w), 2314 (w), 
1630 (w), 1535 (w), 1514 (s), 1450 (m), 1259 (m), 1022 (m), 769 (s); MS (FAB) m/z (%) 
329.2 (M+) (100), 193.6 (10), 180.8 (15); HRMS (FAB) for (C22H21N2O)+ calcd 329.1654, 
obsd 329.1659. 
 
9.11.43 5-(2-(3,4-Dimethoxyphenyl)-aminoethyl)-phenanthridinium 
chloride; hydrochloride (13i). 
 
NH2
N
Cl
Cl
MeO
MeO
 
 
To a suspension of 1-(3,4-dimethoxyphenyl)-1,2,3,12b-tetrahydroimidazo[1,2-
f]phenanthridine (100 mg, 0.32 mmol) in MeOH (4 mL) was added conc. HCl (4 drops) 
and the resultant solution was stirred for 5 min.  The solution was then concentrated under 
vacuum to give an orange oil which was vitrified by addition of acetone.  The product was 
collected by filtration and dried under vacuum and collected as pale yellow powder (61 
mg, 0.14 mmol, 50.0 %):  mp 187-189 ˚C (MeOH-Et2O); 1H NMR (DMSO, 400 MHz) δ 
10.23 (s, 1H), 9.22 (d, 1H, J=8.0 Hz), 9.15 (d, 1H, J=8.0 Hz), 8.75 (d, 1H, J=8.0 Hz), 8.53 
(d, 1H, J=8.0 Hz), 8.42 (t, 1H, J=8.0 Hz), 8.14 (m, 3H), 6.67 (d, 1H, J=8.0 Hz), 6.38 (brd, 
1H), 6.32 (brd, 1H), 5.37 (t, 2H, J=5.8 Hz), 3.86 (t, 2H, J=5.8 Hz); 13C NMR (DMSO, 100 
MHz) δ 156.6 (CH), 149.5 (C), 138.1 (CH), 134.5 (C), 133.2 (C), 132.9 (CH), 132.1 (CH), 
130.33 (CH), 130.25 (CH), 125.9 (C), 125.1 (CH), 123.4 (C), 123.1 (CH), 119.9 (CH), 
113.1 (CH), 56.1 (CH3), 55.7 (CH2), 55.3 (CH3), 46.4 (CH2); IR (KBr, cm-1) 3433 (m), 
3005 (w), 2590 (w), 2214 (w), 1626 (s), 1515 (s), 1448 (m), 1263 (m), 1018 (m), 758 (s); 
MS (FAB) m/z (%) 359.4 (M+) (100), 193.7 (13), 180.8 (34); HRMS (FAB) for 
(C23H23N2O2)+ calcd 359.1760, obsd 359.1767. 
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9.11.44 5-(2-Phenylaminoethyl)-phenanthridinium chloride; 
hydrochloride (13j). 
 
NH2
N
Cl
Cl
 
 
1-phenyl-1,2,3,12b-tetrahydroimidazo[1,2-f]phenanthridine (200 mg, 0.671 mmol, 1.0 eq) 
was dissolved in chloroform (6 mL), conc. HCl (3-5 drops) was added and the reaction 
stirred at room temperature for 30 min.  The reaction mixture was diluted with water (10 
mL).  Layers were then separated and the organic layer further extracted with water (2 × 10 
mL).  The combined aqueous extracts were concentrated under vacuum to give an orange 
oil.  Addition of acetone crystallized out a pale yellow solid product which was collected 
by filtration (224 mg, 0.603 mmol, 90.0%):  mp 212-214 ˚C; 1H NMR (D2O, 400 MHz) δ 
9.42 (s, 1H), 8.74 (d, 1H, J=7.8 Hz), 8.63 (d, 1H, J=7.8 Hz), 8.33 (d, 1H, J=7.8 Hz), 8.13 
(t, 1H, J=7.8 Hz), 8.09 (d, 1H, J=7.8 Hz), 8.01 (t, 1H, J=7.8 Hz), 7.93 (t, 1H, J=7.8 Hz), 
7.81 (t, 1H, J=7.8 Hz), 6.72 (t, 2H, J=7.6 Hz), 6.36 (t, 1H, J=7.6 Hz), 6.32 (d, 2H, J=7.6 
Hz), 5.15 (t, 2H, J=5.3 Hz), 3.86 (t, 2H, J=5.3 Hz); 13C NMR (DMSO, 100 MHz) δ 156.0 
(CH), 138.0 (CH), 134.4 (C), 133.2 (C), 132.8 (CH), 132.0 (CH), 130.4 (CH), 130.3 (CH), 
129.1 (CH), 125.9 (C), 125.1 (CH), 123.4 (C), 123.1 (CH), 119.9 (CH), 113.0 (CH), 58.8 
(CH2), 42.2 (CH2); IR (KBr, cm-1) 3406 (m), 3066 (w), 2579 (m), 2336 (m), 1626 (s), 1446 
(m), 761 (s); MS (FAB) m/z (%) 299.3 (M+) (64), 232.3 (17), 179.7 (15), 158.0 (64), 81.1 
(100); HRMS (FAB) for (C21H19N22)+ calcd 299.1548, obsd 299.1547. 
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9.11.45 5-(2-(3,5-Dimethylphenyl)-aminoethyl)-phenanthridinium 
chloride; hydrochloride (13k). 
 
NH2
N
Cl
Cl
 
 
To a suspension of BEP 10 (700 mg, 1.91 mmol, 1.0 eq) in CHCl3 (40 mL) was added 3,5-
dimethylaniline (238 µL, 1.91 mmol, 1.0 eq) and TEA (798 µL, 5.73 mmol, 3.0 eq).  The 
resultant suspension was stirred under a nitrogen atmosphere for 40 min.  The reaction 
mixture was transferred to a separating funnel and washed with water (2×20 mL) and 5% 
Na2CO3 (aq) (2×20 mL).  The organic phase was then dried over MgSO4 and the solvent 
removed under vacuum to give an off-white powder.  The dry residue was dissolved in 
DCM (30 mL) and extracted into 1.0 M HCl (2×20 mL).  The aqueous extracts were 
combined and concentrated under vacuum to give a mobile yellow oil which was vitrified 
by addition of acetone.  The product was collected by filtration under a flow of nitrogen 
due to the hygroscopic nature of the product, which was then dried under vacuum and 
collected as pale orange powder (620 mg, 1.55 mmol, 81.3 %):  mp 207-209 ˚C (MeOH-
Et2O); 1H NMR (D2O, 400 MHz) δ 9.45 (s, 1H), 8.76 (d, 1H, J=7.8 Hz), 8.62 (d, 1H, J=7.8 
Hz), 8.34 (d, 1H, J=7.8 Hz), 8.16 (t, 1H, J=7.8 Hz), 8.05 (m, 2H), 7.97 (t, 1H, J=7.8 Hz), 
7.83 (t, 1H, J=7.8 Hz), 5.84 (s, 2H, 5.73 (s, 1H), 5.23 (t, 2H, J=4.8 Hz), 3.95 (t, 2H, J=4.8 
Hz), 1.51 (s, 6H); 13C NMR (D2O, 100 MHz) δ 154.8 (CH), 140.4 (C), 139.4 (CH), 134.7 
(C), 132.7 (C), 132.6 (CH), 132.5 (CH), 131.7 (C), 130.8 (CH), 130.4 (CH), 125.7 (C), 
124.9 (CH), 122.8 (C), 122.5 (CH), 118.7 (CH), 50.0 (CH2), 44.2 (CH2), 19.5 (2×CH3); IR 
(cm-1) 2336 (w), 1627 (w), 923 (w), 854 (w), 765 (s); MS (FAB) m/z (%) 327.3 (M+) 
(100), 206.5 (8) ,193.6 (20), 180.8 (34), 149.1 (18); HRMS (FAB) for (C23H24N2)2+ calcd 
328.1939, obsd 328.1935. 
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9.11.46 5-(2-(4-Fluorophenyl)-aminoethyl)-phenanthridinium chloride; 
hydrochloride (13n). 
 
NH2
N
Cl
Cl
F
 
 
A solution of 1-(4-fluorophenyl)-1,2,3,12b-tetrahydroimidazo[1,2-f]phenanthridine (100 
mg, 0.32 mmol) in DCM (30 mL) was extracted with 1.0 M HCl (2×20 mL).  The aqueous 
extracts were combined and concentrated under vacuum to give a yellow oil which was 
vitrified by addition of acetone.  The product was collected by filtration, dried under 
vacuum, and collected as pale yellow powder (108 mg, 0.28 mmol, 86.7 %):  mp 220-222 
˚C (MeOH-Et2O); 1H NMR (D2O, 400 MHz) δ 9.61 (s, 1H), 8.68 (d, 1H, J=8.0 Hz), 8.60 
(d, 1H, J=8.0 Hz), 8.20 (d, 1H, J=8.0 Hz), 8.15 (m, 2H), 7.96 (t, 1H, J=8.0 Hz), 7.86 (m, 
2H), 7.03 (m, 2H), 6.72 (m, 2H), 5.38 (t, 2H, J=5.8 Hz), 4.13 (t, 2H, J=5.8 Hz); 13C NMR 
(D2O, 100 MHz) δ 161.6 (d, JC-F=246.0 Hz, C), 155.2 (CH), 139.1 (CH), 135.2 (C), 132.6 
(CH), 132.5 (CH), 132.2 (C), 130.7 (CH), 130.5 (CH), 130.2 (C), 126.2 (C), 124.9 (CH), 
123.2 (C), 123.1 (CH), 122.7 (CH), 118.6 (CH), 117.0 (d, JC-F=23.0 Hz, CH), 54.2 (CH2), 
46.4 (CH2); IR (KBr, cm-1) 3439 (s), 3055 (w), 2563 (w), 2362 (w), 1625 (s), 1509 (s), 
1233 (w), 759 (s); MS (FAB) m/z (%) 317 (M+) (14), 307 (28), 289 (18), 147 (91), 136 
(100); HRMS (FAB) for (C21H18FN2)+ calcd 317.1454, obsd 317.1450. 
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9.11.47 5-(2-(3-Trifluoromethylphenyl)-aminoethyl)-phenanthridinium 
chloride; hydrochloride (13p). 
 
NH2
N
Cl
ClF3C
 
 
To a suspension of BEP 10 (700 mg, 1.91 mmol, 1.0 eq) in CHCl3 (50 mL) was added 
TEA (798 µL, 5.73 mmol, 3.0 eq) and 3-(trifluoromethyl)aniline (239 µL, 1.91 mmol, 1.0 
eq).  The reaction was stirred under N2 for 3.5 h.  The reaction mixture was transferred to a 
separating funnel and the layers were separated, washing the organic layer further with 
H2O (2×20 mL) before drying over MgSO4.  Solvent was then removed under vacuum to 
give a yellow oil, addition of MeOH (20 mL) precipitated a pale yellow solid which was 
collected by filtration.  The Filter residue was resuspended in MeOH (10 mL) and acidified 
with conc. HCl (5 drops).  The reaction was stirred for 5 min then solvent was removed 
under vacuum to give an orange oil, addition of acetone vitrified the oil to give a pale 
orange crystalline solid which was collected by filtration and dried under vacuum (404 mg, 
0.92 mmol, 48.1 %):  mp 203-205 ˚C (MeOH-Et2O); 1H NMR (CD3OD, 400 MHz) δ 9.92 
(s, 1H), 9.15 (d, 1H, J=8.0 Hz), 9.05 (d, 1H, J=8.0 Hz), 8.71 (d, 1H, J=8.0 Hz), 8.45 (d, 
1H, J=8.0 Hz), 8.39 (t, 1H, J=8.0 Hz), 8.20 (m, 2H), 8.06 (t, 1H, J=8.0 Hz), 7.09 (t, 1H, 
J=8.0 Hz), 6.69 (d, 1H, J=8.0 Hz), 6.50 (s, 1H), 5.36 (t, 2H, J=5.2 Hz), 4.01 (t, 2H, J=5.2 
Hz); 13C NMR (CD3OD, 100 MHz) δ 156.8 (CH), 149.1 (C), 139.6 (CH), 136.7 (C), 134.9 
(C), 133.89 (CH), 133.56 (CH), 132.31 (C), 131.85 (CH), 131.6 (CH), 131.0 (CH), 128.0 
(C), 126.9 (C), 126.4 (CH), 125.1 (C), 124.2 (CH), 120.5 (CH), 116.7 (CH), 114.6 (CH), 
108.8 (CH), 59.4 (CH2), 42.9 (CH2); IR (KBr, cm-1) 3262 (m), 3008 (m), 2268 (m), 1627 
(s), 1534 (m), 1447 (s), 1326 (s), 1123 (s), 872 (m), 766 (s); MS (FAB) m/z (%) 367.3 (M+) 
(100); HRMS (FAB) for (C22H18F3N2)+ calcd 367.1422, obsd 367.1424. 
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9.11.48 5-(2-(3,4-Difluorophenyl)-aminoethyl)-phenanthridinium 
chloride; hydrochloride (13t). 
 
NH2
N
Cl
Cl
F
F
 
 
A solution of 1-(4-fluorophenyl)-1,2,3,12b-tetrahydroimidazo[1,2-f]phenanthridine (100 
mg, 0.32 mmol) in DCM (30 mL) was extracted with 1.0 M HCl (2×20 mL).  The aqueous 
extracts were combined and concentrated under vacuum to give a yellow oil which was 
vitrified by addition of acetone.  The product was collected by filtration, dried under 
vacuum and collected as pale yellow powder (56 mg, 0.14 mmol, 45.8 %):  mp 165-167 ˚C 
(MeOH-Et2O); 1H NMR (D2O, 400 MHz) δ 8.81 (d, 1H, J=8.0 Hz), 8.70 (d, 1H, J=8.0 
Hz), 8.35 (d, 1H, J=8.0 Hz), 8.18 (m, 2H), 8.02 (t, 1H, J=8.0 Hz), 7.96 (t, 1H, J=8.0 Hz), 
7.86 (t, 1H, J=8.0 Hz), 8.66 (m, 1H), 6.20 (m, 1H), 6.13 (m, 1H), 5.22 (t, 2H, J=5.6 Hz), 
3.88 (t, 2H, J=5.6 Hz); 13C NMR (DMSO, 100 MHz) δ 156.1 (CH), 150.0 (dd, JC-F=242.0, 
13.6 Hz, CF), 145.0 (d, JC-F=13.6 Hz, CH), 141.3 (dd, JC-F=242.0, 13.6 Hz, CF), 138.0 
(CH), 134.4 (C), 133.1 (C), 132.8 (CH), 132.0 (CH), 130.4 (CH), 130.3 (CH), 125.9 (C), 
125.0 (CH), 123.4 (C), 123.1 (CH), 119.9 (CH), 117.4 (d, JC-F=, 13.6 Hz, CH), 108.3 (CH), 
100.4 (d, JC-F=, 13.6 Hz, CH), 56.78 (CH2), 41.9 (CH2); IR (KBr, cm-1) 3432 (m), 3000 
(m), 2568 (w), 2135 (w), 1629 (m), 1517 (s), 1452 (m), 1294 (m), 754 (s); MS (FAB) m/z 
(%) 335.3 (M+) (100), 307.4 (23), 155.2 (44), 137.4 (44); HRMS (FAB) for (C21H17F2N2)+ 
calcd 335.1360, obsd 335.1365. 
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9.11.49 5-(2-Methylaminoethyl)-phenanthridinium chloride; 
hydrochloride (13b’). 
 
NH2
N
Cl
Cl
 
 
To a suspension of BEP 10 (500 mg, 1.36 mmol, 1.0 eq) in EtOAc (20 mL) was added 
methylamine hydrochloride (460 mg, 6.81 mmol, 5.0 eq) and 5% Na2CO3 (10 mL).  The 
reaction mixture was stirred for 5 min at room temperature before transferring to a 
separating funnel.  Phases were separated and the organic phase was washed with water (1 
× 10 mL) then extracted into 1N HCl (1 × 10 mL).  The acidic extract was concentrated 
under vacuum and the residue triturated with acetone to afford a white powder as the 
product (356 mg, 1.15 mmol, 84.7%):  mp 254-255 ˚C; 1H NMR (D2O, 400 MHz) δ 9.91 
(s, 1H), 8.90 (d, 1H, J=8.2 Hz), 8.81 (d, 1H, J=8.2 Hz), 8.40 (d, 1H, J=8.2 Hz), 8.29-8.24 
(m, 2H), 7.99 (m, 3H), 5.40 (t, 2H, J=6.6 Hz), 3.76 (t, 2H, J=6.6 Hz), 2.69 (s, 3H); 13C 
NMR (D2O, 100 MHz) δ 155.5 (CH), 139.1 (CH), 135.3 (C), 132.9 (CH), 132.6 (CH), 
132.5 (C), 130.8 (CH), 130.6 (CH), 126.3 (C), 125.0 (CH), 123.3 (C), 122.7 (CH), 118.4 
(CH), 53.5 (CH2), 46.7 (CH2), 33.5 (CH3); IR (KBr, cm-1) 3447 (m), 2999 (m), 2682 (m), 
2406 (m), 1626 (s), 1534 (m), 1447 (m), 1345 (m), 1259 (m), 1154 (w), 1032 (m), 760 (s), 
719 (m), 613 (w); MS (FAB) m/z (%) 237.4 (M+) (100), 206.6 (26), 180.8 (87), 60.4 (51); 
HRMS (FAB) for (C16H17N2)+ calcd 237.1392, obsd 237.1391. 
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9.11.50 5-(2-Cycloheptylaminoethyl)-phenanthridinium chloride; 
hydrochloride (13c’). 
 
NH2
N
Cl
Cl
 
 
To a suspension of BEP 10 (700 mg, 1.91 mmol, 1.0 eq) in DCM (40 mL) was added 
cycloheptylamine (243 µL, 1.91 mmol, 1.0 eq) and 5% Na2CO3 (20 mL).  The reaction 
mixture was stirred for 2.5 hr under nitrogen before transferring to a separating funnel.  
Phases were separated and the organic phase was washed with water (1 × 10 mL) then 
extracted into 1N HCl (2 × 20 mL).  The acidic extract was concentrated under vacuum 
and the residue triturated with acetone to afford a pale yellow powder as the product (740 
mg, 1.89 mmol, 99.0%):  mp 254-255 ˚C; 1H NMR (D2O, 400 MHz) δ 9.74 (s, 1H), 8.53 
(d, 1H, J=8.4 Hz), 8.43 (d, 1H, J=8.4 Hz), 8.21 (d, 1H, J=8.4 Hz), 8.12 (d, 1H, J=8.4 Hz), 
8.03 (t, 1H, J=8.4 Hz), 7.89 (t, 1H, J=8.4 Hz), 7.78 (m, 2H), 5.21 (t, 2H, J=6.8 Hz), 3.60 (t, 
2H, J=6.8 Hz), 3.19 (m, 1H), 1.85 (m, 2H), 1.45 (m, 4H), 1.28 (m, 6H); 13C NMR (D2O, 
100 MHz) δ 155.4 (CH), 138.9 (CH), 135.1 (C), 132.7 (CH), 132.5 (CH), 132.3 (C), 130.6 
(CH), 130.47 (CH), 126.05 (C), 124.81 (CH), 123.18 (C), 122.5 (CH), 118.3 (CH), 60.7 
(CH), 53.5 (CH2), 42.6 (CH2), 30.2 (2×CH2), 27.1 (2×CH2), 23.0 (2×CH2); IR (KBr, cm-1) 
3397 (m), 2928 (m), 2857 (m), 2694 (m), 2455 (m), 1627 (s), 1579 (m), 1534 (m), 1448 
(m), 1347 (m), 1261 (m), 1032 (m), 920 (m), 762 (s), 721 (m), 610 (m), 494 (m); MS 
(FAB) m/z (%) 319 (M+) (59), 307 (27), 289 (23), 180 (8), 154 (100), 136 (75); HRMS 
(FAB) for (C22H27N2)+ calcd 319.2174, obsd 319.2176. 
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9.11.51 5-(2-Butylaminoethyl)-phenanthridinium chloride; hydrochloride 
(13d’). 
 
NH2
N
Cl
Cl
 
 
To a suspension of BEP 10 (700 mg, 1.91 mmol, 1.0 eq) in DCM (40 mL) was added 
cyclopentylamine (189 µL, 1.91 mmol, 1.0 eq) and 5% Na2CO3 (20 mL).  The reaction 
mixture was stirred for 2.5 hr under nitrogen before transferring to a separating funnel.  
Phases were separated and the organic phase was washed with water (1 × 10 mL) then 
extracted into 1N HCl (2 × 20 mL).  The acidic extract was concentrated under vacuum 
and the residue triturated with acetone to afford a pale yellow powder as the product (579 
mg, 1.65 mmol, 86.4%):  mp 223-224 ˚C; 1H NMR (D2O, 400 MHz) δ 9.87 (s, 1H), 8.68 
(d, 1H, J=8.4 Hz), 8.59 (d, 1H, J=8.4 Hz), 8.35 (d, 1H, J=8.4 Hz), 8.23 (d, 1H, J=8.4 Hz), 
8.18 (t, 1H, J=8.4 Hz), 8.03 (t, 1H, J=8.4 Hz), 7.92 (m, 2H), 5.36 (t, 2H, J=6.6 Hz), 3.74 (t, 
2H, J=6.6 Hz), 3.05 (t, 2H, J=7.4 Hz), 1.58 (p, 1H, J=7.4 Hz), 1.29 (sext, 2H, J=7.4 Hz), 
0.81 (t, 3H, J=7.4 Hz); 13C NMR (D2O, 100 MHz) δ 155.5 (CH), 139.1 (CH), 135.2 (C), 
132.8 (CH), 132.6 (CH), 132.5 (C), 130.7 (CH), 130.6 (CH), 126.2 (C), 124.9 (CH), 123.3 
(C), 122.7 (CH), 118.4 (CH), 53.5 (CH2), 48.3 (CH2), 45.2 (CH2), 27.4 (CH2), 19.1 (CH2), 
12.7 (CH3); IR (KBr, cm-1) 3375 (m), 2963 (s), 2702 (m), 2409 (m), 2359 (m), 1628 (s), 
1535 (m), 1459 (s), 1262 (m), 1155 (m), 1040 (m), 761 (s), 720 (m); MS (FAB) m/z (%) 
279 (M+) (100), 180 (24), 154 (37), 136 (32); HRMS (FAB) for (C19H23N2)+ calcd 
279.1861, obsd 279.1858. 
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9.11.52 5-(2-Nonylaminoethyl)-phenanthridinium chloride; hydrochloride 
(13e’). 
 
NH2
N
Cl
Cl
 
 
To a suspension of BEP 10 (700 mg, 1.91 mmol, 1.0 eq) in DCM (40 mL) was added 
cyclopentylamine (350 µL, 1.91 mmol, 1.0 eq) and 5% Na2CO3 (20 mL).  The reaction 
mixture was stirred for 2.5 hr under nitrogen before transferring to a separating funnel.  
Phases were separated and the organic phase was washed with water (1 × 10 mL) then 
extracted into 1N HCl (2 × 20 mL).  The acidic extract was concentrated under vacuum 
and the residue triturated with acetone to afford a pale yellow powder as the product (511 
mg, 1.21 mmol, 63.5%):  mp 213-215 ˚C; 1H NMR (D2O, 400 MHz) δ 9.88 (s, 1H), 8.81 
(d, 1H, J=8.2 Hz), 8.72 (d, 1H, J=8.2 Hz), 8.35 (d, 1H, J=8.2 Hz), 8.23 (d, 1H, J=8.2 Hz), 
8.20 (t, 1H, J=8.2 Hz), 8.00 (t, 1H, J=8.2 Hz), 7.93 (t, 1H, J=8.2 Hz), 7.90 (t, 1H, J=8.2 
Hz), 5.34 (t, 2H, J=6.7 Hz), 3.70 (t, 2H, J=6.7 Hz), 2.95 (t, 2H, J=7.7 Hz), 1.51 (q, 2H, 
J=7.7 Hz), 1.10 (m, 12H), 0.67 (t, 3H, J=6.7 Hz); 13C NMR (D2O, 100 MHz) δ 156.2 
(CH), 139.9 (CH), 136.2 (C), 133.6 (CH), 133.3 (CH), 131.5 (CH), 131.3 (CH), 127.2 (C), 
125.8 (CH), 124.2 (C), 123.5 (CH), 119.0 (CH), 54.1 (CH2), 49.2 (CH2), 45.8 (CH2), 31.5 
(CH2), 28.8 (CH2), 28.7 (CH2), 28.5 (CH2), 26.0 (CH2), 25.8 (CH2), 22.4 (CH2), 13.8 
(CH3); IR (KBr, cm-1) 3409 (s), 2924 (s), 2853 (s), 2727 (m), 2399 (w), 1626 (s), 1536 (m), 
1458 (s), 1348 (m), 1263 (m), 1150 (w), 1032 (m), 758 (s), 720 (m), 611 (m), 493 (w); MS 
(FAB) m/z (%) 349.6 (M+) (100), 180.0 (18), 171.1 (17); HRMS (FAB) for (C24H33N2)+ 
calcd 349.2644, obsd 349.2642. 
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9.11.53 5-(2-Dodecylaminoethyl)-phenanthridinium chloride; 
hydrochloride (13j’). 
 
NH2
N
Cl
Cl
 
 
To a suspension of BEP 10 (700 mg, 1.91 mmol, 1.0 eq) in DCM (40 mL) was added 
cyclopentylamine (354 mg, 1.91 mmol, 1.0 eq) and 5% Na2CO3 (20 mL).  The reaction 
mixture was stirred for 4 hr under nitrogen before transferring to a separating funnel.  
Phases were separated and the organic phase was washed with water (1 × 10 mL).  
Addition of 1N HCl (40 mL) gave an emulsion which was concentrated under vacuum and 
the residue triturated with acetone to afford a pale peach powder as the product (742 mg, 
1.60 mmol, 83.8%):  mp 212-213 ˚C; 1H NMR (D4-Methanol, 400 MHz) δ 9.87 (s, 1H), 
8.56 (d, 1H, J=8.2 Hz), 8.49 (d, 1H, J=8.2 Hz), 8.14 (d, 1H, J=8.2 Hz), 8.06 (d, 1H, J=8.2 
Hz), 7.83 (t, 1H, J=8.2 Hz), 7.62 (t, 1H, J=8.2 Hz), 7.55 (t, 1H, J=8.2 Hz), 7.52 (t, 1H, 
J=8.2 Hz), 5.06 (t, 2H, J=6.7 Hz), 3.30 (t, 2H, J=6.7 Hz), 2.72 (m, 1H), 2.55 (t, 2H, J=7.7 
Hz), 1.94 (p, 2H, J=7.7 Hz), 0.74 (m, 18H), 0.30 (t, 3H, J=7.7 Hz); 13C NMR (D4-
Methanol, 100 MHz) δ 156.3 (CH), 138.4 (CH), 135.4 (C), 133.0 (C), 132.8 (CH), 132.2 
(CH), 130.2 (CH), 130.0 (CH), 126.3 (C), 124.7 (CH), 123.7 (C), 122.6 (CH), 118.9 (CH), 
53.2 (CH2), 48.2 (CH2), 45.2 (CH2), 31.3 (CH2), 29.0 (CH2), 28.9 (CH2), 28.8 (CH2), 28.5 
(CH2), 25.8 (CH2), 25.6 (CH2), 22.0 (CH2), 12.8 (CH3); IR (KBr, cm-1) 3433 (m), 2921 (s), 
2848 (m), 2671 (w), 2413 (w), 1629 (m), 1454 (m), 1363 (w), 764 (m), 722 (w); MS 
(FAB) m/z (%) 391.4 (M+) (100), 212.7 (27), 180.8 (30); HRMS (FAB) for (C27H39N2)+ 
calcd 391.3113, obsd 391.3111. 
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9.11.54 5-(2-Isobutylaminoethyl)-6H-phenanthridine (14b). 
 
N
HN
 
 
In an NMR tube, 5-(2-isobutylaminoethyl)-phenanthridinium chloride; hydrochloride (30 
mg, 0.085 mmol, 1.0 eq) was dissolved in D2O (1 mL).  CDCl3 (1 mL) was then added 
follwed by sodium cyanoborohydride (6.4 mg, 0.102 mmol, 1.2 eq) and the reaction 
shaken until a biphasic solution formed.  The aqueous phase was removed and the organic 
layer was washed with a 5% Na2CO3 in D2O solution (2 × 1 mL).  The organic layer was 
concentrated under vacuum to give the product as a yellow oil (20 mg, 0.713 mmol, 
71.3%):  1H NMR (DMSO, 400 MHz) δ 7.74 (d, 1H, J=8.0 Hz), 7.73 (d, 1H, J=8.0 Hz), 
7.30 (t, 1H, J=8.0 Hz), 7.23 (t, 1H, J=8.0 Hz), 7.18 (m, 2H), 6.83 (d, 1H, J=8.0 Hz), 7.75 
(t, 1H, J=8.0 Hz), 4.32 (s, 2H), 3.38 (t, 2H, J=8.0 Hz), 2.76 (t, 2H, J=8.0 Hz), 2.37 (d, 2H, 
J=7.6 Hz), 1.65 (sept, 1H, J=6.8 Hz), 0.87 (d, 6H, J=6.8 Hz); 13C NMR (DMSO, 100 
MHz) δ 146.0 (C), 132.6 (C), 131.6 (C), 129.1 (C), 128.1 (CH), 127.5 (CH), 126.9 (CH), 
125.7 (CH), 123.6 (CH), 122.1 (CH), 117.4 (CH), 112.3 (CH), 57.7 (CH2), 51.9 (CH2), 
50.1 (CH2), 45.2 (CH2), 28.0 (CH), 20.8 (2×CH3); IR (KBr, cm-1) 3424 (w), 3067 (w), 
2954 (m), 2352 (w), 2251 (w), 1602 (m), 1496 (s), 1444 (s), 1289 (w), 1103 (w), 749 (s); 
MS (EI) m/z (%) 280.2 (M+) (31), 235.1 (79), 194.0 (100), 180.0 (63), 165.1 (41), 152.0 
(19), 86.1 (32); HRMS (EI) for C19H24N2 calcd 280.1939, obsd 280.1936. 
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9.11.55 AEDP disulfide (15) 
 
N
H
N
S
N
N
H
S
 
 
To a solution of AEP disulfide (220 mg, 0.27 mmol, 1.0 eq) in MeOH (25 mL) was added 
NaBH4 (82 mg, 2.18 mmol, 8.0 eq).  The reaction was stirred at room temperature for 5 h.  
A 5% Na2CO3 (aq) solution (10 mL) was added to the reaction mixture and the precipitated 
product was collected by filtration.  The dried product was a pale beige powder (127 mg, 
0.19 mmol, 70.1%):  mp > 160˚C (degrad); 1H NMR (CDCl3, 400 MHz) δ 7.77 (m, 2H), δ 
7.37 (m, 2H), δ 7.25 (m, 3H), δ 7.13 (d, 1H, J=8.0 Hz), δ 6.92 (t, 1H, J=8.0 Hz), δ 6.84 (d, 
1H, J=8.0 Hz), δ 6.54 (d, 2H, J=8.0 Hz), δ 4.29 (s, 2H), δ 4.11 (s, 1H), δ 3.58 (t, 2H, J=6.0 
Hz), δ 3.47 (t, 2H, J=6.0 Hz); 13C NMR (CDCl3, 100 MHz) δ 148.5 (C), 145.9 (C), 134.4 
(CH), 132.7 (C), 132.1 (C),129.2 (CH), 127.9 (CH), 127.2 (CH), 125.7 (CH), 124.1 (CH), 
123.6 (C), 122.6 (CH), 118.9 (CH), 113.33 (C), 113.30 (CH), 112.6 (CH), 52.9 (CH2), 49.5 
(CH2), 40.3 (CH2); IR (cm-1) 3304 (w), 1592 (m), 1444 (s), 868 (m), 749 (s); MS (FAB) 
m/z (%) 329.0 (42), 307.0 (18), 289.0 (10), 176.7 (100); Anal. Calcd for C42H38N4S2 C, 
76.10; H, 5.78; N, 8.45; Found C, 73.27; H, 5.74; N, 8.45. 
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9.11.56 AEP disulfide (16). 
 
N
H2N
S
N
NH2
S
4Cl
 
 
To a suspension of TIP disulfide (200 mg, 0.304 mmol, 1.0 eq) in MeOH (20 mL) was 
added HCl conc. (1.0 mL) and the reaction stirred for 20 min.  Solvents were remeoved 
under vacuum and the oily residue was vitrified with acetone.  The product was collected 
by filtration to give an orange powder (221 mg, 0.275 mmol, 90.3%, hygroscopic):  mp 
193-197 ˚C; 1H NMR (CD3OD, 400 MHz) δ 9.97 (s, 1H), 8.84 (d, 1H, J=8.0 Hz), 8.71 (d, 
1H, J=8.0 Hz), 8.62 (d, 1H, J=8.0 Hz), 8.35 (d, 1H, J=8.0 Hz), 8.18 (t, 1H, J=8.0 Hz), 8.12 
(t, 1H, J=8.0 Hz), 8.02 (t, 1H, J=8.0 Hz), 7.89 (t, 1H, J=8.0 Hz), 6.76 (d, 2H, J=8.4 Hz), 
6.38 (d, 2H, J=8.4 Hz), 5.36 (brd, 2H), 3.93 (brd, 2H); 13C NMR (CD3OD, 100 MHz) δ 
156.8 (CH), 147.7 (C), 139.6 (CH), 136.3 (C), 134.6 (C), 134.0 (CH), 133.8 (2×CH), 133.7 
(CH), 131.8 (CH), 131.5 (CH), 127.6 (C), 126.8 (C), 126.2 (CH), 124.8 (C), 124.1 (CH), 
120.6 (CH), 114.9 (2×CH), 58.7 (CH2), 43.7 (CH2); IR (cm-1) 3337 (m), 3017 (w), 1626 
(m), 1590 (m), 1449 (m), 1259 (m), 1015 (m), 821 (m), 757 (s), 719 (m); MS (FAB) m/z 
(%) 659.9 (M+) (49), 331.1 (M2+/2) (100), 181.7 (86); HRMS (FAB) for C21H19N2S calcd 
331.1269, obsd 331.1263. 
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9.11.57 TIP disulfide (17). 
 
N
N
S
N
N
S
 
 
To a solution of 4-aminophenyl disulfide (236 mg, 0.96 mmol, 1.0 eq) and TEA (798 µL, 
5.73 mmol, 3.0 eq) in MeCN (25 mL) was added BEP 10 (1.91 mmol, 2.0 eq).  The 
resultant suspension was stirred under a nitrogen atmosphere for 5 h at room temperature.  
The reaction mixture was filtered, washing the residue with a little MeOH.  After drying 
under vacuum the product was obtained as a dirty yellow powder (550 mg, 0.83 mmol, 
87.4%):  mp 190-192 ˚C; 1H NMR (CDCl3, 400 MHz) δ 7.87 (d, 2H, J=8.0 Hz), 7.78 (d, 
2H, J=8.0 Hz), 7.42 (m, 6H), 7.34 (m, 2H), 7.26 (d, 2H, J=8.0 Hz), 7.14 (d, 2H, J=8.0 Hz), 
7.05 (m, 2H), 6.83 (d, 2H, J=8.0 Hz), 6.68 (d, 4H, J=8.0 Hz), 5.32 (s, 2H), 4.07 (m, 2H), 
3.89 (m, 2H), 3.67 (m, 2H), 3.39 (m, 2H); 13C NMR (CDCl3, 100 MHz) δ 148.9 (C), 143.1 
(C), 133.9 (C), 133.6 (CH), 132.9 (C), 131.9 (C), 129.2 (CH), 128.0 (CH), 127.2 (CH), 
125.4 (C), 124.2 (CH), 123.8 (CH), 123.6 (CH), 120.2 (CH), 114.4 (CH), 113.2 (CH), 75.0 
(CH), 50.7 (CH2), 44.9 (CH2); IR (KBr, cm-1) 3384 (w), 3060 (w), 3030 (w), 2933 (w), 
2883 (w), 2808 (w), 1587 (s), 1490 (s), 1446 (s), 1357 (s), 1232 (m), 1187 (m), 1087 (m), 
1016 (m), 816 (s), 755 (s), 729 (s); MS (FAB) m/z (%) 659.1 (M+H)+ (35), 329.1 (100), 
193.6 (52), 180.7 (67); HRMS (FAB) for (C42H35N4S2)+ calcd 659.2303, obsd 659.2299. 
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9.11.58 DIP disulfide (18). 
 
N N
NN
S
S
2Cl
 
 
NH4Cl (100 mg, 1.87 mmol, 12.3 eq) was added to a suspension of TIP disulfide (100 mg, 
0.152 mmol, 1.0 eq) in DMSO (2 mL) and the reaction was heated to boiling for ~ 2min.  
The reaction was allowed to cool before acetone was added to precipitate the product.  The 
crude product was collected by filtration.  The crude residue was triturated with water and 
dried under vacuum to give a pale brown powder (98 mg, 0.134 mmol, 88.5%):  mp > 
250°C (degrad); 1H NMR (DMSO, 400 MHz) δ 8.93 (d, 1H, J=8.0 Hz), 8.84 (d, 1H, J=8.0 
Hz), 8.03 (t, 1H, J=8.0 Hz), 7.94 (t, 1H, J=8.0 Hz), 7.89 (d, 2H, J=8.4 Hz), 7.88 (m, 2H), 
7.81 (d, 2H, J=8.4 Hz), 7.72 (m, 2H), 4.97 (t, 2H, J=10.6 Hz), 4.62 (t, 2H, J=10.6 Hz); 13C 
NMR (DMSO, 100 MHz) δ 152.5 (C), 138.5 (C), 137.3 (C), 135.3 (CH), 135.1 (C), 132.5 
(C), 131.6 (CH), 128.9 (2×CH), 128.7 (CH), 127.9 (2×CH), 130.0 (CH), 125.8 (CH), 124.4 
(CH), 124.1 (CH), 120.4 (C), 116.3 (CH), 115.1 (C), 54.3 (CH2), 47.1 (CH2); IR (cm-1) 
3122 (m), 3029 (m), 2808 (m), 1577 (m), 1396 (s), 1311 (m), 1024 (w), 752 (m); MS 
(FAB) m/z (%) 655.9 (M+) (12), 328.0 (M2+/2) (67), 171.8 (100); HRMS (FAB) for 
C21H16N2S calcd 328.1034, obsd 328.1032. 
 
9.11.59 [4-(5-[1,2]Dithiolan-3-yl-pentanoylamino)-phenyl]-carbamic acid 
tert-butyl ester (19). 
 
S S
HN
O
NHBoc
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To a solution of Lipoic acid (2.00 g, 9.69 mmol, 1.0 eq) and N-Boc-p-phemylenediamine 
(2.00 g, 9.69 mmol, 1.0 eq) in toluene (70 mL) was added p-Bromobenzoic acid (40 mg, 
0.19 mmol, 0.02 eq).  The reaction was refluxed through a Soxhlet condenser containing 
3Ǻ molecular sieves for 44 hrs.  Solvent was removed under vacuum to give a grey powder 
as the crude product.  Purification by flash column chromatography afforded the pure 
product as a beige powder (2.91 g, 7.34 mmol, 75.8%):  mp 177-179 ˚C; Rf = 0.38 in 3:2 
PE/EtOAc; 1H NMR (CDCl3, 400 MHz) δ 7.46 (d, 2H, J=8.2 Hz), 7.34 (d, 2H, J=8.2 Hz), 
7.07 (s, 1H), 6.45 (s, 1H), 3.62 (m, 1H), 3.19 (m, 2H), 2.50 (m, 1H), 2.38 (m, 2H), 1.96 (m, 
1H), 1.79 (m, 4H), 1.58 (m, 2H), 1.54 (s, 9H); 13C NMR (CDCl3, 100 MHz) δ 170.9 (C), 
152.9 (C), 134.7 (C), 133.2 (C), 120.8 (CH), 119.2 (CH), 56.4 (CH), 40.3 (CH2), 38.5 
(CH2), 37.3 (CH2), 34.7 (CH2), 28.9 (CH2), 28.4 (3×CH3), 25.3 (CH2); IR (KBr, cm-1) 3331 
(s), 2923 (m), 1694 (s), 1660 (s), 1539 (s), 1520 (s), 1404 (s), 1310 (m), 1245 (m), 1160 
(s), 1058 (m), 834 (m); MS (CI) m/z (%) 397.4 (M+H)+ (8), 297.3 (14), 179.2 (32), 153 
(31), 107.2 (19); Anal. Calcd for C19H28N2O3S2  C, 57.54; H, 7.12; N, 7.06; Found C, 
57.33; H, 7.06; N, 7.28; HRMS (CI) for (C19H29N2O3S2)+ calcd 397.1620, obsd 397.1621. 
 
9.11.60 5-[1,2]Dithiolan-3-yl-pentanoic acid (4-amino-phenyl)-amide (20). 
 
S S
HN
O
NH2
 
 
To a solution of [4-(5-[1,2]Dithiolan-3-yl-pentanoylamino)-phenyl]-carbamic acid tert-
butyl ester (1.20 g, 4.04 mmol) in MeOH (150 mL) was added conc. HCl (10 mL) and the 
reaction was stirred at room temperature for 18 hrs.  The reaction mixture was reduced to 
half volume and then partitioned between H2O (200 mL) and Et2O (200 mL).  The layers 
were separated and the aqueous layer was washed with a further portion of Et2O (100 mL).  
The Aqueous layer was then neutralized by addition of solid NaHCO3 and extracted into 
Et2O (3 × 100 mL).  The combined ether extracts were dried over MgSO4 and concentrated 
under vacuum to give a brown oil (320 mg, 1.08 mmol, 35.6%):  1H NMR (CDCl3, 400 
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MHz) δ 7.29 (d, 2H, J=8.0 Hz), δ 7.09 (brd, 1H), δ 6.67 (d, 2H, J=8.0 Hz), δ 3.60 (m, 1H), 
δ 3.52 (brd, 2H), δ 3.17 (m, 2H), δ 2.49 (m, 1H), δ 2.35 (t, 2H, J=7.4 Hz), δ 1.94 (m, 1H), 
δ 1.77 (m, 4H), δ 1.42 (m, 2H); 13C NMR (CDCl3, 100 MHz) δ 136.7 (C), 134.2 (C), 122.8 
(CH), 119.4 (CH), 56.4 (CH), 40.3 (CH2), 38.5 (CH2), 37.3 (CH2), 34.7 (CH2), 28.9 (CH2), 
25.3 (CH2); MS (EI+) m/z (%) 296.2 (M+) (82), 150.1 (21), 108.1 (100). 
 
9.11.61 5-[1,2]Dithiolan-3-yl-pentanoic acid [4-(2,3-dihydro-12bH-
imidazo[1,2-f]phenanthridin-1-yl)-phenyl]-amide (21). 
 
S S
HN
O
N N
H
 
 
To a solution of 5-[1,2]Dithiolan-3-yl-pentanoic acid (4-amino-phenyl)-amide (320 mg, 
1.08 mmol, 1.0 eq) and TEA (452 µL, 5.73 mmol, 3.0 eq) in CHCl3 (30 mL) was added 5-
(2-Bromo-ethyl)-phenanthridinium bromide (317 mg, 0.864 mmol, 0.8 eq).  The resultant 
suspension was stirred under a nitrogen atmosphere for 0.5 h.  The reaction mixture was 
transferred to a separating funnel and washed with water (3×15 mL).  The organic phase 
was then dried over MgSO4 and the solvent removed under vacuum to give the crude 
product as an orange foam.  Trituration with MeOH afforded the product as an off-white 
powder (349 mg, 0.697 mmol, 64.4%):  mp 131-133 ˚C; 1H NMR (DMSO, 400 MHz) δ 
9.64 (s, 1H), 7.91 (d, 1H, J=7.8 Hz), 7.84 (d, 1H, J=7.8 Hz), 7.44 (d, 2H, J=8.9 Hz), 7.41 
(t, 1H, J=7.8 Hz), 7.31 (t, 1H, J=7.8 Hz), 7.27 (t, 1H, J=7.8 Hz), 6.99 (m, 2H), 6.87 (d, 1H, 
J=7.8 Hz), 6.67 (d, 2H, J=8.9 Hz), 5.20 (s, 1H), 4.09 (m, 1H), 3.95 (m, 1H), 3.77 (m, 1H), 
3.65 (m, 2H), 3.17 (m, 2H), 2.43 (m, 1H), 2.57 (m, 1H), 1.89 (m, 1H), 1.69 (m, 1H), 1.60 
(m, 4H), 1.41 (m, 2H);  13C NMR (CDCl3, 100 MHz) δ 171.3 (C), 146.3 (C), 143.7 (C), 
134.4 (C), 132.2 (C), 129.5 (CH), 129.2 (C), 128.2 (CH), 127.6 (CH), 124.7 (CH), 124.5 
(C), 124.1 (CH), 123.8 (CH), 122.2 (CH), 120.3 (CH), 114.6 (CH), 113.3 (CH), 75.6 (CH), 
56.8 (CH), 51.6 (CH2), 45.2 (CH2), 40.6 (CH2), 38.8 (CH2), 37.6 (CH2), 35.0 (CH2), 29.3 
(CH2), 25.8 (CH2); IR (KBr, cm-1) 3295 (w), 3033 (w), 2926 (m), 1652 (s), 1601 (s), 1515 
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(s), 1445 (s), 1299 (s), 1158 (s), 819 (m), 750 (s), 730 (s); MS (FAB) m/z (%) 502.4 
(M+H)+ (61), 414.4 (100), 180.8 (43); HRMS (FAB) for (C29H32N3OS2)+ calcd 502.1987, 
obsd 502.1982. 
 
9.11.62 1-[4-(5-[1,2]Dithiolan-3-yl-pentanoylamino)-phenyl]-2,3-dihydro-
1H-imidazo[1,2-f]phenanthridin-4-ylium bromide (22). 
 
S S
HN
O
N N
Br
 
 
To a solution of Lipoic amine SM (130 mg, 0.44 mmol, 1.0 eq) and TEA (275 µL, 1.97 
mmol, 4.5 eq) in CHCl3 (10 mL) was added 5-(2-Bromo-ethyl)-phenanthridinium bromide 
(240 mg, 0.66 mmol, 1.5 eq) and the reaction was stirred at room temperature for 4 d.  
Solvents were removed under vacuum and the brown residue was triturated with acetone 
then sonicated in H2O and filtered to give a brown powder after drying under vacuum (55 
mg, 0.095 mmol, 21.5%):  mp 252-258 ˚C (degrad); 1H NMR (DMSO, 400 MHz) δ 10.32 
(brd, 1H),8.91 (d, 1H, J=8.0 Hz), 8.82 (d, 1H, J=8.0 Hz), 8.07 (t, 1H, J=8.0 Hz), 7.88 (m, 
3H), 7.83 (d, 1H, J=8.0 Hz), 7.71 (t, 1H, J=8.0 Hz), 7.65 (d, 2H, J=8.0 Hz), 7.60 (t, 1H, 
J=8.0 Hz), 7.40 (d, 1H, J=8.0 Hz), 4.93 (t, 2H, J=10.6 Hz), 4.57 (t, 2H, J=10.6 Hz), 3.67 
(m, 1H), 3.19 (m, 2H), 2.44 (m, 2H), 1.92 (m, 1H), 1.72 (m, 1H), 1.65 (m, 4H), 1.45 (m, 
2H); 13C NMR (DMSO, 100 MHz) δ 171.7 (C), 152.5 (C), 140.6 (C), 135.3 (CH), 135.0 
(C), 133.3 (CH), 132.6 (C), 131.5 (C), 128.7 (CH), 127.2 (CH), 127.0 (CH), 125.7 (CH), 
124.3 (CH), 124.1 (CH), 120.5 (CH), 120.3 (C), 116.5 (CH), 115.3 (C), 56.2 (CH), 54.1 
(CH2), 46.8 (CH2), 38.1 (CH2), 34.2 (CH2), 28.4 (CH2), 24.8 (CH2); IR (cm-1) 3041 (w), 
2933 (w), 1680 (m), 1602 (m), 1575 (m), 1541 (s), 1516 (s), 1442 (m), 1311 (m), 756 (s); 
MS (FAB) m/z (%) 500.1 (M+) (69), 232.3 (39), 179.7 (39), 157.9 (98), 81.0 (100); HRMS 
(FAB) for (C29H30N3OS2)+ calcd 500.1830, obsd 500.1828. 
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9.11.63 1-Methyl-4-nitro-2,6,7-trioxabicyclo[2.2.2]octane (23). 
 
O O
NO2
O
 
 
Synthetic procedure derived from synthesis of Yokoyama et al:206  In a 250 mL RB flask 
fitted with a distillation condenser; 2-(hydroxymethyl)-2-nitro-1,3-propanediol (28.9 g, 
190.9 mmol, 1.0 eq) was suspended in dioctylphthalate (90 mL).  Triethyl orthoacetate (35 
mL, 190.9 mmol, 1.0 eq) was added and the reaction mixture was heated to 120˚C for 2 
hrs.  The distillation condenser was replaced with a vertical air condenser and a catalytic 
amount of p-toluenesulfonic acid (5-10 mg) and a further portion of DOP (50 mL) were 
added.  The pressure was reduced to < 50 mbar and the reaction was heated to 160˚C for a 
further 2 hrs.  The crude product sublimed and crystallized on the condenser.  The crude 
material was recrystallized from hexane to give white needle-like crystals (12.70 g, 72.5 
mmol, 38.0%):  mp 113-115 ˚C (Hexane); 1H NMR (CDCl3, 400 MHz) δ 4.43 (s, 6H), 1.55 
(s, 3H); 13C NMR (CDCl3, 100 MHz) δ 110.1 (CMe), 75.4 (CNO2), 67.6 (3×CH2), 22.1 
(CH3); IR (KBr, cm-1) 3489 (w), 3049 (m), 2916 (m), 1560 (s), 1302 (s), 1126 (s), 1029 (s), 
863 (s); MS (CI) m/z (%) 176.2 (M+H)+ (100), 149.2 (29), 131.2 (37). 
Product Reference:  Yokoyama, Y.; Padias, A. B.; Bratoeff, E. A.; Hall, H. K. 
Macromolecules 1982, 15, 11-17. 
 
9.11.64 1-Methyl-2,6,7-trioxabicyclo[2.2.2]oct-4-ylamine (24). 
 
O O
O
NH2
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Autoclave:  1-methyl-4-nitro-2,6,7-trioxa-bicyclo[2.2.2]octane (3.87 g, 22.10 mmol), 10% 
Pd/C (1200 mg), EtOAc (50 mL), 6 bar, 10d.  Product isolated as a white solid after EtOAc 
recryst. (1.211 g, 8.34 mmol, 37.7%):  mp 90-100 ˚C; 1H NMR (CDCl3, 400 MHz) δ 3.82 
(s, 6H), δ 1.43 (s, 3H), δ 1.18 (brd, 2H); 13C NMR (CDCl3, 100 MHz) δ 108.3 (C), δ 72.7 
(3×CH2), δ 45.0 (C), 22.9 (CH3); IR (cm-1) 3313 (m), 3265 (m), 2953 (m), 1626 (m), 1560 
(m), 1402 (m), 1294 (m), 1120 (s), 1047 (s), 1043 (s); MS (CI) m/z (%) 299.16 (40), 
164.92 (M+18) (23), 147.13 (M+2) (100), 145.14 (M+) (43), 116.54 (29). 
Product Reference:  Yokoyama, Y.; Padias, A. B.; Bratoeff, E. A.; Hall, H. K. 
Macromolecules 1982, 15, 11-17. 
 
9.11.65 N-(1-methyl-2,6,7-trioxa-bicyclo[2.2.2]oct-4-yl)-hydroxylamine 
(27). 
 
O O
NH
O
HO
 
 
H-Cube:  10% Pd/C catcart, EtOAc, 0.5 mL/min, rt˚C, 20 bar, 3 d.  1-methyl-4-nitro-
2,6,7-trioxa-bicyclo[2.2.2]octane (4.23 g, 24.17 mmol) in EtOAc (400 mL) was 
continuously flowed through the system for 3 d.  The solvent was removed under vacuum 
to give the product as a white powder (3.30g, 20.48 mmol, 84.8%):  mp 155-157 ˚C; 1H 
NMR (CDCl3, 400 MHz) δ 5.01 (brd, 2H), 4.04 (s, 6H), 1.49 (s, 3H); 13C NMR (CDCl3, 
100 MHz) δ 108.9 (C), 68.7 (3×CH2), 52.9 (C), 22.9 (CH3); IR (KBr, cm-1) 3105 (m), 3097 
(m), 2953 (m), 1739 (w), 1552 (m), 1388 (m), 1190 (M), 1126 (m), 1047 (s), 1030 (s); MS 
(CI) m/z (%) 162.1 (M+H)+ (100), 146.1 (69). 
Product Reference:  Studer, A., Angew. Chem. Int. Ed.  2000,  39, 1108-1111. 
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9.11.66 2-(1-Methyl-2,6,7-trioxa-bicyclo[2.2.2]oct-4-yl)-3,4-dihydro-
2H,12bH-1-oxa-2,4a-diaza-triphenylene (28). 
 
N
O
OO
O
N
 
 
BEP 10 (400 mg, 1.09 mmol, 1.0 eq) was added to a solution of N-(1-methyl-2,6,7-trioxa-
bicyclo[2.2.2]oct-4-yl)-hydroxylamine (158 mg, 0.98 mmol, 0.9 eq) and TEA (456 µL 
3.27 mmol, 3.0 eq) in DMSO (20 mL) and the reaction was stirred at room temperature for 
1.5 hrs.  MeOH (80 mL) and H2O (20 mL) were added to precipitate the product which 
was collected by filtration, washing with MeOH.  After drying under vacuum the product 
was obtained as a white powder (194 mg, 0.53 mmol, 54.2%): mp 215-217 ˚C (DMSO-
MeOH); 1H NMR (CDCl3, 400 MHz) δ 7.91 (d, 2H, J=8.0 Hz), 7.50 (m, 1H), 7.39 (s, 2H), 
7.33 (t, 1H, J=8.0 Hz), 7.00 (t, 1H, J=8.0 Hz), 6.95 (d, 1H, J=8.0 Hz), 6.13 (s, 1H), 4.22 (d, 
1H, J=11.2 Hz), 4.12 (d, 3H, J=7.6 Hz), 4.06 (d, 3H, J=7.6 Hz), 3.56 (t, 1H, J=11.2 Hz), 
3.19 (t, 1H, J=11.2 Hz), 2.79 (d, 1H, J=11.2 Hz), 1.47 (s, 3H); 13C NMR (CDCl3, 100 
MHz) δ 140.9 (C), 131.0 (C), 129.7 (CH), 129.4 (CH), 127.9 (CH), 127.6 (C), 127.5 (CH), 
124.0 (CH), 121.9 (CH), 121.3 (C), 119.4 (CH), 112.8 (CH), 108.8 (C), 89.8 (CH), 67.1 
(3×CH2), 55.6 (C), 46.7 (CH2), 45.4 (CH2), 22.8 (CH3); IR (cm-1) 2958 (w), 2895 (w), 
1604 (w), 1494 (w), 1447 (w), 1296 (m), 1122 (s), 1070 (m), 864 (s); MS (FAB) m/z (%) 
367.3 (M+H)+ (100), 307.1 (18), 206.6 (23), 193.7 (18); Anal. Calcd for C21H22N2O4  C, 
68.84; H, 6.05; N, 7.65; Found C, 68.34; H, 5.96; N, 7.58; HRMS (FAB) for 
(C21H23N2O4)+ calcd 367.1658, obsd 367.1654. 
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9.11.67 5-(2-(1-Methyl-2,6,7-trioxa-bicyclo[2.2.2]oct-4-yl)-
hydroxylaminoethyl)-phenanthridinium chloride; hydrochloride (29). 
 
NH
N
HO
HO
HO 2Cl
OH
 
 
To a solution of 2-(1-methyl-2,6,7-trioxa-bicyclo[2.2.2]oct-4-yl)-3,4-dihydro-2H,12bH-1-
oxa-2,4a-diazatriphenylene (100 mg, 0.28 mmol, 1.0 eq) in CHCl3 (10 mL) was added 5N 
HCl (aq) (10 mL), and the reaction was stirred for ~15 min.  The layers were separated and 
the organic phase was further extracted with 1N HCl (aq) (5 mL).  The combined aqueous 
extracts were heated to reflux for 3h.  The solvent was removed under vacuum and the 
residue was triturated with acetone.  Filtration and drying under vacuum afforded the 
product as a pale yellow powder (104 mg, 0.25 mmol, 91.4%):  mp 158-160 ˚C; 1H NMR 
(D2O, 400 MHz) δ 9.69 (s, 1H), 8.77 (d, 1H, J=8.0 Hz), 8.70 (d, 1H, J=8.0 Hz), 8.34 (d, 
1H, J=8.0 Hz), 8.30 (d, 1H, J=8.0 Hz), 8.20 (t, 1H, J=8.0 Hz), 7.99 (t, 1H, J=8.0 Hz), 7.92 
(m, 2H), 5.13 (t, 2H, J=5.2 Hz), 3.59 (t, 2H, J=5.2 Hz), 3.41 (s, 6H); 13C NMR (D2O, 100 
MHz) δ 155.1 (CH), 138.4 (CH), 134.8 (C), 132.5 (CH), 132.2 (CH), 130.3 (CH), 125.9 
(C), 124.6 (CH), 123.0 (C), 122.5 (118.6), 69.6 (C), 59.4 (3×CH2), 54.9 (CH2), 51.4 (CH2); 
IR (cm-1) 3266 (w), 1749 (s), 1627 (m), 1448 (m), 1360 (m), 1228 (s), 1064 (s), 912 (m), 
759 (s); MS (FAB) m/z (%) 343.3 (M+) (100), 295.3 (7), 206.6 (10), 103.8 (32); HRMS 
(FAB) for (C19H23N2O4)+ calcd 343.1658, obsd 343.1676. 
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9.11.68 1-[4-(5,5-Dimethyl-[1,3]dioxan-2-yl)-phenyl]-2,3-dihydro-1H-
imidazo[1,2-f]phenanthridin-4-ylium bromide (31). 
 
N
N
BrO
O
 
 
To a solution of 4-(5,5-dimethyl-[1,3]dioxan-2-yl)-phenylamine (169 mg, 0.817 mmol, 1.0 
eq) and TEA (342 µL, 2.451 mmol, 3.0 eq) in CHCl3 (30 mL) was added  BEP 10 (300 
mg, 0.817 mmol, 1.0 eq) and the reaction stirred at room temperature for 2 hrs.  The 
reaction mixture was concentrated under vacuum and the foam-like residue was triturated 
with MeOH to give a pale peach powder.  The residue was redissolved in CHCl3 (30 mL) 
and NBS (131 mg, 0.735 mmol, 0.9 eq) was added.  After stirring the reaction mixture for 
1 h the solvent was removed under vacuum.  Trituration of the residue with acetone and 
drying the residue under vacuum afforded the product as a white powder (255 mg, 0.519 
mmol, 63.5%):  mp 318-319 ˚C (MeOH-Et2O); 1H NMR (DMSO, 400 MHz) δ 8.93 (d, 1H, 
J=8.0 Hz), 8.84 (d, 1H, J=8.0 Hz), 8.08 (t, 1H, J=8.0 Hz), 7.94 (t, 1H, J=8.0 Hz), 7.86 (d, 
1H, J=8.0 Hz), 7.59 (m, 5H), 7.58 (t, 1H, J=8.0 Hz), 7.35 (d, 1H, J=8.0 Hz), 5.58 (s, 1H), 
4.96 (t, 2H, J=10.6 Hz), 4.61 (t, 2H, J=10.6 Hz), 3.76 (d, 2H, J=10.8 Hz), 3.72 (d, 2H, 
J=10.8 Hz), 1.24 (s, 3H), 0.81 (s, 1H); 13C NMR (DMSO, 100 MHz) δ 152.5 (C), 140.2 
(C), 139.5 (C), 135.4 (CH), 135.1 (C), 132.6 (C), 131.6 (CH), 128.6 (3×CH), 126.9 (CH), 
126.4 (2×CH), 125.8 (CH), 124.4 (CH), 124.1 (CH), 120.4 (C), 116.3 (CH), 115.2 (C), 
99.9 (CH), 76.6 (CH2), 54.4 (CH2), 47.0 (CH2), 29.9 (C), 22.8 (CH3), 21.4 (CH3); IR (cm-1) 
2937 (w), 2862 (w), 1575 (s), 1545 (s), 1390 (s), 1215 (m), 1111 (s), 1099 (s), 1016 (m), 
842 (m); MS (FAB) m/z (%) 411.2 (M+) (100); HRMS (FAB) for (C27H27N2O2)+ calcd 
411.2073, obsd 411.2069. 
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9.11.69 1-(4-Formylphenyl)-2,3-dihydro-1H-imidazo[1,2-f]phenanthridin-
4-ylium bromide (32). 
 
N
N
Br
O
 
 
To a suspension of 1-[4-(5,5-dimethyl-[1,3]dioxan-2-yl)-phenyl]-2,3-dihydro-1H-
imidazo[1,2-f]phenanthridin-4-ylium bromide (150 mg, 0.305 mmol, 1.0 eq) in H2O (15 
mL) was added con. HBr (48% by wt, 2 mL) and the reaction stirred at 90˚C for 2 hrs.  The 
suspension was filtered and the residue was dried under vacuum to give a yellow powder 
(85 mg, 0.210 mmol, 68.8%):  mp 350-352 ˚C; 1H NMR (DMSO, 400 MHz) δ 10.15 (s, 
1H), 8.95 (d, 1H, J=8.0 Hz), 8.87 (d, 1H, J=8.0 Hz), 8.24 (d, 2H, J=8.0 Hz), 8.12 (t, 1H, 
J=8.0 Hz), 7.94 (m, 4H), 7.76 (t, 1H, J=8.0 Hz), 7.57 (t, 1H, J=8.0 Hz), 7.40 (d, 1H), 5.00 
(t, 2H, J=10.6 Hz), 4.68 (t, 2H, J=10.6 Hz); 13C NMR (DMSO, 100 MHz) δ 192.4 (CH), 
152.6 (C), 144.3 (C), 136.3 (C), 135.6 (CH), 135.2 (C), 132.4 (C), 131.6 (CH), 128.8 (CH), 
127.3 (CH), 127.0 (CH), 126.1 (CH), 124.4 (CH), 124.1 (CH), 120.8 (C), 116.4 (CH), 
115.1 (C), 53.9 (CH2), 47.2 (CH2); IR (cm-1) 3045 (w), 1697 (m), 1572 (s), 1541 (s), 1309 
(m), 819 (m), 794 (m), 752 (s), 719 (m); MS (FAB) m/z (%) 325.2 (M+) (16), 307.1 (46), 
289.1 (18), 155.0 (100), 137.2 (71); HRMS (FAB) for (C22H17N2O)+ calcd 325.1341, obsd 
325.1339. 
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9.11.70 TRIS-Dawson 1-(4-formylphenyl)-2,3-dihydro-1H-imidazo[1,2-
f]phenanthridin-4-ylium salt (33). 
 
N
N
O
[TRIS-Dawson]5-
 
 
A solution of TRIS-Dawson TBA salt (30 mg, 0.0058 mmol, 1.0 eq) in MeCN (0.5 mL) 
was added to a solution of DIP-aldehyde 32 (2.3 mg, 0.0058 mmol, 1.0 eq) in MeCN and 
the mixed solution was left to stand for 1 h.  The precipitate was collected by filtration and 
dried to give a greenish yellow powder (28 mg, 0.0049 mmol, 85%):  1H NMR (DMSO, 
400 MHz) δ 10.14 (s, 10H), 8.94 (d, 10H, J=8.0 Hz), 8.86 (d, 10H, J=8.0 Hz), 8.39 (s, 3H), 
8.23 (d, 20H, J=8.0 Hz), 8.11 (t, 10H, J=8.0 Hz), 7.93 (m, 40H), 7.75 (t, 10H, J=8.0 Hz), 
7.56 (t, 10H, J=8.0 Hz), 7.39 (d, 10H), 5.40 (s, 6H), 5.07 (brd, 20H), 4.77 (brd, 20H); 13C 
NMR (DMSO, 100 MHz) δ 192.3 (CH), 152.5 (C), 144.3 (C), 136.2 (C), 135.5 (CH), 
135.2 (C), 132.4 (C), 131.7 (CH), 131.6 (CH), 128.7 (CH), 127.3 (CH), 127.0 (CH), 126.1 
(CH), 124.3 (CH), 124.0 (CH), 120.7 (C), 116.6 (CH), 114.0 (C), 54.0 (CH2), 47.3 (CH2); 
IR (cm-1) 3457 (w), 3050 (w), 1693 (w), 1573 (m), 1522 (m), 1308 (m), 1084 (m), 949 (m), 
903 (m), 808 (s), 716 (s); Anal. Calcd for [NH2C(CH2O)3P2W12V3O59] [C22H17N2O]5  C, 
24.19; H, 1.66; N, 2.72; Found C, 22.12; H, 1.68; N, 2.60). 
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9.11.71 4-[2-(6-Oxo-6H-phenanthridin-5-yl)-ethylamino]-benzaldehyde 
(34). 
 
NO
HN
O
 
 
DIP basic hydrolysis and acetal acid hydrolysis:  A Mixture of DIP-aldehyde and DIP 
acetal (814 mg) was suspended in ~0.2M NaOH (150 mL) and heated to 60˚C for 16 hrs.  
The reaction mixture was cooled and filtered to give a pale peach solid residue.  The 
residue was resuspended in H2O (50 mL), AcOH (20 mL) was added and the reaction was 
heated to 60˚C for a further 2 hrs.  The reaction mixture was filtered and after drying under 
vacuum the product was collected as an off-white powder (490 mg, 1.43 mmol, ~78%):  
mp 196-198 ˚C; 1H NMR (CDCl3, 400 MHz) δ 9.62 (s, 1H), 8.49 (d, 1H, J=8.0 Hz), 8.27 
(d, 1H, J=8.0 Hz), 8.23 (d, 1H, J=8.0 Hz), 7.74 (t, 1H, J=8.0 Hz), 7.56 (m, 3H), 7.48 (t, 
1H, J=8.0 Hz), 7.37 (d, 1H, J=8.0 Hz), 7.30 (t, 1H, J=8.0 Hz), 6.57 (d, 2H, J=8.8 Hz), 5.44 
(brd, 1H), 4.71 (t, 2H, J=5.6 Hz), 3.66 (dt, 2H, J=5.2, 5.6 Hz); 13C NMR (CDCl3, 100 
MHz) δ 190.1 (C), 162.5 (C), 153.3 (C), 136.8 (C), 133.6 (C), 132.9 (CH), 132.2 (CH), 
129.8 (CH), 128.6 (CH), 128.1 (CH), 126.1 (C), 125.0 (C), 123.7 (CH), 122.8 (CH), 121.7 
(CH), 119.5 (C), 114.6 (CH), 111.6 (CH), 41.8 (CH2), 41.7 (CH2); IR (cm-1) 3379 (w), 
1651 (s), 1589 (s), 1556 (s), 1533 (m), 1437 (m), 1354 (m), 1317 (m), 1161 (s), 804 (m); 
MS (EI+) m/z (%) 342.2 (M+) (20), 209.1 (73), 196.1 (81), 179.3 (64), 147.1 (94); HRMS 
(EI+) for C22H18N2O2 calcd 342.1368, obsd 342.1370. 
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9.11.72 LiAlH4 DIP reduction. 
 
N
N
N
HN
H
H
DIP  12b AEDP  14b
LIAlH4
THF
70oC
 
 
To a suspension of isobutyl-DIP (500 mg, 1.40 mmol, 1.0 eq) in dry THF (10 mL) was 
added a solution of LiAlH4 (2.0 M in THF, 7 mL, 14.0 mmol, 10.0 eq) dropwise over ~5 
min.  The reaction was heated to reflux (70°C) and stirred for 18 h (note: reaction was 
complete after 2 h).  The reaction was cooled to rt°C and quenched by dropwise addition of 
H2O (2 mL).  The resultant suspension was filtered and the filtrate was reduced by volume 
to ~10 mL before partitioning between H2O (20 mL) and Et2O (100 mL).  The layers were 
separated and the organic layer was washed with H2O (20 mL) before drying over MgSO4 
and concentrating under vacuum.  The crude product was purified by flash colomn 
chromatography (~15g silica, Et2O then 5% TEA in Et2O).  the product was collected as a 
yellow oil (114 mg, 0.41 mmol, 29.0 %):  1H NMR (CDCl3, 400 MHz) δ 7.64 (m, 2H), 
7.22 (t, 1H, J=8.0 Hz), 7.14 (m, 2H), 7.04 (d, 1H, J=8.0 Hz), 6.76 (m, 2H), 4.24 (s, 2H), 
3.43 (t, 2H, J=8.0 Hz), 2.86 (t, 2H, J=8.0 Hz), 2.39 (d, 2H, J=7.6 Hz), 1.68 (sept, 1H, 
J=6.8 Hz), 0.81 (d, 6H, J=6.8 Hz); 13C NMR (DMSO, 100 MHz) δ 146.2 (C), 132.9 (C), 
132.2 (C), 129.1 (C), 127.7 (CH), 127.0 (CH), 125.6 (CH), 123.9 (CH), 122.5 (CH), 118.2 
(CH), 112.6 (CH), 58.2 (CH2), 53.1 (CH2), 50.8 (CH2), 46.2 (CH2), 28.4 (CH), 20.8 
(2×CH3). 
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9.11.73 AEDP acidic oxidation. 
 
N
H2N
N
HN
H
H
AEP  13bAEDP  14b
2Cl
HCl(aq)
50oC
 
 
A mixture of isobutyl-AEDP 14b (80 mg, 0.28mmol) in H2O (5mL) was acidified by 
addition of HCl conc. (0.5 mL) and the reaction stirred at 50°C for 24 h.  The solvent was 
removed under vacuum and the oily residue was vitrified by addition of acetone.  The 
product was filtered and dried to give a pale yellow powder (61 mg, 0.17 mmol, 61.0 %):  
1H NMR (DMSO, 400 MHz) δ 10.72 (s, 1H), 10.08 (s, 2H), 9.25 (d, 1H, J=8.0 Hz), 9.18 
(d, 1H, J=8.0 Hz), 8.89 (d, 1H, J=8.0 Hz), 8.60 (d, 1H, J=8.0 Hz), 8.43 (t, 1H, J=8.0 Hz), 
8.15 (m, 3H), 5.69 (t, 2H, J=6.2 Hz), 3.69 (m, 2H), 2.84 (m, 2H), 2.10 (sept, 1H, J=6.8 
Hz), 0.99 (d, 6H, J=6.8 Hz). 
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